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The thesis comprises of seven chapters, which includes:
Chapter 1
This chapter precisely highlights the background, rationale, and relevance of the study and 
further stated the intended aims and objectives. Lastly, the chapter was concluded with the 
general outline and structure of the thesis. 
Chapter 2
The provision of a broad overview of the global impact of drug resistance tuberculosis (TB) 
morbidity and mortality and effectiveness and limitations of World Health Organization 
control plan (End TB strategy) are included in this chapter. Additional pieces of literature 
contain the cascade of Mycobacterium tuberculosis transmission cycle, prevention/vaccine, 
diagnosis, the therapeutic intervention of drug-resistance TB. Also discussed are the critical 
roles of the study drug targets of the Mtb. The targets include the demethylmenaquinone 
methyltransferase, N-acetylglucosamine-6-phosphate deacetylase, and secreted antigen 
proteins.
Chapter 3
This chapter dispenses a concise introduction into the computational chemistry, integrated 
molecular dynamics simulation protocols, and their applications in drug design and discovery 
process. The in-silico techniques theoretically discussed in this chapter were applied in this 
research work.
Chapter 4 (Published work): The chapter is presented in the required format of the Journal 
that published the full research article. Hence it is the final version of the accepted 
manuscript.
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This chapter provides the dynamic structural and functional on the NagA due to its crucial 
biosynthesis role within the cell wall of Mycobacterium tuberculosis. The chapter also 
includes homology protocol amalgamated for the creation of the predicted structures of NagA 
enzyme homologs. Comparative sequence analysis was performed among the NagA of 
smegmatis, marinum, leprae, ulcerans, africanum, and microti. Mutation impact on the active 
site of then NagA was explored. The loop dynamics of NagA was investigated in this chapter 
to gain cognizance into the biological activity of the protein. This article has been published 
in The Protein Journal (IF = 1.317).
Chapter 5 (Published work): This chapter is presented in the required format of the Journal 
that published the full research article. Hence it is the final version of the accepted 
manuscript).
The chapter includes homology protocol integrated for the creation of the predicted structures 
of the methyltransferase family exhibited within the Mycobacterium tuberculosis menG. The 
study intimates the effectiveness of DG70 compound as a potential inhibitor of menG 
enzymes. Thermodynamics analysis incorporating per-residue energy decomposition were 
calculated to underline the critical amino acid residues of menG that are involved in binding 
and. Besides, the loop dynamics of menG was investigated to gain cognizance into the 
biological activity of the protein. This article has been published in the RSC Advances (IF = 
3.070).
Chapter 6 (Published work): This chapter is presented in the required format of the Journal 
that published the full research article. Hence it is the final version of the accepted 
manuscript).
The chapter includes the creation of 3D Structures of the homologs of the Mycobacterium 
tuberculosis Ag85C enzyme using homology modelling protocol. Comparative multiple 
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sequence analysis was performed among the Ag85C protein of tuberculosis, smegmatis, 
marinum, leprae, ulcerans. Chapter 6 also unravels the structural dynamics and functional 
characterization of Ag85C protein. Thermodynamics analysis incorporating per-residue 
energy decomposition were calculated to underline the critical amino acid residues of Ag85C 
that are involved in the binding. Again, the loop dynamics of menG was investigated to gain 
cognizance into the biological activity of the protein. The loop dynamics of NagA was 
investigated in this chapter to gain cognizance into the biological activity of the protein. The 
article has been published in the RSC Advances (IF = 3.220)
Chapter 7




The world has witnessed several decades of Tuberculosis (TB) pandemic and numerous 
advanced scientific efforts to control the invasiveness of the newly evolving Mycobacterium 
tuberculosis strains (Mtb) resulting in drug resistance. TB disease has killed hundreds of 
millions of humans and left millions maimed that need to be rehabilitated; about 10.0 million 
infections and 1.5 million annually in the last decade. Drug-resistant TB has remained more 
challenging in the previous 20 years than drug-susceptible TB and is chromosomal 
mutations-associated in selected genes of the Mtb. Notable mutations identified by 
biomarkers are related to phenotypic drug resistance, and these include; an 81 bp region in 
rpoB gene with > 95 % mutations in rifampicin (RIF) clinical isolates and katG gene 
promoter of the mabA-inhA showed to be associated with INH-resistance. Different 
Strategies, including the recent WHO End TB approach, have been employed to alleviate or 
stop TB. The current identification of the critical roles of Mtb demethylmenaquinone 
methyltransferase (menG) target in the survival, pathogenesis, virulence, and drug resistance 
created an avenue for the development of efficacious therapeutics that can eradicate TB. 
MenG is a member of the methyltransferase superfamily. It catalyzes one of the last steps of 
the menaquinone biosynthesis pathway, requires for maintenance of the Mtb cell envelope. 
The other two studied targets investigated in this work are N-acetylglucosamine-6-phosphate 
deacetylase enzyme (NagA), which represents a critical enzymatic step in the production of 
essential amino sugar required by Mtb for the cell wall biosynthesis and the secreted antigen 
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85C enzyme (Ag85C) target. The latter target catalyzes the synthesis of trehalose derivatives 
and attachment of mycolic acids. These targets have gained considerable attention in drug 
discovery pipelines. However, there is little information about menG, as it lasks structural 
dynamics due to the lack of crystal structure, active site regions, and amino acids of it 
Mycobacteria homologs. Similarly, the dynamics of the NagA and Ag85C proteins structure 
are still unknown. Therefore, justifications led to the modelling of the 3D Structure of menG 
to understand the structural and functional features that could be investigated at the atomistic 
level. Homology models were also created for the five (5) mycobacterial homologs. 
Furthermore, the inevitable need for new drugs has led to the application of in silico 
techniques including molecular modelling and molecular dynamics simulations, which 
provide opportunities for the chemists to evaluate and assess numerous compounds that can 
lead to potential drugs against the mycobacterial disease. Furthermore, these computational 
techniques justify the present incorporation of several computational tools integrated into this 
study to provide insights into the conformational changes that illuminate potential inhibitory 
mechanism, identification of the binding site amino acids, and characterization. Here, we 
analyze the weak hotspots dynamics specific to each of the Mtb targets, most notably the loop 
and active residues around or within the ligand-binding sites to obtain useful findings for the 
design of higher efficacious potential antitubercular drugs. Molecular dynamics simulations 
were performed to gain molecular standpoints of the conformational binding of the 
experimental drugs, which were reported to be highly effective against each respective target. 
Structural dynamics and motions behaviour of menG upon the binding of inhibitor (DG70, 
biphenyl amide compound) were estimated. Additional in silico thermodynamic analyses 
were further employed to explore intuitions into the binding mode of each inhibitor mainly 
for the proposed binding site of menG to identify the residues for binding. Sequence analysis 
of the homologs of Mycobacterium tuberculosis NagA and Ag85C targets, including those of 
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smegmatis, marinum, leprae, ulcerans, were performed to obtain unique sequence similarities 
and differences and the structural and functional characterization upon the binding of the 
ligand. An experimental protocol let to the discovery of a selective covalent inhibitor, β-
isomer monocyclic enolphosphorus Cycliphostin, of Ag85C SER-124. Moreover, chapter 4 
also unravels the impact of the function of the non-synonymous single nucleotide 
polymorphisms of NagA target. The desired expectation is that the implementation of the 
information extricated from this study would provide the structural silhouette for 
pharmaceutical scientists and molecular biologists to abet in the identification and design of 
novel antimycobacterial drugs most especially for TB. 
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1.1 Background and Rationale of the study
Tuberculosis (TB) has continued to remain the world most health-threatening pandemic. The 
disease is too complicated, and factors like latency, dormancy and drug resistance in the 
Mycobacterium tuberculosis (Mtb) make its treatment and cure challenging. TB infection is 
still the primary factor of mortality and socioeconomic disaster for millions of people 
globally1 as its pathogen has persisted in the host man for more than 50 years. Despite several 
years of available TB control strategies encompassing effective therapy,2 diagnostic tools; 
rehabilitation; preventive efforts; and a global awareness campaign to end its monster 
causing-organism, this common human enemy continues to succeed. TB has remained the 
leading cause of human death3; hence, it is regarded as the ‘crown’ cause of death globally, 
and ranked above HIV/AIDS infections (World Health Organization, WHO: 2019 reports). 
Specifically, the WHO estimated 10 million TB infection cases and about 1.2 million TB 
deaths among TB/HIV-negative co-infected persons in 2018; these numbers have remained 
unchanged in the last few years.4 According to WHO, prevalence of  TB cases is in the trend: 
South-East Asia (44 %), Africa (24 %), Western Pacific (18 %), Eastern Meditteranean (8 
%), Americas (3 %), Europe (3 %). Notably, Nigeria (4 %) and South Africa (3 %) are two 
countries in Africa, accounting for two-thirds of worldwide’s total TB incidences. The TB 
mortality rate in South Africa (SA) is relatively high in Africa continents because SA is the 
epicentre of the HIV epidemic globally, with 7.7 million people living with HIV in the 
country.5 The association of TB with HIV is a global challenge since it increased patients’ 
mortality rate with HIV.
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More challenging about TB is the mutations-mediated drug resistances, which initially 
occurred as mono-drug resistance but now multidrug and extensively drug resistance TB 
(MDR/XRD-TB). The most common type of this mutation is the non-synonymous single-
nucleotide polymorphisms (nsSNPs). Recently, a form of XRD-TB strains known as the total 
drug resistant-TB (TDR-TB), first reported in South Africa, was highly resistant.6 There is a 
need for a combined radical approach of expanded preventive medication for persons with 
and without HIV and treatment with improved surveillance to improve global control of TB.
Drug resistance TB has caused several drawbacks to WHO EndTB strategy started in 2017, 
which compares the combination of bedaquiline and delamanid with current more extended 
treatment regimens for MDR-TB and XRD-TB. Almost 184 772 new cases of MDR/RR-TB 
persons were reported in 2018, which reflected 51 % confirmed bacteriological TB infected 
peoples.4 TB drug resistances occur due to spontaneous mutation of genes to result in the 
resistance to antitubercular drugs. However, the most signalled reason for drug resistance is 
non-compliance with dosage regimens. The rifampicin/multidrug-resistant (MDR/RR-TB) 
patient treatment lasts for at least 18-24 months of administration of second-line drugs 
accompanied by counselling and monitoring.7 Whereas, the standard treatment of TB only 
spans through 6-months regimens. The late emergence of drug-resistant strains and the 
continual treatment to eliminate the organism underlies the importance of compliance, and 
the risk involves early discontinuity of therapy.8 Hence, non-adherence is very high with 
consequential poor outcomes, leading to the MDR strains dissemination. There are instances 
where drug resistance in the pathogens’ genes are not traceable to mutations; thus, 
MDR/XRD TB is a complex phenomenon. Secondly, the success of TB pathogen is due to its 
complex mycobacterial cell wall comprising of three distinct macromolecules: peptidoglycan 
(PG), arabinogalactan (AG) and mycolic acids; which underly the slow growth rate of the 
pathogens and their characteristic thick, greasy, and impermeability nature of the cell 
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envelope. Also, the TB drugs undermine by adverse drug occurrences, lack of adherence to 
optimal therapy, and high costs of purchasing drugs also lead to drug resistance.9 Also 
aggravate TB pandemic is the co-infection of some disease such as HIV and diabetes. The co-
infection of HIV/AIDS or diabetes mellitus with RR/MDR- and XDR-TB also contributes to 
TB treatment’s ineffectiveness, which further has a consequential impact on TB mortality. 
Although the recent use of newer frontline drugs has ameliorated the therapeutic intervention 
of TB, several shortcomings, especially drug resistance, continue to plague their applications. 
Drug resistance causes arduous treatment and relapse rate to tuberculosis, leading to the 
disuse and discontinuation of some of these drugs. About one-half of the multidrug or 
extensive drug resistances have been affected by mutation-mediated or acquired resistance.10, 
11 Isoniazid, linezolid, and bedaquiline (BDQ) are few examples. TB treatment outcome using 
first-/second-line drugs and the newer drugs is discouraging, with success rates as low as 54 
% and 30 % for MDR and XRD, respectively.12 Drug design involves an interdisciplinary 
approach to enhance the discovery of more TB drugs because there is still a limited drug in 
the pipeline. New therapeutic strategies’ goals include; ensuring TB cure without relapse; 
reducing TB mortality, contagions, and the formation of drug-resistant strains; search for low 
cost, little or no toxic model that interferes with biology Mtb protein functions. 
Antitubercular therapy approach to developing a new chemical entity with a novel 
mechanism of action is a promising alternative, which shows significant activity against the 
Mtb strains and the expensive and time-consuming processes of drug discovery and 
development spans through 10-20 years of intensive laboratory research. Computer-aided 
drug design (CADD) methods have significantly improved drug discovery and development 
processes by overcoming some disadvantages with the subsequent possibility of having drug 
candidates with little or no toxicity. Applications of computational chemistry incorporated 
into biology provide clear-cut added advantages over the conventional drug discovery 
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process in a manner that reduces drug development steps by a fraction of the regular 
timescale. Computational techniques, including molecular modelling, hot spots 
pharmacophore identification, and Molecular dynamics (MD) simulations, furnish the 
biologists and medicinal chemists with information to design potent drugs to treat 
tuberculosis and other bacterial infections. The application of bioinformatics and molecular 
dynamics simulations methods have proven to alleviate the concept of “shooting in the dark” 
with experimental screening by reducing the protracted time scale of drug discovery. These 
methods have been substantially used in protein-ligand and protein-protein interactions. 
Taken together, identification and selection of critical Mtb receptors incorporated with the 
development of high inhibitory protocols that use low cost, non-toxic, high % potent 
compounds may contribute to the discovery of future lead compounds against TB. 
The molecular and structural insights of three Mycobacterium tuberculosis targets; were 
unravelled in this study. They include the N-acetylglucosamine-6-phosphate deacetylase, 
demethylmenaquinone methyltransferase, and antigen 85C enzymes. The proteins drive the 
pathogen’s virulence, survival, and drug resistance success against the frontline antitubercular 
drugs. The targeting of protein roles such as catalysis of sugar production steps, attachment of 
mycolic acids, and the synthesis of trehalose derivatives in the Mtb cell wall is an attractive 
approach towards the significant development of vaccines and drugs. Moreover, these 
findings’ outcome is essential in the structure-based design of specific and selective small 
molecules that can inhibit the Mtb receptors, thereby discovering more potent, less toxic, and 
more specific antitubercular drugs. 
1.2 Aims and objectives of the study
This thesis’s primary aim unravels the structural dynamics and functional insights of selected 
crucial targets of Mycobacterium tuberculosis involved in the virulence, pathogenesis, and 
drug resistance using bioinformatics and computational techniques to identify and develop 
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probable potential inhibitors against Mtb. The Mtb targets investigated are N-
acetylglucosamine-6-phosphate deacetylase (NagA), demethylmenaquinone 
methyltransferase (menG) antigen 85C enzyme.
The specific goals include:
1. To investigate the structural and functional features of Mtb NagA protein, which aid 
the structure-based design of novel chemical entities with potential potent anti-TB activities. 
The following objectives were considered to achieve this goal:
1.1 prediction of 3D structures of the homologs of MtbNagA, which include MSNagA, 
MANagA, MCNagA, MMNagA, and MUNagA using the homology modelling protocol.
1.2 amino acids sequence analysis of MtbNagA, MSNagA, MANagA, MCNagA, 
MMNagA, and MUNagA using to obtain similarities and differences in their primary 
structures
1.3 computation of 350 ns MD simulations on MtbNagA, MSNagA, MANagA, MCNagA, 
MMNagA, and MUNagA and estimated post-MD analysis to validate and obtain the stability 
and flexibility.
1.4 investigation of the critical Mtb NagA mutants, including D267A, H56Q, H56N, and 
H56A on the amino acids using the online mutation resources (Dynamut and Polyphen2), to 
analyse the impact of functional of non-synonymous single-nucleotide polymorphisms.
1.5 comparative analysis of both static and dynamic structural conformational changes 
2. To provide the structural and dynamic impacts of a biphenyl amide compound named 
DG70, we docked on demethylmenaquinone methyltransferase (menG), using integrated MD 
simulations. The following objectives were considered to achieve this goal.
2.1 prediction of 3D structures of the MtbmenG using the homology modelling protocol.
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2.2 docking of DG70 and demethylmenaquinone, DMK9 (menG substrate) compounds 
following the identification of the poses with the most negative docking score and the active 
site identification-validation of the residues. 
2.3 computation of 300 ns molecular dynamics simulations of unbound menG and DG70-
bound menG and post-MD analysis.
2.4 investigation of the structural and functional binding landscape of DG70 against the 
menG protein.
2.5 obtaining the thermodynamic data of the target-inhibitor systems to calculate the 
binding energy between DG70 compound and menG
2.6 obtaining the energy contribution from each interacting residue in the binding analysis 
based on the MM/GBSA approach to identify the amino acid residues with highest binding 
free energy contributions.
3. Investigate structural characteristics and motions and dynamics of the Mtb target 
(Ag85C) upon the binding of the selective covalent β-isomer enolphosphorus Cycliphostin 
(CyC8β)-bound and CyC8β open model conformations. 
3.1 prediction of 3D structures of A85C proteins of the mycobacteria, including 
smegmatis, marinum, leprae, and ulcerans using homology modelling protocol 
3.2 amino acids sequence analysis of the target Ag85C among the mycobacteria species 
including; Mtbs, smegmatis, marinum, leprae, and ulcerans to explore the levels of structural 
conservation and the unique similarities or differences, which could be vital in future for the 
identification and development of potential inhibitors against tuberculosis.  
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3.3 computation of 300 ns molecular dynamics simulations of unbound A85C and CyC8β-
bound A85C and the estimation of post-MD analysis including stability, flexibility, system 
and compactness.
3.4 investigation of the structural and functional behaviours of A85C protein upon the 
binding of CyC8β-compound
3.5 obtaining the thermodynamic terms to determine the binding free energy
3.6 implementation of a PRED of each system based on the MM/GBSA approach.
1.3 Novelty and significance of this study 
Although the global average TB incidence rate indicated a decline by 1.6 % per year from 
2000 to 2018 and 2.0 % between 2017-2018, new drug-resistant Mtb strains are evolving to 
develop mutations in every frontline drug. Therefore, TB is still the number one global death 
cause and the principal cause of an infectious agent. For these reasons, the considerations of 
critical Mtb targets combined with selective inhibitory strategies furnish potential 
opportunities for some weak hotspots that produce highly effective TB treatment with little or 
no toxic level. The search for therapeutic targets and their drug design use to effectively treat 
tuberculosis is a very significant route. The roles of proteins, including menG, NagA, and 
Ag85C, are crucial to Mtb survival, virulence, and drug resistance attributes. They are 
involved in the organism’s cell envelope’s respiration or maintenance, especially menG, 
which has no crystallised structure. The targets are considered a means to end the menace of 
TB. Moreover, several CADD approaches that enhance experimental methods speed up drug 
discovery and present the means to overcome conventional therapy’s shortcomings.
This research work focuses on investigating unique features and changes in the structures and 
functions of the conformations of the whole protein and specific loops of the homologs of 
Mycobacterium tuberculosis NagA, menG, and Ag85C of Mycobacterium tuberculosis. Also, 
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the homology model of Mtb menG was constructed due to the unavailability of the crystal 
structure. Similarly, the models of the NagA and Ag85C proteins of the other mycobacteria, 
including smegmatis, marinum, leprae, africanum, microti, and ulcerans, were constructed 
for sequence analysis determination. The study further pinpoints each target’s sequential and 
structural behaviour to their respective enzyme family, thus elucidating the importance of 
understanding the binding landscape with their inhibitors and providing insights that could 
help design specific inhibitors to ameliorate drug resistance. The molecular perspectives into 
the binding of respective experimental inhibitors to the menG and Ag85C were provided 
here, specifically, bindings of DG70 chemotype to menG and CyC8β compound to Ag85C. 
These were achieved by characterising the proteins’ active sites, analysing the structural and 
functional conformations, and identifying the absolute amino acids necessary for the binding. 
The design of the enzymes’ plausible binding features proffers an approach to design 
inhibitors that are selective and distinct with polypharmacological properties, which would 
enhance the development of effective, stable, and efficacious small molecules inhibitors. 
Further to the above NagA molecular insights, this study predicted the critical residues’ 
mutation effect, including HIS56 and D267 at the binding site. The NagA mutants; D267A, 
H56N, H56Q, and H56A, have been reported to reduce the NagA protein’s catalytic activity. 
On these notes, this thesis’s research contents underlay the fundamental principle towards 
drug design against tuberculosis. 
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Tuberculosis pathogen remains the single infectious agent that has killed more than a billion 
people globally over the last two centuries.1 Unfortunately, it was not later than 1882 that the 
incidences and mortality were well underway before Robert Koch announced his discovery of 
Mtb.2, 3 Despite working alone, Koch completed outstanding medical-scientific achievements 
in less than just a year in human history. He named the TB pathogen Mycobacterium 
tuberculosis (Mtb) as globally called to date.4 The genus Mtb belongs to the 
Mycobacteriaceae family and is an obligate pathogen thought to have co-existed with humans 
(its host) over several millions of years.5, Mtb’s ancient Origin is over 70 000 years, and it 
infected nearly 2 billion people recently.3 Mtb is highly infectious and contagious, possesses 
complex immunological response, and chronic progression.3,6, 7 
An estimation of ≥ 90 % of people who develop TB are adults (>15 years) in the ratio of male 
2:1 female. Perhaps, the lack of available effective vaccines in adults contributes to the higher 
number of TB infections. The 30 high-TB burden countries are responsible for more than 90 
% of the global cases annually.8 Presently, more than 20 drugs are used for TB treatment, 
which was developed over 40 years ago.9 Unlike drug-resistant TB, drug-susceptible TB can 
be effectively treated with anti-TB first-line medicines. Mutations in many of the Mtb genes 
are associated with drug resistance.9 The Mtb’s ability to acquire resistance by mutations was 
discovered when the first clinical trial with streptomycin was carried out about seven decades 
ago.10 Figure 2.1 illustrates the proportion of infected people relative to men, women, 
children, and TB/HIV co-infection.
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Figure 2.1. Epidemiology of Tuberculosis.11
WHO launched the End TB strategy in 2017 and unanimously adopted the milestones (2020 
and 2025) and targets (2030 and 2035) to end the global TB pandemic. However, TB 
infection numbers must be falling by 10 % yearly (by 2025), and the mortality proportion 
falls by 6.5 % (same year) to achieve the milestones and goals of the WHO EndTB strategy12. 
The global incidence rate of TB (new cases per 100 000 population per year) falls by 2 %, 
with the average decreasing rate at 1.6 % per year in the period 2000-2018 and 2.0 % 
between 2017 and 2018,12, indicating a low declining rate. Figure 2.2 illustrates graphically 
incidence and mortality curves projection needed to reach the EndTB targets and milestones 
between 2015-203513. Achieving the WHO milestones and targets with the time range 
requires sustaining TB diagnosis, treatment, prevention services, and multisectoral action to 
address socioeconomic factors that drive TB epidemics. 
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Figure 2.2. Predicted curves of incidence and mortality to attain the targets and milestones of the 
EndTB, 2016-2035 (WHO, 2017).
Mtb spreads when TB-infected people expel the bacteria into the air through coughing, 
sneezing, or laughing.14, 15 Better still, the infection is transmitted from an infected person to 
an airborne particle susceptible person.16 The transmission occurs when the inhaled droplet 
nuclei containing the pathogen travels via the mouth or nasal passages into the upper 
respiratory tract and further proceed to the bronchi until it enters the lung and the alveoli. 
Thus, ending the TB pandemic requires altering the germ transmission processes.17 Figure 2.3 
illustrates the Cascade of the Mycobacterium tuberculosis transmission cycle.
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Figure 2.3. Cascade of Mycobacterium tuberculosis transmission cycle. Source: Japan Anti-
Tuberculosis Association: Common sense of Tuberculosis, 2007
The TB infection can be pulmonary (lung) or extrapulmonary (hematogenous and lymphatic 
TB). Moreover, TB infection can be classified as latent and active. Latent TB occurs when a 
person harbours a germ, but the immune system holds them back from spreading, while 
active TB causes the pathogen’s spread. A patient with latent TB shows no symptoms and is 
not contagious, but an active TB multiplies and causes sickness.18 Latent TB is still alive and 
can become active anytime. 
2.1 Multiple and Extensively Drug-Resistant Tuberculosis: Challenges & Treatment 
MDR-TB and XRD-TB) have remained pervasive in the last couple of years.19,20 Both the TB 
resistance types pose formidable challenges in diagnosis and treatment.21, 22 Multidrug-
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resistant TB  occurs when the first-line drugs RIP and INH, that are the first two most 
effective, becomes resistant to by the pathogen. MDR-TB treatment requires less effective 
second-line drugs, more expensive, and associated with too many side effects and toxicity.23 
Drug resistance diagnosis is quite challenging because it may take up to 6-16 weeks and 
requires advanced laboratory tools. MDR-TB has a higher overall mortality rate than drug-
susceptible TB.19 It can be cured, but it takes at least three times longer to be cured than 18-24 
months.19, 24 In contrast, XRD-TB is the MDR-TB, which fails to respond to the multiple 
second-line drugs or resistance to not less than one drug in the two most important classes of 
medicines in an MDR-TB regimen.8 XRD-TB treatments demand even more expensive and 
toxic third-line drugs such that a course of treatment is tailored to individual TB samples. The 
first remedy success against TB was introduced as the sanatorium cure in 1854.3 The 
difficulty involved in diagnosing XRD-TB could be why many patients with XRD-TB do not 
survive tuberculosis infection. A more challenging situation is that HIV-positive patients are 
at greater risk of acquiring MDR-TB strains.
Initially, combined therapy comprises isoniazid (INH) plus para-aminosalicylic acid has been 
practised to overcome drug resistance development. Subsequently, the combination of 
pyrazinamide (PZA) and rifampicin (RIF) drugs are still being used. However, penurious 
drug prescription, impoverish patient adherence, drug supply/quality, and other factors lead to 
acquired drug resistance. MDR-TB can be primary, which occurs when a person is infected 
by someone having a resistant strain or contracted when regular TB is inadequately treated, 
allowing bacteria to develop resistance. MDR/XRD-TB’s primary cause is the patients’ 
failure to complete their total TB doses and regimen, which results in the disease relapse and 
resistance that is very challenging to cure. The treatments of MDR/XRD-TB are often longer 
than the standard therapies. The disease condition requires expensive second-line drugs that 
show no assurance of effectiveness and severe toxicity, resulting in an undesirable outcome. 
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Several newer medications, including bedaquiline, delamanid, SQ109, pretomanid, and 
linezolid, have effectively treated DR-TB. Unfortunately, they have “black-boxed” as a result 
of their highly toxic effect. 
Moreover, new mechanisms of resistance have been identified. The resistance to 
antitubercular drugs dates back to the beginning of chemotherapy discovery, and there have 
been newly reported findings into the mechanisms of the Mtb strains resistance. 
2.2 Diagnosis and Detection of TB infection
The ameliorative control towards ending TB pandemic tuberculosis includes prevention, 
diagnosis, and treatment plans and continuously posing more problems. Diagnosis and 
treatment must be specifically achieved to control drug-resistant TB. There is an urgent need 
for better testing, rapid diagnostics. Doing better testing of drug-susceptibility is not 
sufficient for maintaining drug resistance. The lack of adequate and straightforward point-of-
care TB tools to accurately diagnose all kinds of TB, especially MDR and XRD, is 
challenging. Conventional TB diagnosis methods include the clinical diagnosis of active TB, 
Mantoux test, Chest X-ray radiographs, and classical laboratory methods. The sensitivity to 
the tuberculum in TB patient can be obtained by carrying out a test called Mantoux. 
Advanced stage of pulmonary tuberculosis  is confirmed if lung caverns are shown by chest 
X-ray test.
The classical laboratory method is the most used worldwide due to its reliability. Therefore, 
continuing efforts towards improving the coverage and diagnosis quality, drug-resistant TB 
infected people, plus treatments are necessities. Mtb drug resistance can be determined using 
conventional methods, Agar proportion method, Fluorometric method (BACTEC 960 
system), Microplate Alamar Blue Assay (MABA), molecular diagnosis tools, and the primary 
genetic markers to identify Mtb. Currently, the WHO recommends rapid molecular tests 
(Xpert, MTB/RIF assay (Cepheid, USA) to be the initial diagnostic test for TB disease13, 25. 
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The MTB/RIF test (Xpert ) is highly efficient in sputum samples to detect susceptible TB and 
RIP-resistance due to mutation  within 2 hours. Besides, molecular data obtained from 
epidemiologic study can reveal the outbreak all forms of TB including  drug-resistant TB hot 
spots. However, there are still significant and persistent gaps in detection.15 The mortality rate 
of TB disease would continue to increase without timely diagnosis and essential operational 
research investment in diagnostic tools to enhance the cure of most TB patients. However, 
excellent knowledge of drug resistance mechanisms helps develop new tools for the rapid 
diagnosis of drug-resistant TB.
2.3 Prevention of TB infection
According to Desiderius Erasmus, a great Dutch philosopher (1500), “Prevention is better 
than cure.” The menace of drug-resistant TB and its evolution must be pevented, especially in 
regions with prevalent HIV/AIDS cases. The reason being that co-infection of HIV and TB is 
more devastating that when single TB infection. The prevention of MDR/XRD-TB and TDR-
TB require designed infection control strategies. The strategies include to involve 
campaigning to patients and the community, planning of infection control, collecting safe 
sputum samples, etiquette and hygiene surrounding coughing, rapid TB diagnosis and 
treatment, improve room air ventilation, etc. The discovery of effective TB vaccines could be 
a landmark for the reduction of TB infection. The bacilli Calmette-Guerin (BCG) vaccine, 
developed 100 years ago, is effective against TB in children and is recommended by WHO. 
Contrastingly, there is still no vaccine for TB in adults currently. Vaccine serves as a 
preventive treatment that elicited immune responses against TB. Although 14 vaccine 
candidates are in clinical trial Phase IIb, which could transform global TB preventive efforts, 
there could still be limitations in the effective control of the new and re-emerging strains of 
Mycobacterium tuberculosis. 
2.4 Post-treatment Patient Rehabilitation 
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Tuberculosis may impose certain physical limitations and injuries that trigger reaction and 
chest wall retraction, compromising expansion.26 Hence it is necessary to highlight the need 
for post-treatment rehabilitation of TB patients, including social, psychological, 
physiotherapy (exercise), and economic aspects.27 Although most TB control programmes 
admit work completion after a patient is successfully cured, patients often experience 
prolonged sufferings with post-treatment or pulmonary rehabilitation (PR) or sequelae. 
Evidence supports the importance of a thorough and adequate evaluation of patients after TB 
cure to identify pulmonary rehabilitation beneficiaries. PR is effective in patients with 
tuberculosis28, and the rehabilitation process involves a multidisciplinary approach.27 
Pulmonary rehabilitation makes the evolution and the increase in the chances of healing and 
social reintegration possible. Considering the length of TB treatment, in which the minimum 
is six months, in some cases, treatment may last for over five years, little or no attention is 
given to the social, psychological, and economic impact extended treatment can have on the 
patients’ lives.29 To a large extent, TB patients, especially in many high-burden countries, 
continue to face high levels of stigma and obstacles, even pre-diagnosis, which persist at 
every stage of the treatment process. 
Research reports have shown that most individuals face high out-of-pocket expenses, 
including additional medication, nutritional supplements, and transport, despite the free 
diagnoses and treatment they received.29 Nutritional supports and physiological challenges 
have not been adequately maintained.30 Malnutrition increases the risk of TB mortality in 
patients with a low body mass index than those with a high body mass index. Psychological 
and emotional support should be provided to TB patients before diagnosis, treatment, and 
post TB sequelae. Therefore, it could be said that affected individuals do not often prepare for 
the financial, time, physiological, and psychological effects. Sometimes, the side effects of 
TB medication may be extreme to require extensive therapy and rehabilitation. Nutritional 
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supports and physiological challenges have not been adequately maintained. The friends, 
families, and even health workers of TB people often labelled them with various constant 
stigmas. 
2.5 Mycobacterium tuberculosis drug resistance, targets and therapeutic 
interventions
The complete genome sequence of the Mtb provides opportunities to inhibit the organism 
target enzymes’ activity by implementing screening campaigns that focus on identifying low 
molecular mass chemical compounds.24 Currently, robust Whole-genome sequencing (WGS) 
technology is used to uncover the drug resistance mechanism in Mtb, and it rapidly sequences 
the complete mycobacterial genome.31 Moreover, WGS can be used to identify signatures of 
convergent evolution and positive selection of newly associated drug resistance genes in 
Mycobacterium tuberculosis.32 The essentiality of the Mtb protein target is very critical 
towards drug design development processes. The current consideration of targeted therapy, 
specifically the molecular targets towards TB treatment, has been the researchers’ focal point. 
The needs for new drugs to improve the current TB therapy, especially with the worsening 
cases of drug resistance, are inevitable. Therefore, it is imperative to explore novel drug 
targets while developing new agents to enhance drug efficacy and circumvent resistance. 
Several Mtb targets have been identified over the years, but few are well-known drug targets, 
including InhA, FabD, FabC, KasA, etc.33 
Many recognized promising pathways pertinent to drug targets include cell wall 
metabolism,34 cellular respiration,35 protein synthesis, etc. Table 2.1 highlighted some 
promising drug targets, functions, and inhibitors.16 Several anti-TB drugs were discovered 
based on the screening compounds against the bacterial cells. Many drugs have more than 
one protein targets. However, some drug compounds may not enter the mycobacterial cell 
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wall because of their architectural structure; thick and greasy characteristics.36,37 Yet, the 
target/activator’s crystal structures can be resolved, improving the current drugs. 
Table 2.1 Drug targets in Mycobacterium tuberculosis.
Target protein Function        Inhibitor
Secreted antigen 85 TDM/TMM synthesis, Cyclophostin 
phosphonate
complex and mycolic acid cell (CyC8β)
wall attachment
Demethylmenaquinone Menaquinone synthesis DG70 compound
methyltransferase, menG for cell wall maintenance
(rv0558)
N-acetylglucosamine-6- Essential amino sugal M-methylhydroxyphos-
phosphate (GlcN6P) for Cell wall phenyl-Dglucosamine-6-
biosynthesis & glycolysis phosphate
betabolic pathways
Polyketide synthase(pks13) Mycolic acid synthesis Cerulenin, Thiopene
Acyl-AMP ligase (fadD32) Mycolic acid synthesis 4, 6-diaryl-5,7-dimethyl 
coumarin
Mycobacterial transmembrane Mycolic acid synthesis Adamantyl ureas, 
reporter protein (mmpL3)
ATP synthase/cytochrome bc1 ATP synthase Imidazopyridine 
complex (qcrB) amide (IPA), imidazo 
[1,2-a} pyridine, 
IPA compound Q203
2.6 Selected targets and their essentiality in the Mycobacterium tuberculosis Success
2.6.1 Mycobacterium tuberculosis N-acetylglucosamine-6-phosphate deacetylase, NagA
Mycobacteria species enciphers enzyme GlcNAc-6-phosphate deacetylase34 which play 
critical functions in the production of acetylglucosamine-6-phosphate (GlcNAc6P) sugar and 
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its flow within the cell wall to build cellular envelopes.34 NagA enzymes occur both in 
prokaryotic and eukaryotic, including the non- and mycobacteria.34, 39  Essentially, they are 
members of the amidohydrolase superfamily. 40,41 The enzyme possesses a characteristic 
active site consisting of triose-phosphate isomerase (TIM)-like barrel fold and metal ions that 
are very critical to the protein functions 34, 40 Moreover, NagA enzymes has similar structure 
domains I and II. The Domain I contains eight alpha/beta (β/α)8-barrel-like,34. and Domain II 
includes a small β-barrel with unknown biological function. However, a study by Ahangar et 
al. 2018, suggested that NagA enzyme Domain II confers stability.
The whole cell of mycobacteria comprises of four thick layers called an envelope, which 
suggest why the pathogens are resistant to acid/alkaline media 42. The cell wall of 
Mycobacterial is crucial for their survival and virulence 34. Embedded within the envelope are 
unique and diffused macromolecules. These include peptidoglycan, lipids, arabinogalactan, 
proteins, capsules of polysaccharides, and mycolic acids.43 The glucosamine-6-phosphate 
(GlcN6P) is isomerised to form glucosamine-1-phosphate, processed to produce 
peptidoglycan. Cell wall’s alteration is a potential therapeutic opportunity to terminate 
Mycobacterium tuberculosis or its homologs.
2.6.2 Mycobacterium tuberculosis demethylmenaquinone methyltransferase (menG)
MenG enzyme is a potential target that involves in the biosynthesis of menaquinone (MK) 
prokaryotes (such as Mtb) require for maintaining cell wall.44,35,45 Mycobacterium tuberculosis 
menG amino acids are conserved and common among its homologs.46 53 Demethylmenaquinone 
methyltransferase is a member of SAM-dependent methyltransferase (MTase) enzyme family, 
which have membrane domain and α/β/α fold pattern structure.47,48 The domain is a potential 
molecular target towards designing an effective drug against TB. Mtb menG encodes Rv0558, 
which catalyses menaquinone (or known as [MK9(H2)] production for respiration via the 
transfer of a C-methyl transfer from SAM structure.49 Thereafter the catalytic transfer, SAM 
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is reduced to S-Adenosyl homocysteine (SAH).48 The MenG protein is a Class I enzyme, 
which has at least two or more GXG motifs. One motif is found in the protein first β-sheet 
while the other motif is bound to a different β-sheet.50,51 Mycobacterium smegmatis menG 
comprises of about 234 amino acids and a GXG motif.52 Various classes of the 
methyltransferases are; Class I (Rossmann-like α/β), Class II (TIM α/β-α/β), etc.53 Class 
transferase enzymes have remarkable compatible primary structures of 10 % similarity.51
2.6.3 Mycobacterium tuberculosis Secreted Antigen protein (Ag85C)
The mycobacterial cell envelope contains different proteins responsible for the success of the 
microorganisms in pathogenesis, survival, and resistance to many drugs.54,34 Mtb antigen 
complex (Ag85A, Ag85B, and Ag85C) bind to the human fibronectin via heparin and 
cellular-binding domains or collagen-binding domain when it escapes the host immune 
system. Ag85 proteins are potential targets for treating drug-susceptible and drug-resistant 
TB because they catalyse mycolic acids’ attachment in the cell wall and biosynthesis pathway 
of TMM and TDM. Mycobacterium tuberculosis cell envelope comprises the mycolyl-
arabinogalactan-peptidoglycan. In other words, the macromolecules include mycolic acids, 
arabinogalactan (AG), and peptidoglycan (PG) (mAGP complex). PG is found outside the 
plasma membrane covalently linked to the AG. The mycolic acids are long-chain α-alkyl-β-
hydroxyl fatty acids (C70-90) that occupy about 60 % of the whole cell wall and are attached 
to the AG. Long fatty acids undergo an esterification process to produce trehalose 
derivatives. These include monomycolate (TMM) and dimycolate (TDM), which serve as 
donors in mycolic acid metabolism. Moreover, the mycolic acids are interspersed with non-
covalent glycolipids, proteins, and outer polysaccharide capsules.34 
Mtb antigen 85 enzymes are crucial in the attachment of mycolic acids to the cell wall and the 
synthesis of trehalose moieties. Besides, this protein involves the efflux mechanism, which 
may result in phenotypic resistance. The enzymes share common structural and functional 
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similarities, such as mycolic acid donor TMM and 68-79 % conserved catalytic site sequence 
identity. Additionally, they have serine mycolyl esterase activity, carboxylesterase consensus 
sequence (GXSXG), among others.55 Therefore, a single removal of one of the enzymes 
affects the complex containing the three proteins. Precisely, the alteration of the fbpC2 gene 
result in a 40 % reduction in the AG-attached mycolic acids, and the reductive impact on 
either fbpA or fbpB genes leads to TDM reduction, which indicates low functional activity 56, 
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CHAPTER 3
3 Analysis of Biomolecular Structures and Therapeutic Targeting: Applications of 
Computational drug design and Molecular Modelling Analysis  
3.1 Computational drug design and Molecular modelling 
Computational chemistry (CC) is a field of Theoretical chemistry that has been very useful in 
molecular drug design,65 and it focuses on finding solutions to chemical-related issues using 
computers. 66, 67, 68, 69 CC involves obtaining relevance of results to chemical problems and not 
directly developing theoretical methods. Simply put, CC allows the dynamics and motions, 
structure characterisation, and energetics of protein-ligand interactions, thus provide crucial 
application in drug design research. The incorporation of computational chemistry can unfold 
new and challenging issues to be solved during the search for lasting solutions.70, 71 The 
standard CC protocols used in CC are Quantum mechanics and molecular dynamics.72 The 
former method is used to study molecules’ chemistry at the electronic level, while the latter 
used physics’ classical laws without considering explicit electrons. The drug discovery 
process is quite complex, requiring interdisciplinary efforts to design effective and 
marketable plausible drugs.67 The drug designing provides an avenue to search for chemical 
entities that can bind to a protein target cavity or active site geometrically and chemically. 
Cellular receptors serve as the mediators of several functions of the organism since they 
involve in the mechanism of physiology and disease.69 A specific target disease can be 
modulated with an outcome lead compound that affects a protein’s function.69 The chemical 
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structures of leads can be modified to improve efficacy, reduce side effect, and improve 
selectivity based on the findings from receptor-ligand interaction. 
Computational drug discovery has proved to be an effective strategy to accelerate and 
economise drug design/development processes.73 Computer-aided techniques for drug design 
(CADD) is a modern rational design technology that facilitate researching the discovery of 
new drugs based on the knowledge of target structures’.74 Conventional drug design methods 
include a random screening of chemical compounds found in nature or laboratory-based 
synthesised. The CADD techniques’ ability to overcome traditional methods’ shortcomings 
has accounted for its tremendous progress in the last years.75, 73 The CADD application can 
make drug discovery more cost-effective by comparing the predicted and actual drug activity 
findings using the experimental data.67, 69 Iteratively, this result provides clues to improve the 
properties of a chemical compound. Moreover, CADD techniques complements and enhances 
the efficiency of the drug discovery process and the technique.68
CADD techniques incorporate both structure-based accurate model, where protein structures 
are required, and ligand-based exact model, which ligand activities to design compounds 
interacting with the protein structure.73 Structure-based drug design approaches include 
docking, pharmacophore modelling, de novo design and fragment-based drug design. 
Moreover, CADD methods combine computational chemistry applications with molecular 
modelling, which have been developed into techniques like molecular modelling (MD) 
simulations, free binding energy, which were applied in this study to achieve some of the 
objectives and the overall goal. Figure 3.1 highlights various computational approaches in 
drug design. CADD strategy can be classified into conformational modelling, property 
modelling and molecular drug design. Conformational modelling is defined as the study of 
the complexes of macromolecules and small molecules. The property modelling molecular 
drug design involves studying and optimising the biological, chemical, and physical 
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properties. This chapter discusses the applicable scope of computational and theoretical tools 
in this study.
Figure 3.1. Computational approaches in drug design
Specifically, in drug design, molecular modelling allows scientists to use computers to 
visualise molecules, representing numerical molecular structures and describes all theoretical 
methods, including computational methods to simulate the biosystems and attributes of 
biochemical and chemical molecules. Computational drug design models can also be used for 
repositioning or repurposing and combination therapy design.76, Figure 3.2. illustrates the 
basic molecular modelling strategies. Therefore, the computational drug design approaches 
are specially prioritised and outstanding features and applications in de novo designing.
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Figure 3.2. Basic molecular modelling strategies
3.2 Quantum mechanics and Schrodinger equation: Applications in drug design
Quantum mechanics (QM) involves calculating molecular orbital and offers the most detailed 
description of a molecule’s chemical behaviours. The application of QM protein-drug 
interactions in empirical methods cannot be overplayed even though it provides limited 
applications. QM method considers molecules as collections of nuclei and electrons without 
referring to chemical bonds, detailing the understanding of system behaviour at the atomic 
level. The laws of quantum mechanics are applied in QM methods to solve the equations of 
Schrodinger and approximate wave function. The Schrodinger equation is fundamental to 
Physics and involves an analytical description of a quantum mechanical characteristic within 
a system.77
 An Austrian physicist, Ervin Schrodinger, introduced the equation in 1926.78 The 
Schrodinger equation’s role is synonymous with Hamilton’s laws of motion in mathematical 
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physics; non-relativistic of quantum and classical mechanics.79 Schrodinger equation is either 
dependent or independent of time.80 The time-independent Schrodinger equation is mostly 
used when solving computational chemistry problems. It expresses Hamiltonian operator as 
the potential energy that accumulate and kinetic energy.80 Mathematical, simplest form of the 
equation is presented as:
Hψ = Eψ …………………………………. Eqn. 3.1
H is the Hamiltonian. H = kinetic energy (T) plus potential energy (V), 
H = T + V,
wave function, ψ, advances the electron possibility in the nucleus within certain regions. 
The E term is the system energy, y, given in the following H term relation 
 …………………. Eqn. 3.2
1st term = the operative of the electron kinetic energy,
2nd term = the nuclei operator energy due to movement
Electron-nuclei attractions operator potential energy is the 3rd term, 
Operator for electron-electron repulsions potential energy is estimated as the 4th term
Last term, operator for nuclei-nuclei repulsion potential energy, is equal to 5th term.
Schrodinger expression is very complex; hence it proves to be an in-executable solving 
molecular system, thus limited to solve the molecular structure of H2.81 Approximation of the 
equation by Born-Oppenheimer implementation is a compensation for molecular structures 
rather than atomic structures.
Furthermore, some few methods in QM are density functional theory (DFT), semi-empirical 
based calculations, and ab initio techniques. MP2 and CCSDT are electron correlation 
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methods that present better accurate QM calculations.72 In contrast, the DFT calculations uses 
electron correlation approximation for analysis.72 These methods may be used to obtain 
molecular system properties including but not limited to dipole moments, molecular structure 
equilibrium, reaction free energy, and vibrational frequencies, experimentally.  
3.3 Born-Oppenheimer Approximations
Born-Oppenheimer approximation results in splitting the molecular Schrodinger equation 
into one part for the electronic wave function and the second part for the nuclear motions that 
resolve the vibration and rotation system.72 The essential element of the approximation is as 
follows:
….…… Eqn. 3.3
The application of the nuclear kinetic energy operator in eq. 3.3 to the electronic wave 
function equals zero. The instantaneous positions of the nuclei are required rather than how 
they are moving. Practically, the approximation is used by clamping the atomic nuclei of a 
molecule of interest. The Born-Oppenheimer approximation is one of the best chemical 
physics approximations because it has shown to be valid in most situations. 
Equation 3.4 presents the Schrodinger expression. It estimates the interactions of nuclei 
electrons in a fixed position that contained within the Software for in silico chemistry:
…………………………………. Eqn. 3.4
3.4 Potential Energy Surface (PES)
The interactions between molecules and atoms, depending on the particles’ forces, is a 
dynamic process. It is crucial to understand all the operating Forces within a chemical 
system; hence V (r) must be known. V (r) denotes the potential energy surface (PES) in a 
multi-dimensional complex system. Typically, the Potential energy surface (PES) is defined 
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within the Born Oppenheimer approximation. Electrons move faster than nuclei and adjust 
adiabatically to change the nuclear configuration because they are much lighter.82 The 
phenomenon of Born-Oppenheimer stimulates variation in the electrons’ position about the 
nuclei displacement, thus permitting the depiction of the potential energy surface. The 
potential energy of the surface exhibits electronic interaction regions unfavourable. Low 
energy areas serves as an nuclear reactions indicator to low energized molecular 
conformations and are accompanied by favourable electronic interactions.83 Generally, 
reactants and products structure are stable and have relatively small energy due to position 
that most times correlated with a reaction coordinates’ minima on the PES. 
Examples of the potential energy surface from the QM methods include ab initio MP2 and 
DFTB. These energy surfaces show much lower barriers and more moderate landscapes. The 
electronic energy as a function of the 3N-6 internal nuclear degrees of freedom defines the 
potential energy surface (PES), which is very complicated and can have many minima and 
saddle points. 
3.5 The Molecular Mechanics (MM)
Molecular mechanics (MM) is often used in large systems to calculate molecular structures 
and relative potential energies of molecular conformations or atomic arrangements.84 MM is a 
computational method that computes the Potential energy surface for a particular sequence of 
atoms using Potential functions derived from classical physics. The system electrons are not 
explicitly considered, but every atom in the nucleus and the associated electrons is treated as 
a single particle. The Born-Oppenheimer approximation basis states that electronic and 
nuclear motions can be separated (uncouple)from each other is considered a justifiable reason 
for excluding electrons in MM. The difference in the energy between the system 
conformations during calculation is significant against the absolute potential energy values. 
70
Molecular mechanics is an empirical method that relies on the force field parameters 
comprising a range of experimental data.85
Molecular mechanics is viewed as ball and spring atomic and model of molecule possessing 
classical Forces between the atoms and molecules. The Forces are obtained from the potential 
energy functions relating to the structures, including torsional angles, bond length, bond 
angles, etc. The energy contains designed parameters to reproduce exponential properties. 
Overall potential energy of a molecule, which expresses the MM, is described as the sum of 
bond-stretching energy (Estr), bond angle-bending energy (Ebend), torsion energy (Etor) or 
twisting energy, and energy of interactions among the unbound atoms (Enb). The energy 
contribution by the non-bonding particles is obtained from the van der Waals and 
electrostatic interactions and mathematically stated as follow:
Etot = Estr + Ebend + Etor + EvdW + Eelec ……………………………. Eqn. 3.5
……………………… Eqn. 3.6
Etot is the potential energy, EvdW is the energy contributions from van der Waal’s unbound 
atoms. Eelec is the energy given by the electrostatic interactions of the non-chemically bonded 
atoms.
3.6 Force fields
A force field can be defined to contain a set of functions and constants, known as parameters, 
which can be applied to correlate the system’s energy following its particles.86 Force field 
(FF) is the heart of any MD scheme and is used to describe the atomistic interactions 
analytically.87 The molecular movement is governed by the atomic forces that can be divided 
into:
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1. Those caused by interactions between atoms that are chemically
2.  Those caused by interactions between atoms that are not bonded.
Etotal = Ebonded + Enonbonded ………………………………. Eqn. 3.7.
Ebonded = Ebond + Eangle + Edihedral ………………………… Eqn.3.8
Enonbonded = Eelectrostastic + Evan der Waals ……………………. Eqn. 3.9
FF presents a system’s potential energy surface represented by a closed set of analytical 
potential energy functions. Moreover, the force fields’ kinetic energy is also necessary; thus, 
the system moves across the potential energy surface’s energy barriers. The implication is 
that the system experiences substantial changes such as conformational changes during the 
simulations. Provided the potential energy function can mimic the forces experienced by the 
‘real’ atoms, the simulation results will be realistic. Equation 3.10 presents an example used 
to approximate the atomic forces that govern molecular movement. 
..……… Eqn. 3.10
Typically, chemical bonds and atomic angles are modelled in a typical, using simple springs 
(quadratic energy functions) that do not allow bond breaking. Dihedral angles are modelled 
using a sinusoidal function that approximate the energy differences between eclipsed and 
staggered conformations. 
Examples of popular Force fields include GROMACS, GROMOS, AMBER, NAMD, 
LAMMPS, and CHARMM. They can be parametrised for atoms or biomolecules in 
simulation. In force fields, parameters are generated by ab initio method derivation or semi-
empirical mechanical quantity calculations. The parameters could be experimental data 
sourced, e.g. X-rays, electron diffraction, NMR, and spectroscopy of neutrons..86 There are 
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unique weaknesses and strengths associated with individual force field relative to the data, 
which allow a specific problem to be solved. Moderate low computational cost and accurate 
prediction protocols are incorporated in the application of force fields. Thus, force fields are 
attractive in molecular dynamics simulations and molecular mechanics calculations. 
Although there is a wide range of force fields applicable to any system, one must choose how 
cautiously every force field contains unique parameters designed for a specific molecule. 
Therefore, choosing the correct force field is critical to achieving the study systems’ 
theoretical structure-function’s accuracy and applicability. Force fields cannot be used for 
bond breaking or formation calculations.88 The AMBER force field was used in this study by 
applying the GENERAL AMBER FORCE FIELD (GAFF) parameters incorporated with the 
standard AMBER (14SB) force field89 for the proteins.
3.7 Molecular dynamics
Molecular dynamics (MD) is a form of computer simulation in which atoms and molecules 
can interact for some time.90 Simply, MD is the process of giving movement to proteins 
internally, which is produced by increasing the system’s temperatures and cooling them 
rapidly in a concise time scale.91 It is impossible to find the properties of complex systems 
analytically because molecular systems generally consist of a vast number of particles; MD 
simulation circumvents this problem by using numerical methods92. MD represents an 
interface between laboratory experiments and theory, which can be understood as a “virtual 
experiment”. 
Proteins are considered dynamic when in solutions,93, and challenging to investigate their 
behaviour, structural flexibility, and motions in solution. The structure of small proteins can 
be solved and unravelled using the conventional techniques of x-ray crystallography 
techniques. The methods require strict periodic boundary conditions, which are very difficult 
73
to obtain in non-crystalline structures.93 Molecular dynamics simulations can predict a 
protein’s state in solution and report the outputs as the trajectory states.94 The MD simulation 
predicts the movement of large proteins in the solution, which is not possible in X-ray. MD 
method simulates the exact condition of a protein’s existence and the output structures after 
MD is regarded as the best energy minimised and geometrically optimised. For this reason, 
the MD structure outputs are used in various experiments such as NMR, docking, and 
protein-ligand interactions.95
If the initial geometry of a system is derived from experimental data (X-ray or NMR 
structures), MD techniques can be used to sample the conformational space. The force and 
energy of all the particles within the system must be determined to set up an MD simulation 
protein system. MD incorporates the application of Newton’s equation of motion for atoms 
on the energy surface. The goal of using MD is explicitly to integrate the use of Newton’s 
equations to decipher and gain a fundamental understanding of the energies and structural 
deviation that may occur with a molecular network system. Nevertheless, initial states of the 
particles are needed. These include:
1 the position and velocity of each particle within the molecular network system,
2 a formidable force field to differentiate the forces between atoms, e.g. AMBER or 
CHARMM or GROMACS,
3 boundary conditions must be specified
4 The classical equation of motion can therefore be solved
…………………………………………. Eqn. 3.11
Terms denotation:
Ri (t) represents the particle position vector
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T denoted the time-evolution,
M represents the mass of the particles
Fi implies the interacting force on the particles
The use of MD can be structured into four ongoing technical steps that are continuously 
processed to generate a trajectory. The four technical steps include:
1. the fundamental requirements (states) of the biomolecular system are defined:
a. the coordinates of each atom within the MD system
b.  the bond characteristics present between each atom
c. the acceleration of each atom
2.  The potential energy of each atom must be computed.
3. The equation of motion may be solved, integrating the potential energies extracted 
from step 2.
4. The cycle will proceed to step 1 once the new “state” of the system is saved and 
coordinated by each atom is changed. 
The quantitative analysis will be performed on the system’s time-evolution after the 
trajectory has been completed.
3.8 Post Molecular dynamics analysis
The outputs (trajectories) of the molecular dynamic simulation are obtained directly from the 
production run. The MD simulations trajectories could be outlined as successive snapshots 
defined by each atom’s coordinate and velocity within the system simulated with time 
progression in phase space.84 Essentially, it is necessary to consider the following when 
choosing a software to perform molecular dynamics analysis:
1. high qualitative visualisation properties; it enables accurate depiction of the 
trajectory’s video clips and generation of high-quality snapshots/images
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2. such software must be able to withhold and process large data volumes efficiently
3. contains a range of analytical tools that easily accessible within one program
The chosen post-MD analysis techniques must be directly dependent on the nature of the MD 
study. Detailed analysis remains critical to support any visualisation, even though the 
qualitative evaluation of data is essential. The following reasons detailed the need for the 
post-MD analysis of the trajectories:
1 determine the energetic and stability of conformation of the simulated system
2 calculate the thermodynamic energy fluctuations along the assembled system’s 
trajectory
3 determine and characterise the binding landscape of small molecules
4 presentation of the dynamic conformational changes and variability that may occur 
within the bio-system throughout the MD trajectory. i
3.9 Stability of Simulated systems
3.9.1 System convergence (Stability)
Convergence of a system in molecular dynamics is commonly used to describe a protein 
structure’s stability considering the bond types and vibration of bond angle during the 
system’s structural motion.96 A simulated system must represent a state of equilibrium to 
analyse a molecular dynamics trajectory accurately, which indicates energetic states and 
conformational plateau.97 Thence, this plateau may be directly linked to a protein-ligand 
system’s energetically stable conformations.
3.9.2 Root mean square deviations (RMSD)
The structural variation of systems such as protein-protein, protein-ligand can be obtained by 
the spatial differentiation between two static structures of the same trajectory.98 This 
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(deviation measurement) is known as C-α atoms RSMD of an MD trajectory and can be 
calculated  
…………………………………………Eqn. 3.12
Terms denotation equation: 
N denotes the number of atoms in a protein-ligand complex
Ri indicates the vector position of the C-α atoms of particle i
i is the conformation reference calculated after aligning the structure to an initial 
conformation (O) using the least square fitting protocol.
The average RMSD of a protein complex is the average structural deviation over each 
trajectory’s number of frames. It can be calculated for simulated systems, including ligand, 
receptor, and complex.11
3.9.3 Radius of gyration (RoG)
The radius gyration of protein-ligand complex measures the Root Mean Square distance of 
the atoms from their common gravity centre.99, 100 The C-α atom RoG estimates the 
compactness of the protein complex along a trajectory. The radius of gyration of the complex 
can be mathematically expressed from the following expression: 
………………………………. Eqn. 3.13
Terms denotation in the expression are defined below:
 ri: = position of the ith atom, W = mass/weight of each particle, and r = centre mass of atom i. 
The mean value is calculated by estimating the C-α atoms RoG values over the frames 
number.
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3.10 Conformational features of protein-drug systems
3.10.1 Root mean square fluctuations (RMSF)
The Root Mean Square fluctuation (RMSF) of a protein estimates the C-α atom fluctuations 
based on the average protein structure along the system’s trajectory.101 It further hypothesises 
the flexibility of a protein’s region based on computed RMSF.102 Standardised RMSF values 
are calculated using the following mathematical expression:
………………………………… Eqn. 3.14
Terms denotations:
RMSFi denotes RMSF of the ith residue from which the average RMSF is subtracted, divided 
by the RMSF’s standard deviation [σ(RMSF)] to yield the resultant standardised RMSF 
s(RMSFi)].
RMSF is a post-MD analysis different from the RMSD and RoG methods because it 
computes the total residue fluctuation along the trajectory instead of analysing every frame in 
the output trajectories.
3.11 Thermodynamics calculations
In computational chemistry, thermodynamics validates a profound understanding of chemical 
reactions, calculation of molecular properties and their derivatives, and enables the 
predictions of the chemical reactivities.103 The essential usefulness of thermodynamics 
calculations is detailed because of its present contribution to quantum mechanics. The 
application of thermodynamics in drug design and development in both academic and 
commercial has continued to increase.104 A critical aspect of drug design and development is 
optimising interactions of molecules between a drug agent and its binding target. The 
characterisation of the complex’s binding affinity provides information about the balance of 
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energetic forces that drive the binding interactions.104 This (thermodynamics) is critical for 
optimising molecular interactions.
 Measurement of binding by the thermodynamic method is envisaged to provide useful 
insights regarding the nature and balance of drug-target interactive behaviour. Some binding 
interactions may be significantly more accessible in rational drug design, while some can be 
extremely difficult. The crucial parameter used to describe the molecular interactions 
between two bound partners such as protein-ligand and protein-protein systems is the free 
energy, ΔG, where the magnitude and the sign represent the possibility of biomolecular 
interactions.
3.11.1 Binding free energy calculations
Generally, binding free energy calculations play a significant role in correlating the structure 
and function of proteins. It provides information about the mechanism of binding between a 
ligand and an enzyme by integrating enthalpy and entropy terms.105 The eventual aim of a 
structure-based drug design is a simple, robust process ranging from a high-resolution crystal 
structure to a validated biomolecular target. It reliably produces an easily synthesised, high-
affinity small molecule with desired pharmacological properties. The calculation of binding 
free energy steers in developing different algorithms and approaches, including 
thermodynamic integration, linear interaction energy, free energy perturbation, and molecular 
docking calculations.106, 107 There are large numbers of methods for computing binding free 
energies with atomistic molecular models. However, most of them are still under active 
study, and each of them has different trade-offs between accuracy and computational 
efficiency. 
Two commonly used methods for calculating the binding energy between a small ligand and 
a biological macromolecule include the Molecular Mechanics/Poisson-Boltzmann Surface 
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Area (MM-PBSA) the Molecular Mechanics/Generalised Born Surface Area (MM-GBSA) 
approaches.108, 109 The duo method depends on MD simulations of the complex systems to 
compute painstaking statistical-mechanical binding free energy within a specified force 
field.110 MM-PBSA and MM-GBSA exhibit favourable use, while each of them displays keen 
accuracy and computational effort between empirical scoring and rigorous alchemical 
perturbation methods. The MM-PBSA is more stringent than the MM-GBSA and 
subsequently substitutes the latter approach in water.111 But for the calculations involving 
protein-drug interaction, including nucleic acids and carbohydrates,112 MM-GBSA method is 
the preferred.113 
MM-PBSA and MM-GBSA methods 
This (MM-PBSA) is the end-point free energy calculation method molecular mechanics with 
Poisson-Boltzmann and surface area (MM-PBSA).105 It is a compromise between speed and 
accuracy for physics-based estimates of protein-ligand binding affinities. The method 
requires direct simulations of the bound and unbound states, being an end-point method. The 
simplification is based on the expectation of significantly larger intrinsic errors with MM-
PBSA than other rigorous methods.114 The application of binding free energy calculation may 
enhance virtual screening and molecular docking of therapeutic drugs.115 The binding free 
energy between the receptor and ligand is given by:116
ΔGbind = ΔGcomplex – ΔGreceptor – ΔGligand ………………………. Eqn. 3.15 
ΔGbind = Egas + Gsol – TΔS …………….……………………… Eqn. 3.16
Egas = Eint + Evdw + Eele ………………………………………. Eqn. 3.17
Gsol = GGB + GSA ……………………………………………… Eqn. 3.18
GSA = γSASA …………………………………………………. Eqn. 3.19
80
Where ΔEgas denotes the molecular mechanical energy of the system in a vacuum,
ΔGGB denotes the solvation free energy, TΔS denotes the entropy term, 
ΔEint is the sum of bonded internal energy, ΔEvdW represents the non-bonded van der Waals, 
ΔEelec is electrostatic energy. 
Note that ΔGGB consists of polar contributions that are accounted for by the generalised Born 
model and ΔG SA denotes non-polar contribution.108
The dynamics analysis of binding affinity helps to determine the approximate inhibitory 
activity of each inhibitor.114
3.12 Principal Component Analysis (PCA)
The principal component analysis (PCA) is a technique that helps to understand the dynamic 
behaviour of biological systems.117 PCA describes the atomic displacement and identifies 
conformation changes by removing various conformational modes of the protein complex 
during the MD simulation.118 This (PCA) analysis defines the eigenvectors, the direction of 
motion and the eigenvalues, magnitude for protein systems and are carried out by 
constructing a covariance matrix of the C-α atom displacements.11 Before the principal 
component analysis, the counterions (Na+) and solvent molecules from the MD trajectories 
are stripped.119 After that, PCA will be performed on all the C-α backbone atoms, and average 
the data over several snapshots taken at a specified time (ps or ns) intervals using the 
CPPTRAJ module in AMBER 14 or any other simulation code to generate principal 
components. The first two principal components (PC1 and PC2) are often considered, which 
corresponds to the matrix’s first two eigenvectors. The trajectories are presented as scatter 
plots generated using the Origin Software or other visual molecular dynamics Software. Here, 
Origin was used to create and analyse the plotted data.
3.13 Solvent Accessible Surface Area (SASA)
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Solvent accessible surface area, often referred to as SASA, is an analysis used to measure a 
protein’s exposure with solvent (water in most cases). In general, amino acid residues located 
on a protein’s surface serve as active sites to interact with molecules and ligands. The 
accessibility of solvent plays a vital role in the structure and function of biological 
macromolecules. Essentially, SASA provides insight into the level of exposure of the protein 
residues buried in the active site to contribute to the hydrophobic stabilisation of a protein.120 
The hydrophobic effect is the driving for in protein folding wherein hydrophobic residues 
drift away from water into the solvent-shielded hydrophobic core. Protein folding occurred 
when a polypeptide changes from an unfolded state to its native state. When proteins 
transitioned from an unfolded state to their native state (folded), SASA is lost between the 
two states.121 The calculation SASA for the unfolded protein is more complicated. Muller and 
colleagues (1987) developed the SASA calculation method to calculate SASA for polar, non-
polar and total molecular surfaces. SASA can be used to calculate the solvent accessibility of 
molecules from their 3D structure and predict the accessibility of amino acid sequence using 
the computational procedure. SASA may also be used to identify the active site residues, 
binding sites in DNA binding proteins and functionally essential residues in membranes 
proteins. In this study, SASA was used with the computational procedure, AMBER14 
CPPTRAJ module.122 The trajectories are presented as line plots using the Origin Software or 
other visual molecular dynamics Software. Here, Origin was used to generate and analyse the 
plotted results.
3.14 Define Secondary Structure of Protein (DSSP)
Define Secondary Structure of Proteins is the standard tool for explicating secondary 
elements, including alpha helices, beta sheets, and coils from protein structures.123 The 
secondary protein structures of result from the formation of hydrogen bonds formed between 
atoms of the polypeptide backbones. DSSP is based primarily on hydrogen bonding patterns 
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and some geometric constraints and assigns every residue to one of eight possible states. The 
corresponding forms of helical structures are α-, 310-, and π-helices. The typical secondary 
structure is the beta-pleated sheet. The β-bridges are short fragments that display β-sheets 
such as binding patterns. The β-ladder is formed from the multiple consultive β-bridges 
formed from the state. DSSP does not have a separate state for β-sheet residues, and the one 
for β-ladders can be used. The remaining three states are turn, bend, and others describe the 
loop structures. DSSP was used with the computational procedure, AMBER14 CPPTRAJ 
module.122 The method allows a database of secondary structure assignments (DSSP) to be 
carried out to study the secondary structure elements. The trajectories are obtained at various 
time interval and presented as plots using the Origin Software as visual molecular dynamics 
Software. Here, Origin was used to generate and analyse the plotted results.
3.15 Dynamic cross-correlation matrices (DCCM)
Dynamic cross-correlation matrices (DCCMs) are one of the useful post MD analysis that 
aids in understanding correlated motions of residual-based fluctuations throughout a 
simulation. DCCM analysis is a 3D representation that graphically illustrates the time-
correlated information among the protein systems’ residues.91, 124 Residue-based time-
correlated data can be analysed using visual pattern recognition.91, 124 This analysis (DCCM) is 
taken to depict the cross-correlated displacements of backbone C-α atoms in the trajectories 
using the following equation:
……………….……………. Eqn. 3.21
Terms definitions:
Cy = correlation coefficient, i = ith residues, j = jth residue, where ith and jth are corresponding 
displacement vectors, respectively. Also, Δri and Δrj denote the displacement of ith and jth 
atom from the mean, respectively. The cross-correlation coefficient, Cy, scales from -1 to +1. 
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The upper and lower limits correspond to a fully correlated (+1) and anti-correlated (-1) 
motion throughout the MD simulation. Like other post MD analyses, DCCM analysis can be 
executed using the CPPTRJ module of AMBER14 or AMBER18. Again, the Origin visual 
Software is used to generate and analyse the matrices.
3.16 Other Drug design techniques applied in the Study
3.16.1 Molecular docking
Molecular docking is one of the most employing computational tools nowadays. It involves 
determining the most optimal position of two molecules to each other. Molecular docking 
finds its application in the structured-based drug and has been reported as partly the main 
contributing factor to solving many global optimisation problems.125 The molecular 
recognition of the lock and key mechanism existing between a ligand and a receptor 
determines their dynamical interaction level.126 In bio-computational and drug design, 
docking is mainly defined as the positioning of a small molecule (e.g. an inhibitor or 
chemotype) called a ligand into the active site of biological molecules of a known structural 
conformation.127 Successful prediction of a target protein binding site or cavity for small 
molecules is crucial in structure-based drug design because it allows the screening of virtual 
libraries128 of “drug-like” molecules. The binding energy of the ligand-receptor complex is 
calculated129 as follows:
Ebinding = Etarget + Eligand + Etarget-ligand …………………………… Eqn. 3.22
There are many molecular docking programs available for academic and commercial 
purposes. Examples of the Softwares include FlexX, AutoDock GOLD, GLIDE Ligand 
docking, and SurfflexV. Every docking program displays sufficient precision to the other, but 
the Autodock-Tool generates two-order of magnitude compared with the other Tools. 
Autodock-Tool is substantially accurate in its binding mode predictions.130 The docking 
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method employed in this study is the advanced version of AutoDock Vina.131 The principle is 
based on neglecting the presence of proton of the enzyme and inhibitors while generating the 
binding affinity. Thus, the scores are often said to be unreliable. However, the molecular 
dynamics do consider the protons and the solvent (water in most case). Therefore, the MD 
score for the binding affinity is more accurate than the docking methods.
3.16.2 Homology modelling
The prioritise aim of drug discovery is orchestrating bioactive molecules intended to target a 
disease condition with minimal side effects and significant efficacy.132 The crystal structure of 
a pathogen’s protein is fundamental in drug design/development for the productive outcome, 
especially amid newly evolving infection.133 Some of the techniques used to make biological 
molecules’ structures include electron spectroscopy, NMR spectroscopy, and X-ray 
crystallography. However, these (experiment-based) techniques have multiple 
shortcomings;134, for instance, high-cost increments, considerable experimental time, among 
others, are associated with X-ray crystal structures of high-resolution 3D-structural 
properties.134 Homology modelling (HM) is an emerging technique gaining prominent and 
preferential applications to construct 3D macromolecular structures.
In comparison to the other methods, homology modelling is easy and accurate. HM uses a 
protein sequence whose crystal structure is a reference template to construct the protein 
structure.132 Homology model accuracy depends on the availability, detection, and quality of 
known template structures. Homology modelling does not consume time, cheap to use; many 
HM studies can be obtained within a short time. A 3D model of a target protein may enable 
complete characterisation and exhibition of the mechanism of interaction on a protein-ligand 
complex structural and molecular level, elucidating the mode of action (MOA) of drug 
molecules and thus facilitate drug design.
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The global increase in the morbidity/mortality rate of Mycobacterial infections, 
predominantly renascent tuberculosis, leprosy, and Buruli ulcers have become worrisome 
over the years. More challenging is the incidence of resistance mediated by mutant 
Mycobacterium strains against front-line antitubercular drugs. Homologous to all 
Mycobacteria species is the GlcNAc-6-phosphate deacetylase (NagA), which catalyses 
essential amino sugars synthesis required for cell wall architecture, hence, metamorphosing 
into an important pharmacological target for curtailing virulence and drug-resistance. This 
study used integrated bioinformatics methods, MD simulations, and DynaMut and PolyPhen2 
to; explore unique features, monitor dynamics, and analyze the functional impact of non-
synonymous single-nucleotide polymorphisms of the six NagA of most ruinous 
Mycobacterium species; tuberculosis (Mtb), smegmatis (MS), marinum (MM), ulcerans, 
africanum, and microti respectively. This approach is essential for multi-targeting and could 
result in the identification of potential polypharmacological antitubercular compounds. 
Comparative sequential analyses revealed ≤ 50% of the overall structure, including the 
catalytic Asp267 and reactive Cys131, remained conserved.
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Interestingly, MS-NagA and MM-NagA possess unique hydrophobic isoleucine (Ile) residues 
at their active sites in contrast to leucine (Leu) found in other variants. More so, unique to the 
active sites of the NagA is a 'subunit loop' that covers the protein active site; probably crucial 
in binding (entry and exit) mechanisms of targeted NagA inhibitors. Relatively, nsSNP 
mutations exerted a destabilizing effect on the native NagA conformation. Structural and 
dynamical insights provided, basically pin-pointed the "Achilles’ heel” explorable for the 
rational drug design of target-specific ‘NagA’ inhibitors potent against a wide range of 
mycobacterial diseases.
Keywords: Mycobacterial infections, peptidoglycan, bioinformatics tools, Molecular 
dynamics (MD) simulations, GlcNAc-6-phosphate deacetylase protein, , mutation
4.3 Introduction
Mycobacteria species were discovered over a century ago and include; the non-pathogenic  1, 
pathogenic (tuberculosis), and opportunistic pathogens (non-tuberculosis) 2. Examples of 
pathogenic Mycobacterium species include; Mycobacterium tuberculosis (Mtb) that causes 
tuberculosis (TB) (the most-deadly disease) 3 and Mycobacterium ulcerans (MU) that causes 
chronic-necrotizing Buruli ulcer. 4. Similarly, Opportunistic Mycobacteria such as 
Mycobacterium marinum (MM) and Mycobacterium avium complex (MAC) cause cutaneous 
diseases involving plastic surgery 5. Mycobacterium smegmatis, a non-pathogenic agent, 
causes granuloma. They destroy the human immune system and activate phagocytes-causing 
a respiratory tract or cutaneous disease 5. About 20 Mycobacteria species cause different 
kinds of conditions in humans, but more than 140 of them are recognized [4,7]. Majority of 
them are environmental opportunistic pathogens that exist as saprophytes in soil and water 6. 
Table 4.1 summarizes the human clinical mycobacterial infections and their respective 
causative agent 7. 
Table 4.1 Mycobacterial clinical diseases in humans and their causative mycobacterial species
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Disease Agent
Lymphadenopathy M. avium complex, M scrofulaceum
Skin lesion: Post-trauma abscess, M. chelonae, M. fortuitum, M. ulcerans
Swimming pool granuloma, M. terrae, M. Marinum
Buruli ulcer
Pulmonary disease M. kansasii, M. xenopi, M. avium complex, 
M. tuberculosis
Disseminated disease: AIDS-related, M. avium complex, M.genelonae, M. chelonae
Non-AIDS related
Mycobacterial infections have been a burden to almost every country in the world 8. Despite 
the decades of “war” combating these pathogens, a greater commitment is still required to 
eliminate the menace of the infections. Specifically in 2018, the World Health Organization 
(WHO) again reiterated the estimate of TB to be; 10.0 million people had the infection of 
which 5.8 million were men, 3.2 million were women, and children being the remaining 
people 9. TB may co-infect with either HIV/AIDS or chronic pulmonary diseases in human, 10, 
11 hence, results in a quicker death of the TB patients. The new cases of MDR and XDR 
tuberculosis complicate the impending status of mycobacterial infections.12 Although the TB 
incidence is falling by 2% annually, about 558 000 new cases of TB (known as active TB, 
multidrug- or extensive drug-resistant TB (MDR/XDR) occur annually in countries including 
China, India, and South Africa 13. Almost one-quarter of MDR-TB cases cause resistance to at 
least a first-line drug including Isoniazid, rifampicin, streptomycin, and ethambutol 14. More 
challenging is the increasing MDR/XDR mediated by mutations to newer drugs like 
bedaquiline and delamanid, and these mutation-mediated resistances have subsequently 
remained incurable. Thus, TB remains a public health crisis and health security threat 15,16. 
Therefore, the TB morbidity and mortality rate demands urgent medical treatment and 
preventative measures.
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Mycobacteria species encode a unique enzyme GlcNAc-6-phosphate deacetylase (Ahangar et 
al., 2018) that controls the synthesis and intracellular flow of N-acetylglucosamine-6-
phosphate (GlcNAc6P), an amino sugar used by bacteria to build cellular envelopes.17 NagA 
enzyme is abundant in nature and are found in eukaryotic and prokaryotic including; 
mycobacteria and non-mycobacteria organisms17, 18 and are a member of amidohydrolase 
superfamily 19, 20. The enzyme possesses a characteristic triose-phosphate isomerase (TIM)-
like barrel fold and catalytic metal ions in the active region. 17, 19 All the characterized NagA 
enzymes comprise of two similar architectural domains (I and II); Domain I contains (β/α)8-
barrel structure, 17 while Domain II comprises of small β-barrel with unknown biological 
function. However, a study by Ahangar et al., (2018) suggested that Domain II enhances the 
stability of NagA enzyme.
The mycobacterial cell wall is made up of four thick layers, thus explaining bacteria’s 
resistance to acid or alkaline conditions altogether called envelope 4. The cell wall of 
Mycobacterial is crucial for their survival and virulence 17. The cell wall consists of distinct 
and interspersed constituents including; peptidoglycan, arabinogalactan, mycolic acids, lipids, 
polysaccharide capsules, and proteins 21. The mechanism of biosynthesis involves a 
nucleophilic attack of GlcNAc6P substrate via conserved aspartic acid residues by activating 
a water molecule to protonate amine the group 22. The glucosamine-6-phosphate (GlcN6P) is 
isomerized to form glucosamine-1-phosphate, processed to produce peptidoglycan (Figure. 
4.1). The alteration of Mycobacterial cell wall provides a therapeutic platform to inhibit 
pathogenic mycobacteria.
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Figure 4.1. Metabolic synthesis pathway of GlcN6P by Mycobacteria NagA enzyme
Bioinformatics techniques have contributed significantly to the study of proteins by 
promoting the correlation between proteins sequence analysis and the characterization of 
intrinsic disorders 23,24. These computational tools allow the investigation into the nature of 
protein disorders from large databases, including Ensemble and Swiss-Pro.25, 26 Additionally, 
the use of bioinformatics tools to analyze, simulate and extrapolate chemical information 
allows a reduction in time-consuming and of laboratory-based research and financial 
expenditure 27,28. We employed integrated bioinformatics methods to explore unique features 
pertinent to Mycobacteria NagA across six most detrimental Mycobacterium species; 
tuberculosis (Mtb), smegmatis (MS), marinum (MM), ulcerans, africanum, and microti. In 
addition, it provides a comparative analysis of the 3D homology models of six 
mycobacterium species NagA and the effect of the mutation on the protein, thus elucidating 
on the potential conserved drug binding sites. This information may be utilized in the 
identification of inhibitors that may target multiple pathogenic mycobacteria.
4.4 Methodology
4.4.1 Mycobacteria NagA amino acids sequence acquisition and homology modelling
Two X-ray crystal structures of Mycobacterium smegmatis NagA enzymes were retrieved 
from the RCSB PDB (accession ID: 6FV3 and 6FV4)17. The 6FV3 (Wild type) was used for 
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the MD simulations, and 6FV4 (mutant structure) was used for the mutation analysis. The 3D 
structures of the remaining five other Mycobacterium species NagA including tuberculosis, 
smegmatis, marinum, ulcerans, and microti were not available. Hence, the amino acid 
sequences of the enzymes were retrieved from the UniProt database (29, 
http://www.uniprot.org/) (Table 4.2). We performed the homology modeling using both the 
SWISS-MODEL (30, 31 online resource and the Modeller Software version 9.1 32, 33, add-on in 
UCSF Chimera tools version 1.13.1 34, in which the chain A of template (6FV3) was selected 
to build the model. Furthermore, multiple sequence alignment was done using the 
CLUSTALW server 35, 36 where the Chain A of Mycobacterium smegmatis (6FV3) was 
evidenced to have the best template with the amino acid sequences of the targets. 
Table 4.2 UniProt information of homologs of the five mycobacteria NagA enzymes.







Table 4.3 showed the criteria including sequence identity, sequence similarity, and Global 
Model Quality Estimate (GMQE) used for choosing the template and the quality (QMEAN Z 
Scores) of the models. The sequence identity (%) MANagA, MCNagA, MMNagA, MtbNAgA, 
and MUNagA models are 56.0, 56.0, 51.61, 56.0, and 51.34 and the sequence similarity are 
0.45, 0.45, 0.52, 0.45, and 0.43 respectively. GMQE value ranges between 0 and 1. The 
GMQE values of Mycobacterium species NagA; MANagA, MCNagA, MMNagA, MtbNAgA, 
and MUNagA models were 0.80, 0.80, 0.76, 0.80, and 0.46 respectively. The GMQE values 
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showed that the models are highly stable. To validate the models, the template and the 
models were uploaded on the Chimera Tool and superimposed.
Table 4.3 Summary of template criteria and Quality for choosing Homology models of 
Mycobacterium species NagA proteins
    NagA model      Template         Seq. (%) Seq. (%) QSQE    QMEAN     GMQE
             Identity Similarity
    MA-NagA         6FV3.1. A        56.00    0.45              0.44     -1.35         0.80
    MC-NagA         6FV3.1. A        56.00    0.45              0.44     -1.35         0.80
    MM-NagA        6FV3.1. A        51.61    0.52              0.44     -1.20         0.76
    Mtb-NagA        6FV3.1. A        56.00    0.45              0.44     -1.35         0.80
    MU-NagA        6FV3.1. A        51.34    0.43                0.51     -0.51           0.46
QSQE = Quartenary Structure Quality Estimate, QMEAN = scoring function (Z scores)
GMQE = Global Model Quality Estimate 
4.4.2 Sequence and structural analysis
Sequence alignments and structural investigations among the active site regions of the six (6) 
mycobacterial NagA enzymes were undertaken using the alignment tools available through 
Chimera, with default settings applied 25. The conserved regions across the 6 mycobacterial 
NagA were observed and classified as: fully conserved (identical), partially conserved and 
poorly conserved. The active sites were obtained from previous studies 17 and validated by 
identifying the residues interacting with the substrate (N-acetylglucosamine-6-phosphate-
GlcNAc6). This was completed using the UCSF Chimera visualization software. The other 
vital features of Mycobacterial NagA enzymes include a flexible loop, conserved Asp267, 
binucleate metal-centre, Cys131 residue, and NagA mutants especially D267A.
4.4.3 Molecular dynamics (MD) simulation 
MD simulation is one of the important tools for the theoretical study of molecular systems 
using time-dependent behaviour to provide detail information on the fluctuations, 
conformational flexibility, and thermodynamics of proteins or other biological systems. The 
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free structures of Mycobacterium species were prepared, by removal of the hydrogen atoms, 
using the UCSF Chimera software packages. The protein systems were set up for 350 ns MD 
simulations using the Graphic Processor Unit (GPU) version of Particle Mesh Ewald 
Molecular Dynamics (PMEMD) incorporated into the AMBER18 package 37. The AMBER 
force field was used to parametrize the protein systems and LEAP module was used to add 
hydrogen atoms and counter (Na+ and Cl-) ions to neutralize the systems. All systems were 
solvated in an orthorhombic TIP3P water box of a size of 10 Å. Two minimization steps were 
carried out; first is a partial minimization of 2500 steps using a weak restraint potential of 10 
kcal.mol-1 and second is a full minimization of 2500 steps without restraining the conjugate 
energy. The heating of systems occurred gradually from 0 to 300 K for 5 psec in a canonical 
ensemble (NVT), using harmonic restraint of 10 kcal.mol-1 Å and a Langevin thermostat with 
a 1-ps random collision frequency. Equilibration was carried out at a temperature (T) of 300 
K in NPT ensemble for 350 ns of a time step of 2 fs without any restraint using the 
Berendsen-Barostat was used to maintain the pressure of 1 bar. 
For each system, 350 ns MD simulations were conducted in an isothermal-isobaric (NPT) 
ensemble using Berendsen-Barostat at a pressure of 1 bar and a pressure-coupling constant of 
2 psec. The coordinates and trajectories of the apo structures were saved and analyzed using 
CPPTRAJ and PTRAJ modules of AMBER18 GPU. Subsequently, we determined the 
following post-analysis: root mean square deviation (RMSD) and root means square 
fluctuations (RMSF) for both the whole structure and the loop covering the active site. The 
visualization and graphics software such as Visual molecular dynamics was used to visualize 
trajectories; UCSF ChimeraTools and Maestro software were used to prepare the structures; 
and Origin software (OriginLab, Northampton, MA) were used for the plotting and 
generation of graphs.
4.5 Results and Discussion
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4.5.1 Unique characteristics of structural features of Mycobacteria NagA proteins
The sequence analysis of the static structure of Mycobacterium species NagA protein revealed 
some similarities in the domain region, loop, mutational impact, and the reactive CYS131 
residue. All the structures of NagA enzyme, including non-mycobacteria and mycobacteria 
have two overall common architectural domains 38,39. In this study, we modelled five 
mycobacteria tuberculosis NagA homologs as the targets and subsequently aligned the 
structures to the crystallized structure of MS-NagA enzyme. Figure 4.2 represents the two 
structural domains present in the Mycobacterium NagA protein. Of importance, the amino 
acid sequence of NagA enzymes showed more than 50 % conserved residues.
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Figure 4.2. Overall structure and sequence analysis of the 6 Mycobacteria of; smegmatis, 
tuberculosis, marinum, ulcerans, africanum, & microti. Blue colour represents domain I (residues: 52 
– 344), while the red colour represents domain II (1 – 51 & 345 – 382).
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4.5.2 Domain I
The domain is a twisted (β/α)8 - triosephosphate isomerase (TIM) located within 52-344 
residues which housed the ligand and the metal ion-binding sites. Figure 4.3 revealed 8 
folded alternating β-strands and 8 α-helices17. Generally, NagA proteins undergo dimeric 
interactions to form a homodimer between two monomeric subunits, and each monomer 
contains the active sites as seen in MS-NagA enzyme. The H-bonds are formed between 
residues on α8 and α9 while salt bridges are also formed between Glu230 and Arg251 and both 
confer stability to the structure.
Roles of α-helix and β-strand barrel structures of NagA
The α/β TIM-barrel protein structures occur in about 14 enzymes including/g Mycobacteria 
NagA enzymes. The Mycobacteria NagA TIM-barrel enzymes assume a circular geometry 
and did not deviate from the paradigm-layered structure of the residues in its interior. The 
assembly of α-helices and β-strands secondary structures of a protein is determined by the 
available low-energy conformations and packing of the residues. The first six β-sheets (β1 – 
β6) in domain I are approximately parallel, while the other two are parallel to each other. 
However, the extra helices and stranded sheets involve structurally in the stability of the 
enzyme. For instance, α9 forms an H-bond with α8 of the neighbouring subunit monomer to 
sustain the stability of the homodimer. The same α9 is also involved in the flexible loop 
formed from residues 203 – 223 and 248 – 258. 
The β-strands are characterized by hydrophobic residues and account for why they are found 
in the interior of the protein structure. The domain contains more β-strands than domain II 
though they are not alternating. We represented α-helices and extra β-strands in black colour.
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Figure 4.3. Illustration of the Secondary structure of Mycobacterium smegmatis NagA enzyme
Long flexible loop: In the overall structure of Mycobacteria NagA, this is a formation of a 
long flexible loop from residues 203–223 of one subunit that extends out to α9 of the 
neighbouring subunit residues 243–258. The loop provides additional stability for 
mycobacteria NagA protein and is loop is represented in green, as shown in Figure 4.4 (A). 
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Figure 4.4. A is the Illustration of three Mycobacteria NagA loops; short flexible loop (yellow), 
Long flexible loop (green) and surface-based loop (red). B is the ligand-binding sites (blue) 
and a short flexible loop covering the ligand site
Surface-based loop: This second loop is formed at the surface of NagA and comprises of 
amino acids between Met274 – Ser304. It forms a dynamic “lid” that may enhance the 
binding of substrate and ligand through an opening/closing mechanism. This loop is 
represented in red in Figure 4.4 (A) structure of the Mycobacteria NagA enzyme.
Short flexible loop: This is another structural loop and is called a flexible loop that is formed 
Glu122 to Pro136 at the dimeric interface of mycobacteria NagA enzymes. The loop is 
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represented in yellow (Figure 4.4A). As observed in Figure 4.4B, the loop hinders the binding 
of GlcNAc6P by blocking the active site of the ligand in Chain B 17. Hence, it showed the 
potential to cover any prospective inhibitor. Therefore, the occlusion provides deduction 
towards designing inhibitors that may prevent the synthesis of amino sugar and subsequently 
destroys mycobacterial cell wall synthesis. Figure 4.4B further reveals the binding of 
GlcNAc6P as shown in stick representation of Chain A. The ligand-binding site is shown in 
blue. 
4.5.3 Domain II
This domain (II) region comprises of residues 1 – 51 and 345 – 382 containing small β-barrel 
strands contributed from the N- and C- termini of NagA enzymes. Over the years, the 
biological functions of domain II have not been understood. However, Ahangar et al. 
suggested that the β-barrel domain has a stabilizing role in the enzyme’s structure. 
Structurally, Mycobacteria NagA enzyme β-barrel strands are conserved in mycobacteria 
NagA enzyme. Protein thermodynamics of folding is very important to protein study and is 
determined by protein stability and the hydrophobicity effect of the side-chain residues is the 
driving force 40.
However, the structural sequence analysis showed that while MSNagaA and MMNagA 
contain 381 and 385 residues, respectively, each of the other four NagA structures contain 
382 residues. Hence, the superimposition of the six NagA revealed a closer similarity 
between MSNagA and MMNagA structures while MANagA, MCNagA, MtbNagA, and 
MUNAgA were similar. In addition, the first 16 residues of MSNagA did not have 
corresponding residues in any of the modeled structures, though they are not within the 
binding sites. Second, a hydrophobic leucine (L304) present in MSNagA and MMNagA is 
important for the binding of the substrate. However, we observed a variation in which the 
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leucine was replaced with isoleucine (I302) in MANagA, MCNagA, MtbNagA, and MUNAgA 
proteins as observed in Figure 4.5. 
Furthermore, another variation observed in secondary structures of MSNagA when compared 
with other structures is the loops that were formed in MANagA, MCNagA, MtbNagA, and 
MUNAgA enzymes rather the helices found the template (MSNagA) structure. For instance, 
GLY278 and ARG281 residues constitute part of a long helix present in the MSNagA active 
site but were observed to form a loop in MANagA, MCNagA, MtbNagA, and MUNAgA 
enzymes. 
4.5.4 Sequence analysis of Mycobacteria NagA proteins 
Bioinformatics is a multidisciplinary research area 41 in which the computer is used to store, 
analyze, and interpret a large volume of biological information including; sequence analysis, 
protein structure prediction, comparative genomics, etc. 42, 43 Sequence alignment analysis has 
revealed great applications between the protein regulation and sequence properties. Figure 
4.5 is the sequence multiple alignments of MS-NagA (template) and the homologs; Mtb-
NagA, MM-NagA, MU-NagA, MA-NagA, and MC-NagA enzymes.
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Figure 4.5. Illustration of the active site regions and sequence analysis of Mycobacterial NagA 
enzyme; metal- (M1 & M2) binding sites residues are highlighted in blue and brown colour, whilst the 
ligand-binding site residues are shown in pink colour. The HXH motif residues are seen in M1-
binding site.
The region of maximum conserved residues is between Glu118 and Met214. There is a high 
similarity of NagA amino acid sequence of ≥ 45 % identical residues, 28.76 % less conserved, 
and 27.24 % poorly conserved protein residues among the six Mycobacteria NagA enzyme. 
The 3-D structures of NagA enzyme including those of Mycobacteria contain two active sites 
the metal-binding and the substrate-binding (GlcNAc6P) sites located within domain I 17 and 
provided in Table 4.4. 
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Table 4.4. Mycobacteria NagA active sites consisting of; M1 (Zn), M2 (Zn/Cd), and GlcNAc6P
Substrate Binding Site Residue
Metal M1 HIS-56, HIS-58, GLU-122, ASP-267       
Metal M2 GLU-122, HIS-134, HIS-188, HIS-209
GlcNAc6P ALA-133, ASN-212, ALA-213, ARG-220,
HIS-244, ILE-301
The conserved residues in the ligand- and metal-binding sites include histidine (H), 
asparagine, arginine (N) and alanine (A).  aspartate (D) and glutamate (E). These active 
regions contain both hydrophobic and polar residues. Moreover, the regions also contain 
acidic (D and E) and basic (H and R) amino acid residues. Interestingly, the hydrophobic 
Isoleucine residue found in MS-NagA and MM-NagA is replaced by Leu302 in Mtb-NagA, 
MU-NagA, MA-NagA, and MC-NagA. 
Another feature of NagA protein is the presence of divalent metal ions binding site that 
involved in its catalytic processes. Mycobacteria NagA enzyme possess metals ions (Zn and 
Cd) affects NagA functions including its stability and the design of new inhibitors. Moreover, 
they serve as co-factors which controls metabolism and regulate signal transport. This metal 
binding site is characterized with histidine residues that may impact the overall function of 
acid/base balance maintenance of the site by donating a proton which serving as cation 44 45.
Moreover, the conserved aspartic acid controls the catalytic mechanism of conversion of 
GlcNAc6P substrate to GlcN6Pand acetate 34, 35. Unlike the non-mycobacteria NagA protein, 
Mycobacteria NagA possesses a conserved cysteine (Cys-131)17 within the flexible loop (122 
– 136).
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The cysteine-131 is unique to all Mycobacteria NagA enzymes17. It may be manipulated to 
bind with an inhibitor through which the catalytic activity of NagA may be hindered because 
cysteine residues are generally reactive. For instance, cysteine-targeted therapeutic 
approaches had been used to prepare irreversible peptidomimetic inhibitors in the hepatitis C 
virus protease containing a non-catalytic cysteine 48. Therefore, Cys131 residue is a potential 
target in NagA protein for the inhibitors. 
Mycobacteria NagA is a metalloenzyme, and a metal-binding site is a feature in NagA 
enzymes crucial to the catalytic activity of mycobacterial species 20,49,50. However, there are 
interesting differences in the NagA enzyme metal-binding sites17 across bacteria species. The 
NagA enzyme metal-site may be a mononuclear or binuclear center. Mycobacteria NagA 
enzymes, such as T. marima and B. subtilis NagA, have bi-nuclear metal-binding active sites 
20,50 while Gram-negative non-mycobacterium E. coli has a single metal in the active site. M. 
smegmatis has a binuclear metal-binding site.17 A defined electron density confirmed the two 
bound metal ions with one buried in the cavity of the (α/β)8 barrel for ligand-free and a larger 
metal ion in ligand-bound.
Another feature of mycobacteria NagA enzyme is the formation of an isologous association 
of the enzyme.51 Importantly, the organization of dimers plays a crucial role in the biological 
processes. This gives rise to closed structures with an intrinsic symmetry, enhanced 
conformational stability, and thermal stability 52. The protein subunit functions in the 
allosteric regulation and catalysis of protein functions 51.  the dimer-conformation remains 
conserved among all the analyzed mycobacteria. The active site of the Mycobacteria NagA 
enzymes is formed within the homodimer at the interface of the domain I of NagA protein. 
Based on the minimal amount of literature available, the mechanism of dimeric interactions 
may differ from the general enzyme oligomerization. However, the interactions of the 
mycobacterial NagA enzymes include H-bonding and salt bridges.
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4.5.5 Effect of mutation on NagA proteins
Single nucleotide polymorphisms occurring in protein-coding regions may lead to structural 
defects in the 3D structure of a protein, thus, leading to pathological effects. Both the single 
and the two points mutations have a reductive effect on the catalytic activity of NagA 
proteins. Mycobacterial species NagA enzymes possess a conserved His56 – His58 (HXH) 
motif at the metal-binding sites as seen in the mycobacteria. The mutation of the single point 
amino acid of mycobacterial species causes the complete loss of catalytic activity. Mutants 
such as D267A, H56Q, H56N, and H56A have been reported in the structure of NagA 17. 
We, therefore, used the DynaMut 53 and Polyphen2 54 resources to study the functional impact 
of these nsSNPS occurring in NagA proteins. PolyPhen2 is used to determine if the amino 
acid substitution in the sequence occurs in a conserved region and predicts if the substitution 
has any deleterious impact on the structure of the protein 54. PolyPhen employs the position-
specific independent count (PSIC) score to ascertain the functional and structural impact of 
the substitution. A PSIC score of 1.0 is regarded as damaging. The SNPs are classified as 
benign, possibly damaging and probably damaging 54. DynaMut is a web server that predicts 
the impact of the mutation on protein conformation, flexibility, and stability 53. 
Table 4.5 Respective predicted Free energies and Scores from DynaMut and Polyphen resources for 
Mycobacteria NagA mutants.
  DynaMut Polyphen
Mutant        ▲▲G       ▲Vibration Energy Inference          Score
D267A         -0.155        0.655 Destabilizing        Probably Damaging 1
H56Q          -0.834        0.480 Destabilizing        Probably Damaging 1
H56N          -0.834        0.480 Destabilizing        Probably Damaging 1
H56A          -0.663        1.033 Destabilizing        Probably Damaging 1
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As predicted by DynaMut, change in folding free energy (ΔΔG) of the D267A, H56Q, H56N, 
and H56A variants were -0.155, -0.834, -0.834 and -0663 respectively. While the Δ 
vibrational entropy energy of the variants was 0.655, 0.480, 0.480 and 1.033 respectively 
(Table 4.5). PolyPhen also predicted the four variants to be probably damaging with a PCIS 
score of 1. Overall, these variants were predicted to be destabilizing with increased residual 
fluctuations (Figure 4.6) as corroborated by the Δ vibrational entropy energy.
Figure 4.6. Deformation and fluctuations analysis plots of D267A, H56Q, H56N and H56A 
as predicted by DynaMut.
The interatomic interactions of the wild and mutant protein also showed that the bond 
interaction was affected because of the mutation, accounting for the destabilization of the 
mutant protein. The strong hydrogen and disulphide bridge observed in the wild proteins 
were lost in the mutant proteins (Figure 4.7).
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Figure 4.7. Interatomic interaction of wild NagA and mutated NagA predicted by DynaMut.
4.5.6 Structural perturbation of Mycobacterium species NagA protein 
Structure and dynamics of protein have been linked to its activity, and the understanding of 
this can furnish us with mechanistic insights into the pharmacological activities of therapeutic 
small molecules. We, therefore, elucidated the structural attributes that characterize NagA 
protein in the six Mycobacterium species. RMSD was used to estimate the structural stability 
of the NagA system. Figure 4.8 revealed that while MANagA, MSNagA, and MtbNagA 
systems were relatively stable. MUNagA and MCNagA attained stability at about 40 ns after 
their RMSD increased from 1.8 to 3.0 Å and MMNagA was stable but until it deviated at 
about 130 ns (2.5 Å to 3.8 Å) before it eventually stable. MA-NagA, MC-NagA, MM-NagA, 
MS-NagA, Mtb-NagA, and MU-NagA had an average RMSD value of 2.85 Å, 3.25 Å, 4.25 Å, 
2.15 Å, 3.25 Å, and 3.25 Å. The RMSD plots of the active site loop for all the NagA systems 
indicated high stable conformation having almost the same values. RMSF determines the 
residual fluctuation correlating to the crystallographic B (temperature, T) factors (Figure 
4.8A). MCNagA, MMNagA, and MUNagA fluctuated throughout but the active site elicited 
high residual fluctuation across the systems between residues 205-382. The average RMSF 
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values of MA-NagA, MC-NagA, MM-NagA, MS-NagA, Mtb-NagA, and MU-were 4.8 Å, 8.85 
Å, 9.95 Å, 3.5 Å, 3.85 Å, and 4.55 Å respectively.  
Figure 4.8. Conformational analysis plot showing stability and atomistic motions among 
NagA proteins and active site flexible loop (A). C-α RMSF plot showing the residual 
fluctuation of the NagA proteins and active site loop (B). 
In addition, we superimposed the apo NagA structures (Figure 4.9) after the MD simulations 
to compare their characteristics and mechanistic behaviour. Modelling of the active sites' 
flexible loop provides an additional clue to the comparative analysis of NagA. However, the 
350 ns simulation of the NagA enzymes showed some variations in the conformation of the 
active site loop. We observed if the six NagA maintains their relative superimposition after 
relaxation (see Figure 4.S1 supplementary material). The results showed that Mtb-NagA, MS-
NagA, MM-NagA, and MU-NagA seemed to retain their structural similarity, but MA-NagA 
and MC-NagA structures were relatively different. Furthermore, the β8-strands, specifically, 
residues 33 – 43, 295 – 303, and 322 – 340 revealed decreased atomistic steric hindrance due 
to the energy minimization.
Effect of energy minimization on the superimposition of NagA
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In the initial apo of NagA protein, the flexible loop (Glu122 – Pro136) was conserved and 
relatively superimposable. However, the flexible loop’s positions of the subunit monomers 
(chain B) changed the post-minimized NagA, implying the loss of superimposition. Thus, 
possibly, this provides different mechanism flexibility regarding each mycobacterial species 
(Figure 4.9). The MD simulations identified a potential mechanism by which the enzyme 
may structurally function. Based on this information, it is reasonable to deduce that the 
occluding loop in chain B may have shifted away from the active sites of the ligand after 
relaxation and provides the potential for the ligand to bind.
Figure 4.9. Illustration of the Initial and minimized apo-structures of the Mycobacteria NagA 
enzymes showing the effect of relaxation on the flexible loops (residues: 122-136) that covers 
the binding site of the ligand in chain B
4.6 Conclusion
Mycobacterial infections, especially tuberculosis, have killed millions of human beings for 
many decades. This study revealed profound similarities in the amino acid sequence and the 
structural features of Mycobacteria species using bioinformatics and molecular dynamics 
techniques. Moreover, it elucidates point mutations that alter the function of the protein. The 
mutation destroyed the active sites of NagA, thus leading to drug resistance. The study 
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provides structural insights into the architectural setup of Mycobacterium tuberculosis NagA. 
Furthermore, it unravelled the “NagA-Achilles’s hill” that can be explored in future design 
and development of antitubercular therapy to circumventing drug resistance that is 
characteristic of Tuberculosis.  Therefore, we considered NagA enzyme as a good target that 
can be explored in the search for a new inhibitor of Mycobacterium tuberculosis. Hence, in 
future, a design of a multifaceted drug using computational methods; molecular docking of 
inhibitor, pharmacophore model, and MD simulations would be explored.
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5.1 Graphical Abstract
Graphical superimposed snapshots of Thompson novel loop (yellow) of menG protein: apo (A) and 
bound (B) systems. Loop switches between open and closed conformations; critical for therapeutics.
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5.2 Abstract
Drug-resistant tuberculosis (TB) has remained the top global health challenge, with a yearly 
estimation of 10 million infections and 1.5 million deaths in humans. Demethylmenaquinone 
methyltransferase (menG) catalyzes demethylmenaquinone conversion to menaquinone (MK) 
that is implicated in the TB pathogenesis, hence, has become a major drug target. DG70 is a 
biphenyl amide compound known to be a high binding affinity inhibitor of menG. This study 
investigated the structural and dynamic impacts of DG70 upon binding to menG using atom-
based dynamic simulation. Our findings revealed that the modeled structure of menG 
possesses some Rossman-like methyltransferase characteristic features including two GXG 
motif, omega-like loop (residues 210-220) called the Thompson, nine α-helices, five β-
strands, etc. Furthermore, atom-based dynamic simulations revealed that the Thompson loop 
is critical in the therapeutic activity of DG70. The loop assumed an open conformation in the 
unliganded-menG structure. However, in the DG70-menG, it assumed a tightly closed 
conformation. This explains the high binding affinity (-32.48 kcal mol-1) observed in the 
energy calculations. Interestingly, these findings are further collaborated by the 
conformational perturbation in the menG protein. Conclusively, insights from this study 
highlights the structural “Achilles heel” in menG protein which can be further leverage on by 
inhibitors tailored to specifically target them. 
KEYWORDS: Mycobacterium tuberculosis, demethylmenaquinone methyltransferase, drug-
resistant Tuberculosis, homology modelling, molecular dynamic simulations
5.3 Introduction
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Mycobacterium tuberculosis (Mtb) is the world’s deadliest infection after the renascent 
human immunodeficiency virus/AIDS.1 About two billion latent Mtb in man kill 2-3 million 
people annually.1 Presently, more than 484 000 new cases of multidrug and extensively 
resistant (active) TB kill about 1.5 million death of persons every year.2,3 More disturbing is 
the mutation-mediated and acquired drug resistance by the newer antitubercular drugs 
including linezolid, bedaquiline, (BDQ), etc.4,5 More than one-half of the MDR/XDR-TB 
drugs have failed due to mutation.6 In the quest to search for a promising novel drug over the 
years in this area,  researchers have focused on protein-drug and protein-protein interactions 
for possible tuberculosis cure using various techniques and methodologies through targeting 
protein biocatalysis.7,8 While a lot of studies have reported the targeting of constituents of Mtb 
cell wall, most often, the mycolic acid synthesis, however, only a few reports seem to be 
available on the study of the inhibition of Mtb respiratory pathway using experimental and 
computational tools such as the molecular dynamics (MD). BDQ is the first respiratory 
inhibitor that acts by binding to the oligomeric and proteolipid subunit C of Mtb ATP 
synthase (atpE gene).5,6 BDQ was very effective against both the susceptible and multi-drug 
resistant TB.9 However, there is a high prevalence of mutations in Mtb genes, including atpE, 
atpC, mmpR (Rv0678) to bedaquiline. A whole-genome sequence has revealed a genetic 
signature of BDQ resistance in a clinical Mtb isolate C; a microhetero-resistance found in a 
targeted deep sequencing analysis.10,11 Similarly, a previous study shows that Mtb 
demethylmenaquinone methyltransferase, menG (rv0558) is a potential target and involves 
the biosynthesis of menaquinone (MK), the substance required for the cell maintenance of the 
prokaryotic including Mtb.12,13,14 The amino acids of Mycobacterium tuberculosis menG 
(rv0558) protein are conserved and distributed among Mycobacterium species homologs15  as 
shown in Figure 5.1.13 
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Figure 5.1. Sequence analysis of Mycobacteria menG showing ≥ 80 % conserved amino acid 
residues16
MenG is a membrane domain-associated enzyme and belongs to the SAM-dependent 
methyltransferase (MTase) superfamily comprising of an α/β/α fold structure.17,18 MTase 
domain is an important target in drug design. Mtb menG encodes S-adenosyl-L-methionine 
(SAM)-dependent menG (Rv0558) that catalyses the biosynthesis of menaquinone [in the 
form of MK9(H2)] required for respiration through C-methyl transfer from the SAM.19 After 
the methylation catalysis of the menG enzyme, SAM converted to S-Adenosyl homocysteine 
(SAH) which leaves the protein domain .18 SAM-bound methyltransferases is a Class I 
enzyme and may possess at least two or more GXG motifs located whereby one is located in 
the first β-sheet and the second is bound another β-sheet.20,21 Puffal et al. (2018) also reported 
that Mycobacterium smegmatis (Msmeg) menG has 234 amino acids and GXG motif.22 
Methyltransferases include Rossmann-like α/β (Class I), TIM α/β-α/β (Class II), tetrapyrrole 
methylase α/β (Class III), SPOUT α/β (Class IV), etc.23 MenG is a Class I methyltransferase 
with remarkable structural consistency and a 10 % primary structure similarity.21
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DG70, a biphenyl amide, is a chemotype compound that inhibits the catalytic methylation of 
Mycobacterium tuberculosis demethylmenaquinone methyltransferase enzymes. The whole 
cell-based screen of a Mycobacterium menG using a putative PcydAB reporter strain and 
HRMS analysis identified was used to determine the potency of DG70 as a menG inhibitor.24 
Moreover, this compound is therapeutically active against both the clinical and laboratory 
drug-susceptible and drug-resistance Mtb strains.13 
In drug design and development, protein dynamics study often provides information that may 
result to the desired novel target and its mechanism of catalysis (substrate binding) or 
discovery of an Mtb enzyme inhibitor and its mode of action (MOA).25,26,27 This study 
investigates the changes in the conformational structure of menG and the inhibition of its 
catalytic activity with DG70 using computational approaches to understand its potentiality as 
a pharmacological target to eradicate tuberculosis. We created a homology model of menG 
enzyme and studied its ligand-unbound, substrate-bound (DMK9), and ligand-bound (DG70) 
systems over 300 ns molecular dynamics (MD) simulations at the atomistic level. 
5.3.1 Concise DG70 structural chemistry: probable advantage over the frontline drugs 
The study of menG inhibitors and specifically, the DG70, a potential drug for the treatment of 
TB, is relatively new. Hence, it is considered a probable research area by which this disease 
eradicated. Besides the mutation-mediated resistance in protein residues, including menG that 
militate the cure of TB, the inhibitor activity, which is partly determined by its structure, can 
also serve as a hindrance. We compared the chemical structures of DG70 and BDQ to 
provide a probable justification of why DG70 showed a therapeutic advantage over the BDQ 
drug. 
The functional elements of chemical structures (Figure 5.2) determine their potential 
therapeutic efficacies against infection or disease. They are essential factors in drug design 
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and development. First, the groups have the potentials to form strong interactions with the 
active site of menG. For instance, high electronegative atoms of DG70 can form strong 
bonding interactions with the protein interacting residue thereby preventing the compound 
from moving in and out of the active site. Moreover, the oxygen and hydrogen atoms of the 
methoxy group and the phenyl rings can form strong conventional (carbon) hydrogen bonds, 
electrostatic, and pi-sigma interactions. There can also be a formation of alkyl and mixed/pi-
hydrophobic interactions between DG70 and the interacting residues. 
Figure 5.2. MenG inhibitor (DG70) and potential interacting functional groups shown in 
dotted lines.
5.4       Computational Methods
5.4.1 Homology modelling and binding pockets identification 
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5.4.1.1 Mycobacterium tuberculosis MenG Homology modelling
There was no closely related structure of menG protein found in the protein data bank (PDB) 
during this study. Most protein PDB structures have less than 30 % sequence identity in the 
homologs of the Mtb menG sequence.28 Moreover, the model reported previously by Suhkeja 
et al. (2017) was also not available for use. Hence, we conducted a systematic search for 
possible structural templates by uploading the menG protein sequence (accession code: 
P9WFR3) obtained from the UniProt database29 onto the BLAST. The templates of the 
P9WFR3 sequence were identified from NCBI using the BLASTp (accessed on 28 June 
2019).30,31,32 Table 5.1 showed the sources, the accession codes, and the selection criteria for 
choosing the template. Mtb menG protein templates share some sequence similarities with the 
SAM-dependent methyltransferases crystal structures.
Table 5.1 Criteria for choosing the templates for modelling the Mtb MenG protein   
Template Source PDB code  Query Sequence E-value
cover (%) identity (%)
Saccharomyces cerevissia sp 4OBW.A     91       32.51      0
Lechevalieria aerocolonigenes 3BUS.A     92       23.81      0
Saccharomyces cerevissiae spp 40BW.A     99       37.26      0
Streptomyces luridus spp 3OU2.A     38       21.99      0        
Note: The templates also belong to the transferase family. 
The MODELLER Software version 9.21, an add-on in UCSF ChimeraTools-1.13.1 was used 
to create the homology modelling of the target protein in which all the four templates selected 
to build the model.33,34 We performed multiple sequence alignments using CLUSTALW 
online application35, which uses a BLOSUM matrix and penalties of 10 and 0.1 for gap 
opening and extension, respectively. The multiple sequence provides evidence that the full 
length of chain A Saccharomyces cerevisiae spp is the best template with the highest identity 
score. To obtain a 2D secondary structure of menG enzyme, we uploaded its sequence to 
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UCSF Chimera version 1.13.1. where structural alignment and comparison, matchmaking, 
match-aligning, and modeller (homology) were used to build the model. Five models named 
A, B, C, D, and E having zDope (kcal mol-1) -0.32, -0.28, -0.14, -0.06 and -0.00 respectively 
were generated. Model A (zDope = -0.32) was chosen since it is the best one because it has 
most negative value.  The high structural similarity between the homolog and the template 
used give credence to the modeling strategy used. A Ramachandran plot for the analyses of 
bond angles and torsional strain was generated using MolProbity.36 Of all residues, 
MolProbity results favoured 87.1 % and allowed 96.1 % (223/232), and nine outliers 
residues. The active sites were obtained using Metapocket2.0 and validated using Raptor-X, 
GalaxyWeb, and 3DLIGANDSITE resource. The predicted active site residues were not 
contained in the outliers.
5.4.1.2 Binding pockets identification
Four online resource programs were employed to predict the active sites of menG protein 
structure. Metapocket2.0 server deployed to identify the druggable pockets 37, 38 while cross-
validations of the binding sites sorted out using Raptor-X web, 39 3D-Ligandsite web,40 and 
GALAXYWEB server.41 Metapocket2.0 is a consensus method that incorporates four other 
methods, including the LIGSITE, PASS, Q-SITEFinder, and SURFNET to generate protein 
surface for clefts and cavities. Raptor-X is a web server with evolutionary information. It 
employs a powerful in-house deep learning model Deep Convolutional Neural Fields 
(DeepCNF) to predict the secondary structure and disorder regions, solvent accessibility.42 
GALAXYWEB server predicts protein structure from a sequence by template-based 
modeling and refines loop or terminus regions by ab initio modeling. It relies on the method 
tested in the 9th Critical Assessment of techniques for protein Structure Prediction as Seok-
server.43 GALAXYWEB prediction method generates stable core structures from multiple 
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templates and rebuilds unreliable loops or termini by using an optimized-based refinement 
method.44
5.4.2 `System preparations and docking calculations
DG70 acts against the menG catalysis of methylation of demethylmenaquinone (DMK9) to 
menaquinone (MK9) both in vitro and in vivo. The catalytic methylation of DMK9 by Mtb 
menG produces MK9 that is required for energy. Hence, we considered docking calculations 
on the ligands; substrate (DMK9), and inhibitor (DG70). DMK9 and DG70 were drawn in 
MarvinSketch-17.21 (http://www.chemaxon.com/) and converted to a mol2 format. DMK9 and 
DG70 were separately assessed in Molegro Molecular Viewer (MMV)45,46 to ensure that bond 
angles and hybridization state were corrected. The ligands minimized using the steepest 
descent method and GAFF force field add-on in Avogadro.47 The systems were subjected to 
molecular docking using the predicted active site to refine and reduce the probable false 
positives due to ligands and to assess the geometrical feasibility at the site. The pose with the 
lowest negative value was chosen based on the interactions and binding affinities of the 
ligands. Both DG70 and DMK9 docked using AutoDockTools-1.5.6 graphical user interface48 
to defining the grid box for the active site; the spacing of 5 Å and size 122 × 106 × 86 
pointing in x, y, and z directions. Similarly, the grid box for the same active site of DG70 
docked defined as having a center (-37.66 × -45.85 × 37.45) and dimensions (120 × 106 × 72) 
the spacing of 5 Å and size 124 × 106 × 72 and pointing in x, y, and z directions respectively. 
Docking calculations using the Lamarckian Genetic algorithm carried out with AutoDock 
Vina.48 Using UCSF ChimeraTools-1.13.1, atom types were assigned, Gasteiger charges 
added to the ligands, and merged non-polar hydrogen to carbon atoms. The water molecules 
were removed from the protein and added polar hydrogen and the ligands docked into the 
active site of menG. Finally, docking was validated based on the lowest energy pose. 
5.4.3 Molecular dynamics (MD) simulations
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Molecular dynamics simulations find applications in the study of the atomistic motions of 
biological systems and furnish us with the understanding of the physical movements of atoms 
and molecules. MD provides the interpretations of molecular processes within the 
biosystems. 49,50 We performed the MD simulations using the GPU version of the 
PMEMD.CUDA engine provided with the AMBER package, FF18SB variant of the AMBER 
force field used to describe the protein.51 In applying the restrained electrostatic potential 
(RESP) and the GENERAL AMBER Force Field (GAFF) procedures, the partial charges 
were added to the ligands using ANTECHAMBER.18 The LEAP module in AMBER 18 was 
used to neutralize and solvate the free menG and ligand-bound systems by adding hydrogen 
atoms [H+], sodium ions [Na+], and chloride [Cl-] counter ions. 
Furthermore, all atoms explicit solvation was carried out in an orthorhombic TIP3P box of 
water molecules size 10 Å. The procedure considered initial minimization of 2500 steps with 
an applied restrained potential of 500 kcal mol-1. Additional 5000 steps of full minimization 
were carried out by conjugate algorithm without restraining conditions. The systems were 
gradually heated, starting from 0 to 300 K for 50 psec to maintain a fixed number of atoms 
and volume considering a canonical ensemble (NVT). Using 1 bar pressure provided by the 
Barendsen-barostat, the SHAKE algorithm utilized to constrict the hydrogen bond constraint 
5253. The total time for the MD simulation was 300 ns with a time step of 2 fsec using constant 
pressure of 1 bar, a 300 K, and Langevin thermostat. The coordinates Apo-menG and bound-
menG complexes were each saved every 1ps, and the trajectories were analyzed using the 
CPTRAJ and PTRAJ module in AMBER 18/GPU. The trajectories analyzed for RMSD, 
RMSF, DSSP, principal component and analysis, and radius of gyration using CPPTRAJ and 
PTRAJ. The structural and visual analysis54  done by employing the graphical user interface 
of UCSF Chimera and Discovery studio 2019 Client to analyze the binding mechanism of the 
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ligand-bound systems,55 while the data plotted with MicroCal Origin 6.0 data analysis 
software. 56,53
5.5 Post-dynamics analysis
5.5.1 Binding free energy calculations
Molecular dynamics employs the differences in the free energy to study the mechanism of 
biological processes.57 The binding free energy (BFE) method is important in the 
computational study of protein dynamics to explore their binding mechanism with ligands 
thermodynamically.58 The BFE of the bound system calculated using the molecular 
mechanics/GB surface area method (MM/GBSA) to estimate their binding affinities.51 The 
energies considered over 300,000 snapshots from the 300 ns trajectories. This free binding 
energy (ΔG) calculated for DMK9- and DG70-bounds menG and expressed thus:
ΔGbind = ΔGcomplex – ΔGreceptor – ΔGligand
ΔGbind = Egas + Gsol – TΔS
Egas = Eint + Evdw + Eele
Gsol = GGB + GSA
GSA = γSASA
Egas denotes the gas-phase energy- internal energy: Coulomb (Eele) and van der Waals energies 
(EvdW). The Egas estimated from the FF18SB force field terms. Polar and non-polar states' 
energy contributions accounted for the Solvation free energy, Gsol. The non-polar solvation 
energy, SA.GSA was determined from the solvent-accessible surface area (SASA), using a 
water probe radius of 1.4 A. In contrast, the polar solvation, GGB, was obtained by solving the 
GB expression. S denotes the total entropy and T, the temperature of the systems. The 
contribution of each residue to the total binding free energy obtained at the predicted active 
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site by carrying out per-residue energy decomposition at the atomic level using MM/GBSA 
method in AMBER 18.59  
5.5.2 Receptor-ligand Interactions systems
Analysis of menG active amino acids interaction network with DMK9 and DG70 was carried 
out using the receptor-ligand interaction add-on available on the Discovery studio visualizer 
2019 Client.53 The interactions depicted using the snapshots taken at different periods of 300 
ns MD trajectories for DMK9- and DG70-bound systems and subsequently visualized using 
BIOVIA Discovery Studio software to obtain the molecular forces between the atoms of the 
ligand and interacting residues. These interactions may provide important information that 
would help to discover if menG is a potential target and contribute to the overall design and 
development of contributing to the development of drugs. Using this software allows us to 
depict the interacting residues and the interaction types within the bound systems.
5.5.3 Conformational fluctuations of MenG systems
The RMSF is the fluctuations of individual protein residues to their average positions within 
a given molecular dynamic simulation.60 It provides an understanding of the flexibility of 
various regions of menG while binding to the ligands. Mathematically, RMSF is as follows:
RMSfi is the RMSF of the ith residue from wh
ich the RMSF of the average is taken and divided by the RMSF’s standard deviation 
[σ(RMSF)] to give resultant standardized RMSF s(RMSFi)]. 
5.5.4 Radius of gyration (RoG)
The radius of gyration of both the Apo and the bound system were determined to further 
examine the stability of the system through a compactness test. Statistically, the average 
radius of gyration (RoG) predicts the dimensions of biomolecule as it reflects the molecular 
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compactness of a system to its shape by describing the RMSD of the atoms from the common 
center of gravity of a given protein molecule.61 The compactness of Apo and bound systems 
assessed along 300 ns MD trajectories by taking the average over 300,000 frames. The 
equation below expresses the estimation details of RoG is estimated:
The terms in the equations include the position of the ith atom (ri), mass/weight of each atom 
(W), and the center mass of atom i (r). The mean value calculated by taking the RoG values 
over the number of frames in each trajectory.
5.5.5 Principal component analysis (PCA)
The principal component analysis is an important post-MD analysis that describes the atomic 
displacement and the loop dynamics of a 3D protein. It represents the magnitude 
(eigenvalues) and direction (eigenvectors) of the motion of protein.62 Before processing the 
menG PCA, the MD trajectories of free enzyme, DMK9-, and DG70-bound complex 
enzymes were stripped of solvent and ions using an integrated PTRAJ module in AMBER 
18. Considering the dynamics of the C-α atom of menG, the first two principal components 
(PC1 and PC2) were computed and the conformational patterns of the free and bound menG 
systems projected along the first two eigenvectors, i.e. ev1/PC1 vs ev2/PC2 using the C-α 
atoms Cartesian coordinates.53
5.6 Results and Discussion 
5.6.1 The Homology Structure of Mtb MenG 
The preparation of the 3D structure of a protein is the first step in rational drug design.63,64 
However, there was no available crystal structure of menG for this study. Moreover, a 
previously reported homology model of Mycobacterium tuberculosis menG13 was also not 
available. Hence, a homology model was built using 4 templates; crystal structures of two 
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4OBW, 3BUS, and 3OU2 obtained at resolution range between 1.5 – 2.4 Å from the protein 
data bank (PDB). The criteria (Table 5.1) for choosing the quality templates64 produce 
successful menG protein models from which a model with the best zDope (- 0.32 kcal mol-1) 
was chosen to further this study.  
The menG (rv0558) sequence consists of 234 amino acids corresponding to the 
saccharomyces cerevisiae transferase amino acid residues (74 – 301). The structural features 
of a protein are a good indicator of its functions. Mtb menG showed two conserved cysteine 
residues (CYS76 and CYS146) that tend to form a disulphide bridge, thus act as activators in 
the protein. Site-directed mutagenesis determination and ligand affinity analysis of menG 
could reveal a probable formation of a cysteine bridge. Furthermore, the MenG sequence is 
characterized by hydrophobic amino acids including especially at the active residues.
Topologically, the superimposition of homology menG structure and 4OBW template showed 
high similarity. The secondary structures of a protein including menG are a function of its 
different conformations. The structural features of protein provide a means of understanding 
the molecular interactions.20 In this study, we observed that the Mtb menG possesses parallel 
β-strands and fully formed α-helices (Figure 5.3A); four beta-strands (4β) that are surrounded 
by nine-alpha (9α) helices. This finding correlates with class I methyltransferase.
Figure 5.3B showed two GXG motifs located on two different loops of Mtb menG as against 
the β-sheet that was previously reported. These motifs are conserved in the homologs of 
Mycobacterium tuberculosis menG. Moreover, motif GLY217 played a binding role at the 
active site of this protein. 
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Figure 5.3. A; Secondary structural features of Mtb menG showing 4 parallel β-strands (orange) 
located at the center and surrounded by 9 α-helices (purple). B; GXG motifs residues: GLY140, 
GLY141, GLY217 (interacting residue), and GLY218 (cyan); UniProt annotated residues of the co-
factor binding residues (red) ALA100 and ALA101; and the substrate-binding residues (yellow) 
THR62, ASP80, and SER117 among the active site residues.
5.6.2 Active site determination and validation
The ligand-binding sites of the model with the highest zDope score (-0.32) predicted to 
identify the corresponding pocket sites using Metapocket2.0, raptor-X, 3D-LIGANDSITE, 
and GALAXY (Figure 5.4C). The negative zDope score of -0.32 obtained upon binding the 
menG inhibitor indicates a reasonable accurate structure (native-like structure) and implies 
that the complex is very stable and reliable such that the DG70 is bound to the protein 
without moving in and out of the active site. The selected residues (Figure 5.4A) were 
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considered the active site and used for the molecular docking and modeling of the interaction 
of menG residues with the ligands.  The active site determined for the substrate and the menG 
inhibitor. The site validated by generating a Ramachandran plot (Supplementary Figure 5S1) 
of the active site, which showed that they did not fall within the outlier region. 
Figure 5.4. MenG predicted active sites (green) and the interacting residues (red). A; Secondary 
structure illustration menG of the active site (common residues by predictors). B; The primary 
structure displays predicted active residues (green) and the interacting amino acids (red). C provides 
the corresponding numbers of the predicted active amino acids.
5.6.3 Molecular docking of DMK9 and DG70 
The Uniprot annotated THR62, ASP80, and SER117 to be among the substrate active site 
residues and ASP100 and ALA101 to be among the co-factor active site residues.44 Figure 
5.4C showed that the predicted active site residues agreed with UniProt annotation, though it 
did not differentiate which residues will bind to the substrate or co-factor. Hence, we 
employed a previously reported criterium for choosing the active site residues.38 Moreover, 
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our predicted active site is similar to the one (residues: ARG3, ASP7, VAL20, LYS23, 
ARG40, ARG48, ALA60, TRP75, GLY99, PHE118, ARG121, VAL136, ALA181, SER188, 
and ARG190) that was previously reported by Sukheja et al., (2017), having residues 
ARG40, ALA60, PHE118, and ARG121 in common. 
Molecular docking is a major computational tool that predicts the multiple orientations of a 
ligand at a binding site of receptors.65,66,67 The substrate (DMK9) and DG70 (inhibitor) docked 
separately in the active pockets of the menG and the pose that gave the most favourable 
conformations (highest negative value) considered for the molecular simulation. 
The molecular docking of DMK9 and DG70 on the active pocket of menG showed multiple 
orientations within the binding sites. Although the interacting residues used in this work were 
like those residues reported by the Sukheja group, our Ramachandran plot showed that ASP7, 
ASP9, and PRO10 were outliers. Whereas the outliers reported as interacting residues. Rather 
than using the binding site predicted in the previous work, we chose to predict a new active 
site of menG protein and validated it before use. DG70 docked on the most favourable 
binding mode (score = -7.1 kcal mol-1), and DMK9 produced a score of -5.5 kcal mol-1 using 
the same active site. We observed that both ligands interacted with different residues 
suggesting that one ligand docked at the site of the co-factor site and the second one docked 
at the substrate’s site. 
5.6.4 Per-residue energy decomposition (PRED) and Ligand interactions with MenG
The per-residue energy decomposition revealed the interactions between the interacting 
residues and the ligands.18 Considering the 300 ns MD trajectories, the per-residue 
decomposition of menG residues revealed various contributions of the binding site residues to 
DMK9 and DG70. The ligands adopted favourable orientations or morphology such that 
functional groups including chlorine, fluorine, -OCH3, -(C6H5)2NH-, and residue groups such 
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as -NH2, -COOH, cysteine Sulphur atom interacted with the active site residues formed strong 
bonds. Explicitly, it observes that the methyl C-atoms of side chains of LEU58, ALA60, 
ALA91, LYS93, and VAL94 developed stable and strong alky hydrophobic interactions with 
the methyl C-atom of the prenyl group of DMK9 (Figure 5.5A). Also, there was the 
formation of a conventional hydrogen bond; the primary chain O atom of GLY206 formed 
hydrogen (H-bond) with H-2 of DMK9 phenyl group and the oxygen (O-2) of DMK9 created 
H-bond with the main chain H-bond of VAL210.
The hydrophobic residues that pocket DMK9 predominantly include Ala60, Val91, Lys93, 
Val94, Ala124, Ala129, GLY206, VAL210, and basic LEU58. Except for GLY206 and 
VAL210, the interacting residues formed alkyl hydrophobic interactions with the H-atoms of 
the prenyl group of DMK9. Both GLY206 and VAL210 formed conventional H-bonds 
(classical); backbone O atom of GLY206 bonded with the one prenyl H-atom while backbone 
H-atom of VAL210 bonded with the phenyl hydroxyl O atom of DMK9. 
The residues that pocket DG70 include TYR24, ARG40, GLN126, CYS146, and GLU147. 
LEU26, LEU33, VAL145, and CYS146 formed strong and stable bonds with highly 
electronegative chlorine (Cl) atom of DG70. Figure 5.6A represents the interaction networks 
of the active site residues with DG70. The systems are characterized by stable hydrophobic, 
single halogen and hydrogen bonds. DG70 bound to the active residues including LEU26, 
ILE219, LEU222, and GLN235.
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Figure 5.5. A: Visual representation of the DMK-menG interaction network (Colour online) and B: 
structural view of DMK that bound to the menG the active site. C: energy contributions of the 
interacting residues of menG with DMK9.
The resonating phenyl rings (C13-C18 and C19-C24) of DG70 formed strong pi-alkyl bonds. 
ASP36 and ARG40 formed pi-anion and pi-cation respectively with the phenyl (C1-C6) ring 
of DG70. Moreover, LEU26 and VAL145 formed alkyl hydrophobic and pi-sigma 
interactions with chlorine (Cl-7) and phenyl ring, respectively. Additional interaction is 
stronger interaction between residue LEU33 and fluorine (F-8) of DG70. Other significant 
interactions are the formation of conventional and non-classical H-bonds that were formed 
from the backbones of VAL220 and GLY217 with methyl hydrogen (H-44) and methoxy 
oxygen (O-27) atoms of DG70, respectively.
Using the MM/GBSA approach, we obtained individual residue-based contributions from the 
decomposition of the total binding protein energy (BPE) for DG70. We estimated the van der 
Waals (vdW) and electrostatic (elec.) interactions. The two forces reveal the residue and 
energy that produced an overall greater impact on the total binding energy. The per-residue 
decomposition of menG-DMK9 and menG-DG70 depicted as seen in Figure 5.5C and Figure 
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5.6C, respectively. The binding strength and the extent of stability of DG70 at the pocket site 
depend on the intermolecular forces that occurred between the inhibitor and the active site 
residues. LEU58 (-1.68 kcal mol-1), ALA60 (-1.0 kcal mol-1), ALA91(-0.8 kcal mol-1), 
ALA124 (-1.58 kcal mol-1), ALA129 (-1.05 kcal mol-1), and VAL210 (-1.25 kcal mol-1) 
contributed higher energies to the complex, while VAL94 (-0.35 kcal mol-1) and GLY206 (-
0.4 kcal mol-1) contributed less energy. Therefore, the van der Waals interactions due to 
residues 58, 60, 91, 124, and 210 contributed to the high energy interaction of the covalent 
system (ΔGbind = -31.64 kcal mol-1). 
The per-residue interaction energy of the menG-DG70 system and the residues that 
contributed higher energies towards the complex include LEU26 (-1.15 kcal mol-1), VAL145 
(-1.9 kcal mol-1), CYS146 (-1.2 kcal mol-1), GLU147 (-1.35 kcal mol-1), ILE219 (-2.8 kcal 
mol-1), VAL220 (-1.8 kcal mol-1), LEU222 (-1.8 kcal mol-1), HIS223 (-0.5 kcal mol-1), and 
TYR226 (-0.65 kcal mol-1). Although the per-residue decomposition did not show the 
formation of a disulphide linkage between CYS146 and CYS76, there was a strong alkyl 
hydrophobic interaction between Carbon-Sulphur (C-S bond) of CYS and Cl atom of DG70 
(Figure 5.6A). In contrast, residues LEU33 (-0.35 kcal mol-1), ARG40 (-0.4 kcal mol-1), 
PRO151 (-0.25 kcal mol-1), and GLY217 (-0.28 kcal mol-1) contributed less energies while 
LEU185 did not influence the complex energetically. Therefore, the vdW interactions due to 
residues 145, 146, 147, 219, 220, 222, and 226 and the elec. interactions due to ASP36 (-1.15 
kcal mol-1) contributed to the huge stable covalent system (ΔGbind = -32.48 kcal mol-1). The 
ΔGbind for the menG-inhibitor system showed that DG70 is highly stable. This stable and 
strong interactions between DG70 and menG have a high impact on its inhibitory efficacy. 
Hence, we can correlate this results with the previous experimental report; the minimum 
inhibitory concentrations (MIC) of DG70 against drug-susceptible Mtb H37Rv (be 4.8 µg 
mL-1) and drug-resistant Mtb strains (1.2-9.6 µg mL-1) respectively.16 These strong interactions 
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and high stability of menG-DG70 prevent the synthesis of MK9. However, we improve the 
binding affinity predictions of the complexes by subjecting the systems to 300 ns MD 
simulations to have more realistic flexible menG in an implicit solvent. Protein-ligand 
systems were analysed using the accurate MMGBSA/free binding calculations to obtain the 
most favourable pose of DMK9 and DG70 at the menG active sites. It observes that DMK9 
and DG70 interacted with their respective menG active sites throughout the molecular 
simulations.
5.6.5 Free energy calculations of MenG-DG70 binding affinity 
The binding free energy provides various distinct energy contributions within the binding 
pockets and the binding orientations that gave the best intermolecular interactions at protein 
active sites. The total binding free energy for bound systems; ApoDMK9 and ApoDG70 
systems obtained using the MM/GBSA approach. We further determine the interactions 
networks of the DG70-menG (denoted ApoDG70Exp) reported by Sukheja et al. and 
depicted its residue-ligand interactions to compare with our results. 
The docking pose score (kcal mol-1) for Apo-DMK9, ApoDG70, and ApoDG70Exp- were -
8.1, -7.1, and -5.5, and respectively. The thermodynamic energy contribution of DMK9 and 
DG70 to their respective complex and the total binding free energy determines their stability 
at menG active site. Table 5.2 summarizes the binding free energies of the complexes 
contributed by the protein and the ligand.
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Figure 5.6. Residue-substrate interaction network; energy contributions of the interacting active 
residues at menG active site with DG70.
We docked DG70 on the active site, ran 300 ns MD simulations, and analysed the PRED of 
ApoDG70Exp complex. Figure 5S2 (supplementary) showed the residues-DG70 interactions 
and their energy contributions. The residues that contributed high energies towards the 
complex include THR62 (-0.08 kcal mol-1), ASP80 (-0.12 kcal mol-1), SER117 (-0.05 kcal 
mol-1), ASN122 (-0.13 kcal mol-1); PHE118 (-0.02 kcal mol-1) and ARG121 (1.10 kcal mol-1) 
contributed less energies while VAL20, ALA181, and SER188 did not influence the complex 
energetically. The elec. interactions due to residues 20, 80, 117, and 112 and vdW 
interactions due to residues contributed to the stable system (ΔGbind = -31.41 kcal mol-1), which 
the menG-inhibitor system is stable. For this active site, interactions were mainly 
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electrostatics in comparison to our study where the vdW interactions contributed more to the 
binding of DG70.
Thermodynamically, the analysis of the binding free energy of the DG70-menG systems 
showed proximity with the binding free energy obtained (Table 5.2). Taken together, we can 
infer that our predicted active site is a potential site to consider for the inhibition of the 
catalytic activity of menG protein by DG70. The most favourable binding free energies (kcal 
mol-1) were -32.45, -31.41, and -31.64 and these data thus agreed with molecular docking 
scores. 
Table 5.2. Thermodynamics analysis of menG-DMK9 and menG-DG70 interactions
       Energy components (Kcal mol-1)
Complex    ΔEvdw    ΔEele    ΔGgas    Gsol              ΔGbind
ApoDMK9  -16.87 -13.92 -15.61 -30.69 -31.64
ApoDG70  -16.09 -13.91 -15.52 -31.50 -32.48
ApoDG70Exp  -16.13 -13.99 -15.60 -30.45 -31.41
Note: ApoDG70Exp is the same as menG-DG70 system reported by Suhkeja et al. (2017) whose thermodynamics data was 
obtained to compare with that of ApoDG70 (inhibitor-bound system) studied in this work. ApoDMK9 is the substrate-bound 
system. 
5.6.6 Conformational stability of MenG Apo and bound systems
MD simulations provide useful information about the structures and dynamics of 
biomolecules that may contribute to the development of a drug in design and the overall 
achievement of the cure of TB. Specifically, proteins undergo many biological processes to 
regulate their internal components and maintain cellular functions. For the three studied 
systems, the conformational changes due to the atomistic deviations estimated using C-α 
backbone root mean square deviation. This system explains the structural stability and system 
convergence of the biological systems. For the bound or unbound proteins, attaining the 
structural stability requires longer timescale MD simulations. The C-α atom RMSD metric 
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used to estimate the stability of unbound menG (Apo), DMK9-bound (ApoDMK9), and 
DG70-bound (ApoDG70) systems.
The RMSDs of the alpha carbon (C-α) backbone of both Apo and bound systems determined 
throughout 300 ns MD simulations. Figure 5.7B is a graphical representation of C-α atoms 
RMSD of the systems. The C-α RMSD backbone atoms of all the arrangements were 
relatively stable. However, the RMSD of the Apo (≈ 8.0 Å) was quite higher than the RMSD 
of the bound systems which converged (RMSD = ≈ 4.5 Å) from 0 ns up to 110 ns before the 
RMSD of ApoDG70 rose to 4.7 Å. The average RMSDs (Å) of Apo, ApoDMK9, and 
ApoDG70 systems were 6.83, 4.66, and 4.97 respectively, and the order of increasing 
stabilities follows Apo < ApoDG70 < ApoDMK9. The high stability of the bound systems 
compared with the Apo system could be because of inward pulling interactions of the 
residues with the bound DG70. This difference leads to structural activation and 
conformational transformations.
5.6.7 Conformational fluctuation of Mtb MenG protein
The RMSF analysis furnishes us with the significance of molecular dynamics at the atomistic 
level and a better understanding of the conformational changes that occur upon ligand 
binding. The average RMSF trajectories of MD simulations demonstrate the differences in 
the flexibilities of the residues with or without a ligand. The RMSF of the C-α backbone for 
both Apo and bound systems monitored throughout 300 ns simulations. The C-α backbone 
atoms RMSF of each residue in Apo, ApoDMK9, and ApoDG70 calculated and represented 
graphically (Figure 5.7C).  
The average RMSF (Å) values of Apo, ApoDMK9, and ApoDG70 systems are 2.30, 2.00, 
and 2.40, respectively. The average RMSF of the C-α backbone in ApoDMK9 was lower 
than the RMSF of the Apo and ApoDG70. The fluctuations in the ApoDMK9 system 
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occurred between residues 180-205, which correspond to the ALA91, LYS93, and VAL94 
interacting regions. Similarly, distinct high fluctuations occurred between residues 1-120, 
which contain residues 26, 33, 36 and 40 that formed hydrogen bond, hydrophobic, and salt 
bridge interactions with DG70 at the active site. Moreover, the longest loop (residue 40-54) 
found within this region. The flexibility greatly extended in comparison with Apo, and thus 
confirms the loop flexibility upon DG70-binding.  Another fluctuation occurred between 225-
234, which may also suggest the binding effect of DG70.
Figure 5.7. C-α backbone RMSD and RMSD plot of Apo and the complexed systems based on the 
residues ran for 300 ns simulation.
5.6.8 Distribution of atoms (The radius of gyration) around the MenG backbones
The shape and folding of the Apo and bound-protein systems could further explore by 
measuring the radius of distribution/gyration (RoG) around the residue C-α atoms from the 
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center of mass. Hence, this analysis provides the compactness of a protein that undergoes 
some dynamic forces. High RoG values depict a less tight structure and increased mobility. 
The radius of gyration of C-α atoms of menG measured before and after binding to DMK9 
and DG70 in separate Apo system over 300 ns simulations. The average RoG (Å) of Apo, 
ApoDMK9, and ApoDG70 systems were 18.14, 18.50, and 18.27 respectively, hence implies 
that all the three systems showed very similar compactness. However, Figure 5.8B showed 
the atomic distributions in ApoDG70 from 115-150 ns (low RoG, high stability) and 255-280 
ns (high RoG, low stability). These correlate with the high RMSD observed between 110-160 
ns and 260-300 ns.  
Figure 5.8. A illustrates whole Mtb menG structure showing some residues. B: Radii of gyrations plot 
of Apo and ligands-bound systems measured over a 300 ns simulation showed the differences arising 
in radius deviation. C: Projection of Eigenvalues of the C-α backbone, during 300 ns simulation, for 
Apo, DMK9- and DG70-bound conformations of menG protein along the PC1 and PC2 principal 
components.
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5.6.9 Principal component analysis (PCA) of structural dynamics and motion
PCA is an essential post-dynamics analysis used to measure the conformational transitions 
and variations of the free (Apo) and ligand-bound protein complexes. It has applied 
extensively, to study the experimental data and the trajectory of the changes of simulated 
proteins over a time range. Moreover, the PCA tool is a robust quantitative technique that 
uses the covariance matrix obtained from the averaged structure using Cartesian coordinates 
to get the convergence of MD simulation in the space. It provides the means of determining 
the modes of motion and compares the positional fluctuation in the dynamically simulated 
structures. Lastly, PCA demonstrated the atoms’ displacement and the loop dynamics of a 
protein and was performed on the menG C-α atoms using the CPPTRAJ in AMBER18 GPU 
to compute the first two components; PC1 and PC2 that are shown graphically in Figure 
5.8C. The PC1 (X-axis) and PC2 (Y-axis) represent a covariance matrix after the elimination 
of eigenvectors. During the simulation, each point between the single-directional motions is a 
unique orientation due to the overlapping of similar structural conformations.
 The eigenvectors computed from the MD trajectories of the Apo and the bound systems 
varied greatly. The Apo system showed extensive, restricted structural motions of C-α atoms 
while both DMK9- and DG70-bound have broad spatial coverage which consequently 
showed that the free system is very rigid.26 Once again, this result corroborates with the 
stability of the systems showing the distribution pattern of the around the mass and the 
deviations of the system stability for the substrate- and inhibitor-bound systems. This result 
further demonstrates the structural loop flexibility while DG70 bound to the active site of the 
menG enzyme.  
5.6.10 Loop dynamics of MenG protein and distance metrics 
The evolution of enzymes often involves sequence changes in loop regions. The study of 
loops can provide useful scientific significant reports in determining the protein functions, 
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including shape, dynamics, binding properties, and physicochemical properties of proteins. 
They are located on the surface of the protein and often, follow a regular pattern. They are 
instrumental in protein study whereby loops function as connecting ends for secondary 
structure (α-helices and β-sheet), protein-ligand interactions, protein-protein interactions, 
enzyme catalysis, and recognition of sites.68 The biological function of loops depends on the 
determinants of their plasticity and the time scale of motions. 
There seemed to be little bioinformatics and the experimental findings of methyltransferase 
protein superfamily, especially the loops of the menG enzymes. Generally, the loops are not 
readily observable. However, we found three loops around the active site and studied them to 
determine their probable roles in the menG conformation and the binding properties. The 
three menG loops contain residues 40-54 (blue), 102-112 (green), and 211-220 (yellow) as 
shown in Figure 5.9. The residues 40-54, 102-112 and 211-220 visually looked omega-like 
loop (Ω loop) and showed that the loops involved in the menG molecular recognition and 
regulatory functions.68 Essentially, residue 211-220 may be the common K-loop in the 
methyltransferase family that changes conformation upon activation to block the S-adenosyl-
L-methionine-binding. Hence, we presumed that menG inhibitor bound to the active site of 
co-factor (SAM) against the substrate’s site. Subsequently, residues 211-220, the Ω loop is 
referred to as the Thompson loop and used interchangeably. To determine the potential roles 
of these loops, we studied the visual static loop structures to observe possible conformational 
changes in both the Apo and inhibitor-bound systems. Figure 5.9A and Figure 5.9B showed 
significant conformational changes in the three loops of the Apo and the DG70-bound 
structures, respectively, as the simulation time increases (Pre-MD (0), 0.5, 150, and 300 ns).
Thompson loop is essential in the binding of DG70 because it contains at least three most 
contributing interacting residues, including GLY217, ILE219, and VAL220 of the active site 
and loop. The active site residues GLY217, ILE219, and VAL220 form the part of the 
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Thompson loop that cause open conformation in the Apo system as simulation time increases. 
And the residues GLY217, ILE219, and VAL220 of the Thompson loop cause closing 
conformational changes in the DG70-bound complex as the simulations time increases. 
Figure 5.9. Illustration of the opening and closing conformational change of the unbound and bound 
menG protein. A; Unbound systems superimposed snapshot at 0, 0.5, 150, 300 ns showing the active 
site opening of Thompson loop (yellow) and B; bound systems superimposed picture at 0, 0.5, 150, 
300 ns showing the active site closing conformation by Thompson loop (yellow).
Therefore, the close conformation of the menG loop (Thompson loop) enhances the binding 
of DG70 and subsequently, its therapeutic effectiveness. Specifically, the changes in the 
formation are due to the loop residues ARG40, GLY217, ILE219, and VAL220 which 
control the opening and closing of the active site.
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Second, the RMSD and RMSF were estimated to explore the dynamics of the stability and 
flexibility of the enzyme loops, respectively. According to the Figures 5.10B, 5.11D, and 
5.11F plots), the unbound systems of the loops maintained a stable structure throughout the 
simulation time (RMSD < 6.5 Å) while the binding of DMK9 and DG70 induced 
conspicuous deviations in menG. The fluctuations occurred between residues 115-223, which 
contained GLY217, ILE219, and VAL220 that form hydrophobic and hydrogen bond 
interactions.
Figure 5.10. A; illustrates three loops in menG protein: residues 40-54 (green), 102-112 (yellow), and 
Thompson loop (red) along the trajectory. RMSD (B) and RMSF values (C) of the loops.
The atomistic deviations of < 4.5 characterized the residues 102-112 and 211-220 were 
higher RMSD (~ 6.5 Å) in the region of loop 40-54. Thompson loop was stable throughout 
while loop 102-112 deviated (2.0 to 4.5 Å). DMK9 and un-liganded menG systems had 
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RMSF values of ~ 4.25 Å and 4.00 Å respectively in the first loop (residues 40-54) and 
second (residues 102-112) loop while the DG70-bound complex had a higher RMSF value of 
~ 6 Å. Hence, the binding of DG70 was not felt around these loops although the RMSF 
significantly decrease to ~ 3.2 A in the second loop and remained lower (below 3.0 Å) in 
residues 211-220 than the RMSF of the Apo structure. This finding showed that Thompson 
loop has a profound impact in the binding of DG70 to menG and this correlates with the 
PRED which depicted that three of the interacting residues (GLY217, ILE219, and VAL220) 
found in the third loop. 
Figure 5.11. Conformational dynamics of Loop 102-112 and 210-220. D and E are the RMSD and 
RMSF for loop 102-112. F and G are the RMSD and RMSF for Thompson loop. 
Considering the averaged data, the DG70-bound menG had the highest mean RMSD value of 
5.84 Å and mean RMSD values 3.34 Å in the loop 40-54 region. The mean RMSD value 
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(5.84 Å) of Apo across the loops except for residues 102-112. Therefore, we can infer that the 
binding of DG70 caused instability in the menG structure because of inhibition. 
Figure 5.10C, 11E, and 11G plots showed the RMSF values of the three loops. The highest 
average RMSF values of Apo, DMK9-bound, and DG70-bound were observed in the loop 
40-54 region. In comparison, DG70-bound menG and Apo had RMSF values of 3.34 and 
3.04, respectively, which implies similarities in their flexibilities. Table 5S1 (Supplementary) 
detailed the loops averaged RMSD and RMSF estimated for the unbound and bound-menG 
system.
To further probe into the inhibitory efficacy of DG70 on the inter-residual dynamics and 
motions of menG, the distance, D analysis was estimated from the snapshots of the 300 ns 
MD simulations of the Apo and bound-menG systems. The distances measured at 0, 150, and 
300 ns between the interacting residues VAL145 and ILE219 of the bound and unbound 
menG. Figure 5.12A, 5.12C and 5.12E showed that the distance between the two residues in 
the unbound menG decreases with increasing simulation time. At 0 ns, the distance was 
12.356 Å and rose to 18.91 Å after 150 ns, and 20.49 Å after 300 ns.  On the contrary, the 
distance between the two residues in the DG70 bound system decreases; between 0 ns and 
150 ns, the distance decreased from 11.55 Å to 8.12 Å and again decreased to 7.36 Å after 
300 ns Figure 5.12B, 5.12D and 5.12F. 
The distance increased in the Apo structure and decreased in the DG70-bound in the same 
proportion as the simulation time. The decrease in the distance enhanced the DG70-bound 
menG interactions and the stability of the system. In other words, the decrease in the distance 
caused stronger interactions between the DG70 and the interacting residues at the active site, 
thus, promoting effective inhibition of the methylation activity of menG enzyme.
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Figure 5.12. Distance (D) between VAL145 and ILE219 of the Apo and DG70-bound menG 
measured using the snapshots taken at 0, 150, 300 ns MD simulations. The D (Å) measured from Apo 
snapshots (ns) A (0), C (150), and E (300) are 12.356, 18.911, and 20.493 respectively. The D 
measured from DG70-bound snapshots B, D, and F are 11.549, 8.119, and 7.356, respectively.
5.6.11 Secondary structure (DSSP) analysis of MenG systems
A secondary structure assignment analysis carried out to study the prominent secondary 
structure elements, including alpha helices, beta sheets, loops, and coils in the menG protein 
during the whole 300 ns simulation time. There were 9α-helices, 4β-sheets, and three long 
conspicuous loops in the menG structure discussed above before simulations (supplementary 
Figure 5S3A). However, after post-MD simulations, (supplementary Figure 5S3B) revealed 
the visual transformations in the secondary structure of menG such as conformational 
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changes in the helices and β-sheets, perhaps, changes to the loop structures because there 
seemed to be helices and beta sheets that transformed to loop. 
Therefore, we did a comparative defined secondary structure of the un-liganded, DMK9-, and 
DG70-bound menG systems. The trajectories of the snapshots after at 300 ns were obtained 
and plotted using the in-house protocol. Supplementary Figure 5S4 depicts the secondary 
structures of menG after 300 ns MD simulations. Supplementary Figure 5S4A is the unbound 
menG after 300 ns. We discovered that there were changes from the helices to loop and beta 
to loop after the 300 ns that led to the increased number of loops in the bound systems; there 
was a drastic change from alpha to bend (residues 1-101 and 142-178) and turn (residues 
181-201) in DG70-bound menG (Supplementary Figure 5S4C) at 300 ns. There were 
transitions in the residues 31-39, 154-160, and 225-229 from the helices to bend upon DG70 
binding. There were also transitions in the beta residues 85, 117, and 142-146 to bend. On the 
other hands, there was a change from alpha to bend upon the binding of DMK9 to menG 
(Supplementary Figure 5S4B) in residues 1-31 after the 300 ns. These changes in the 
elements of menG secondary structure were the cause of the instability69 that the DG70-bound 
menG displaced in the RMSF values of the whole and the loop regions stated in sections 5.7 
and 5.10.
5.6 Conclusion
The detailed molecular modelling study and the dynamics analyses provided in this report 
sets out the unique structural features and the conformational changes in menG whole 
structure and the omega-like loops especially the Thompson loop (residues 211-220) region. 
First, the Uniprot annotated residues were among the predicted active site residues. 
Nevertheless, the per-residue decomposition analysis showed that the none of the annotated 
residues did interact with DMK or DG70. On the other hand, PRED revealed that the 
substrate and the inhibitor bound to interacted with different residues which separates 
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different active sites. Second, the predicted active site showed similarity to the previous 
prediction, however, the Ramachandran plot revealed that residues 7, 9, and 10 considered as 
interacting residues in the previous work are outliers. 
Homology modelling revealed the secondary structure of the menG enzyme and some static 
features including the loops, α-helices, β-strands and GXG motif that showed similarities 
with the superfamily of methyltransferase. MD simulations showed motional deviations in 
the menG whole and its loop at the binding site. The stability of the DG70-bound system 
showed the consistency of the bound inhibitor at the active site throughout the 300 ns 
simulations. This complex stability correlates with the high binding free energy calculated 
and the residue-ligand interaction networks characterized by the strong hydrophobic, halogen, 
and hydrogen bond.
The graphical investigation of the loop dynamics at different time intervals confirmed the 
strong flexibilities that occurred in the whole structures of the free and the bound menG 
systems revealed by the RMSF analysis. The decreased distances between the interacting 
residues VAL145 and ILE219 in the DG70-bound system as against the increased distances 
between the same residues in the un-liganded system throughout a 300 ns MD further 
confirmed the binding impact of DG70 on inhibition of menG catalytic activity. The PCA 
eigenvectors obtained from the simulations showed clear variations among the systems which 
confirmed the dynamic conformational changes from the free to ligand-bound protein. 
Visually, there were some transitional changes in the secondary structure of menG to the 
loops hence, the free and the bound systems were analysed using DSSP analysis which 
confirmed some conformational transformations such as helices to the loop. 
Perhaps, it is important to carryout experimental analysis such as crystallographic studies to 
further explore the menG loops in relation to their functions in the ligand binding. The 
homology modelling insights will serve as aid to the researcher to synthesize the crystallized 
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structure of this protein. Moreover, the demonstration of the above binding landscape of 
menG protein provides the basis that can utilize pharmacophore models in screening for 
better effective drugs with tolerable or no toxicity.   
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6.1 Abstract
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Mycobacterium tuberculosis (Mtb) encoded secreted antigen 85 enzymes (Ag85A/Ag85B/ 
Ag85C) play that critical roles in the virulence, survival, and drug-resistant TB of the 
pathogen. Ag85 proteins are potential antitubercular drug targets because they are essential in 
the catalytic synthesis of trehalose moieties and mycolic acid attachment to the Mtb cell wall. 
Recently, experimental protocols led to the discovery of a selective covalent Ag85 inhibitor, 
β-isomer monocyclic enolphosphorus Cycliphostin (CyC8β) compound, which targets the 
Ag85 serine 124 to exhibit a promising therapeutic activity. For the first time, our study 
unravelled the structural features among Mtb Ag85C homologs and motions and dynamics 
of Ag85C when the CyC8β bound covalently and in open model conformations to the protein 
using bioinformatics tools and integrated Molecular dynamics simulations. Comparative 
Ag85C sequence analysis revealed conserved regions; 70 % active site, 90 % Adeniyi loop 
L1, and 50 % loop L2, which acts as a switch between open and closed conformations. The 
average C-α atoms RMSD (2.05 Å) and RMSF (0.9 Å) revealed instability and high induced 
flexibility in the CyC8β covalent-bound compared to the apo and open model systems, which 
displayed more stability and lower fluctuations. DSSP showed structural transitions of α-
helices to bend and loops to 310-helices in the bound systems. SASA of CyC8β covalent bound 
showed active site hydrophobic residues exposure to huge solvent. Therefore, these findings 
present the potential opportunity hotspots in Ag85C protein that would aid the structure-
based design of novel chemical entities capable of resulting in potent antitubercular drugs.
Keyword: Antigen 85, Adeniyi Loops, drug-resistant TB, Molecular dynamics simulations, 
β-isomer enolphosphorus Cycliphostin (CyC8β).
6.2 Introduction
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Tuberculosis (TB) is a lung infection caused by the pathogen known as Mycobacterium 
tuberculosis (Mtb) that has “blown away” human generations. About 10 million new TB 
infections, which result in approximately 1.3 million deaths1 are reported annually in 
humans.2 Although there have been various strategies, including diagnosis, vaccine program, 
and curative therapy channeled toward TB eradication, high morbidity and mortality rate of 
TB has continued for many decades. More challenging TB is the metamorphosising active 
form caused by the evolving Mtb strains due to mutation-mediated resistance such as the 
non-synonymous single-nucleotide polymorphisms (nsSNP)3, 4 in Ag85 protein by insertions 
or deletions in the genes encoding from drug target/drug metabolic pathways. Besides, the 
induced-mutation resistance could also occur due to clonal expansion and independently 
acquired drug resistance.5
Moreover, the slow growth rate of bacilli and the thick, greasy drug-impermeable nature of 
the cell wall contributes to the success of the Mtb drug resistance. The increasing rate of 
active TB (or extensively/multidrug) resistant TB is quite worrisome. Some of the frontline 
antitubercular drugs exhibiting resistance include isoniazid, rifampicin. Moreover, literature 
has shown that new drugs like bedaquiline exhibit frameshift and phenotypic drug-
resistance.6,7 Although some of these drugs are still therapeutically relevant, especially as 
combined anti-TB therapies, an associated severe problem is the many drug dose and dosage 
regimen, requiring two years treatment period, which results in an inherent difficulty in the 
patients' compliance.8 
The cell of mycobacteria contains different proteins that are responsible for the successes of 
the microorganisms in pathogenesis, survival, and resistance to many drugs.8,9 Among these 
proteins, Mtb antigen (Ag) 85 protein complex (Ag85A, Ag85B, and Ag85C) bind to the 
human fibronectin via ether heparin and cellular-binding domains or a collagen-binding 
domain as it escapes the host immune system.10,11 Ag85 proteins are potential targets for the 
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treatment of drug-susceptible and drug-resistant TB because they catalyse the attachment of 
mycolic acids in the cell wall and biosynthesis pathway of TMM and TDM.12 Mycobacterium 
tuberculosis cell envelope comprises macromolecules, the mycolyl-arabinogalactan-
peptidoglycan. In other words, the macromolecules include mycolic acids, arabinogalactan 
(AG), and peptidoglycan (PG), (mAGP complex). PG is found outside the plasma membrane 
covalently linked to the AG. The mycolic acids are long-chain α-alkyl-β-hydroxyl fatty acids 
(C70-90) that occupy about 60 % of the whole cell wall and are attached to the AG. They are 
esterified to the monomycolate (TMM) or dimycolate (TDM) of trehalose, which serve as 
donors in the metabolism of mycolic acids. Moreover, the mycolic acids interspersed with 
non-covalent glycolipids, proteins, and outer polysaccharide capsules.9 
Mtb antigen 85 enzymes are quite crucial in the attachment of mycolic acids to the cell wall 
and synthesis of trehalose moieties. Besides, this protein involves the efflux mechanism, 
which may result in the phenotypic resistance. 
The enzymes share common structural and functional similarities such as mycolic acid donor 
TMM and 68-79 % conserved catalytic site sequence identity. Additionally, they have serine 
mycolyl esterase activity, carboxylesterase consensus sequence (GXSXG), among others.13 
Therefore, a single removal of one of the enzymes affects the complex containing the three 
proteins. Precisely, the alteration of the fbpC2 gene result into 40% reduction in the AG-
attached mycolic acids and the reductive impact on either fbpA or fbpB genes leads to TDM 
reduction, which indicates low functional activity 14, 15 
Figure 6.1 illustrates structural features of Ag85C protein. Mycobacterium 
tuberculosis antigen 85C possesses α/β fold arrangements that are typical of the hydrolase 
family.13 This feature is an implication of similarities in the sequence, mechanism, and 
structural studies for the antigen enzymes. The Ag85C is a 31.5 kDa10 secreted protein 
comprising of about 274 amino acids residues (PDB code 5OCJ)12. The crystallized structure 
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consists of Chain A (8-282 residues) and Chain B (6-282 residues) located in the C-terminus 
except for the FSRPG residues, which are found in the N-terminus.10 The inhibition of the 
catalytic mechanism of the Ag85C enzyme involves the attack of its nucleophilic serine by a 
selective covalent inhibitor. The proteins exhibit a conserved catalytic triad (SER124, 
GLU228, HIS260) at the active site, about nine α-helices arranged in up and down circular 
fashion surrounded by parallel and one opposite β-sheets localised at the centre. 
Figure 6.1. The 3D structure of Ag85C protein detailed some of its structural features; α-helices (lime 
green), β-strands (Salmon), and loops (dark cyan); Serine124 (blue) in complex with open model 
CyC8β (yellow).
Drug-rug-resistance TB, "The wicked monster" and has rendered many novel efficacious 
antimicrobial drugs ineffective for decades. Although some of the current antitubercular 
agents against the cell wall proteins are still relatively potent, as combined therapy, many 
challenges are confronting the long-term effectiveness and efficacy of these drugs. First, poor 
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patient compliance often due to massive doses and lengthy dosage regimen eventually results 
in drug resistance.16 For instance, the inhibitor, including promising ebselen (selective 
covalent inhibitor) bonded with Cysteine-209 (proximal residue to the active site) of Ag85C, 
in synergy with p-chloromercuribenzoic acid and iodoacetamide to inhibit the enzyme's 
catalytic activity.17 However, the studies also revealed that the Mtb Ag85C mutants disrupted 
the essential interactive hydrogen-bond network at the active site linked to selective covalent 
inhibition.17 Second, TB and HIV/AIDS co-infection in human also contributes to the success 
of drug-resistant Mycobacterium strains.18, 19, 20 And again, the impact of the outbreak 
COVID-19 infection caused by new novel severe acute respiratory syndrome coronavirus 
(SAR-CoV-2), was anticipated and found to increase the annual human TB deaths21, 22. 
Moreso, the infections are pulmonary infections.
The design of small molecules against TB recently led to the discovery of some cyclipostins 
and cyclophostin phosphonate analogues (CyCs) and cyclic enolphosph(on)ate compounds.  
The compounds exerted their therapeutic activities by inhibiting the catalytic synthesis of 
Ag85 through the selective covalent bond formation with Ag85 SER124. This intentive 
approach showed potent antimycobacterial activity with low toxicity towards the host cells.23 
The compounds have a strong affinity for lipolytic enzymes bearing a catalytic serine (SER) 
or cysteine (CYS) residues to impair enzyme activity involving a wide range of physiological 
processes.8 The mechanism of action of the compounds follows a putative selective covalent 
inhibition; nucleophilic attack by a catalytic SER or CYS to form a covalent bond between 
the enol-phosphorus atom and the catalytic residue.8 In a previous study, among eight 
members that exhibited antitubercular activities, CyC7β and CyC8β showed strong in 
vivo potencies (MIC50, µM IC50 = 3.1 and ≈11.6 respectively). In contrast, CyC17 showed in 
vitro (MIC50 = 0.5 µM but lack intracellular activity. Again, another study confirmed CyC8β as 
the most potent inhibitor with IC50 =55 ±5 µM) against Ag85C protein, while CyC7β and 
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CyC17 followed.12 The CyC8β inhibited the Ag85C activity onto trehalose, which prevents the 
mycolic acid transfer to AG in the cell wall and the TDM/TMM synthesis. Therefore, we 
considered cis (β-isomer)-monocyclic enolphosphonate cycliphostin (CyC8β). Figure 6.2 is the 
2D chemical structure of CyC8β that was cleaned with 3D add on in the MarvinSketch 
software-17.21. (http://www.chemaxon.com/).
Figure 6.2. 2D structure of Ag85C inhibitor, a monocyclic enolphosphonate cyclophostin. 
Here, the protein sequence alignment analysis among the homologs of Mtb Ag85C protein 
and selective covalent inhibition of Mtb Ag85C using the molecular dynamic (MD) 
simulations of the free and inhibitor-bound in two docked mode studied for the first time. 
Therefore, our study investigated the interactions between the Ag85C protein and inhibitor 
(CyC8β) at the molecular level using bioinformatics Tools and molecular dynamics methods. 
This study unravelled Ag85C structural features using bioinformatics Tool and integrated 
molecular dynamics (MD). Furthermore, we investigate the dynamics and motions of Ag85C 
when CyC8β bound covalently and noncovalently to the protein.
6.3 Bioinformatics Tools and Computational Methodology
6.3.1 Sequence alignment of the homologs of Mycobacterium tuberculosis Ag85C 
protein
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Bioinformatic Tools are useful in the drug design research, and we had used it in our previous 
studies to comparative sequence alignments among the protein homologs.4 The unique 
regions in the primary structures of five (5) homologs of the Mycobacterium 
tuberculosis antigen 85C enzymes investigated using the sequence alignment tools adds-on 
available through UCSF ChimeraTool-1.13.1 with the default setting.24 
Table 6.1 showed the respective Uniprot accession codes and the number of amino acid 
residues of the homologs of Mycobacteria Ag85C protein including M. tuberculosis, M. 
smegmatis, M. marinum, M. leprae, and M. ulcerans used for the multiple sequence 
analysis.25 The mycobacteria species were chosen based on the pathogenesis, virulence, 
survival, and resistance success. 
Table 6.1. UniProt/PDB information of five mycobacteria antigen 85C homologs
Mycobacterium species      Uniprot Number of Amino 
antigen 85 C Accession code     acid residue
M. tuberculosis 5OCJ (PDB chain B) 302
M. smegmatis A0A0D6IE52 335
M. marinum B2HLP6 346
M. leprae Q05862 333
M. ulcerans A0A1B4Y981 346
The conserved regions can be depicted as identical, partially conserved, or poorly conserved 
depending on the similarities across the amino acid residues. The active site was taken from 
the previous studies and validated by the identifying the interacting residues including the 
SER124, ASP38, LEU40, ARG41, ILE222, PRO223, PHE226, LEU227, GLU228, and 
HIS260 with selective covalent inhibitor (CyC8β) of Ag85C enzyme using the crystallised 
structure obtained from the Protein Data Bank (PDB code: 5OCJ).12 Sequence analysis 
completed using the Chimera Tool visualisation software.26 Two Loops of the crystallised 
structure envisaged to be crucial to ligand-binding/inhibitory mechanism. These two Ag85C 
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loops interchangeably call Adeniyi Loops L1 an L2. Therefore, we determined the sequence 
conservation of the flexible Loops LI and L2. 
Furthermore, we carried out the homology modelling of the homologs of Mycobacterium 
tuberculosis Ag85C enzymes using the amino acid sequence of each organisms to determine 
the 2D protein structures of these Mycobacteria for probable future studies. Table 6.2 
summarises the template quality criteria obtained from the SWISS-MODEL online server 
used for choosing the templates; sequence identity and sequence similarity, Global Model 
Quality Estimate (GMQE)27, and Quartenary Structure Quality Estimate (QSQE)28. The server 
models the target with top-ranked templates from the several similar quality templates 
considering the quality criteria. The top-ranked templates and alignments are compared to 
verify alternative conformational states or cover different regions of the target protein. The 
GMQE provides information about the stability of the model, and it scales from 0 to 1. The 
GMQE values of the study models are close to 1 (ranges between 0.63 and 0.83), which 
showed that the models were stable. The Quality Model Energy Analysis (QMEAN) is a 
composite scoring function (or Z scores) describing the major geometrical aspects of the 
protein models,29 which is critical to the model quality. The sequence identity (%) of Mtb, M. 
smegmatis, M. marinum, M. leprae, and M. ulcerans were 100, 78.09, 92.47, 71.79, and 
92.47, respectively. 
Table 6.2. Template and Quality criteria for modelling the homologs of mycobacteria Ag85C protein 
obtained from the Swiss-model resource.30, 31
    Ag85C  Template          Seq. (%) Seq. (%)      QSQE QMEAN  GMQE
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     Model Identity  Similarity
    M. tuberculosis    5kwj (Ag85C)        100.00  1.00  1.49     0.81         0.63
    M. smegmatis.      1va5 (Ag85C)          78.09  0.56  0.00    -0.00         0.76
    M. marinum.        1va5 (Ag85C)           92.47  0.61             0.00     1.07         0.78
    M. leprae.            4qek (Ag85C)           71.79  0.59             0.00     1.02         0.83
    M. ulcerans.        1va5 (Ag85C)            92.47  0.61             0.00     1.07         0.77
Note: M. = Mycobacterium, QSQE = Quartenary Structure Quality Estimate, QMEAN = Quality Model Energy 
Analysis (or Z-scores), GMQE = Global Model Quality Estimate.
6.3.2 Systems preparation
The X-ray crystal structure obtained from the RSCB Protein Data Bank (PDB code: 5OCJ) 12 
consists of two chains of Mtb Ag85C. Chain A contained partial 3D-structure of the inhibitor 
(CyC8β) and chain B included a full 3D-structure of the inhibitor with both modelled in an 
open conformation and other co-crystallised molecules including DMS and water. However, 
since both monomers contained the active residues, we chose chain B because it saves the 
stress and time of extracting the inhibitor from chain A or drawing it. Another reason for 
choosing chain B was because it is co-crystallized with a full structure of Compound CyC8β 
while Chain A was co-crystallized with a partial structure of the CyC8β. We prepared the 
selective covalent system in section 6.3.1 and set up noncovalent inhibition (open model 
system) to compare the activities. The preparation of the unliganded and CyC8β-bound Ag85C 
involves the removal of co-crystallised molecules carried out using UCSF ChimeraTool-
1.13.114 to obtain Ag85C monomer and the CyC8β for molecular dynamics (MD) 
simulations.
6.3.3 Molecular dynamics (MD) simulations
The applications of computational methods provide comprehensive insights into the structural 
dynamics and motions of biological molecules, using and the molecular dynamics (MD) 
simulations methods are extensively useful to study proteins. In other words, the methods 
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assist in the drug discovery and development to explore the biophysical properties of the 
molecules up to the atomistic level.32 The molecular dynamics simulations of the unbound 
and bound systems was set up using the graphic processor unit (GPU)-Compute Unified 
Device Architecture (CUDA) accelerated version of AMBER18 package with integrated 
Particle Mesh Ewald Molecular (PMEMD) engine and LEAP modules.33 Partial atomic 
charges were added to the CyC8β compound using antechamber module by applying a 
ff14SB/General Amber Force Field 34, 35 and restrained electrostatic potential procedures.32 
Before running the LEAP module, the execution of pdb4amber script added hydrogens to the 
histidine residues at a constant pH, which automatically modify the protein system for use 
with tleap. Again, LEAP module was applied to neutralise Ag85C systems and solvate all 
atoms explicit in an orthorhombic TIP3P box of solvent (water) molecules sized 10 Å by 
adding the hydrogen atoms, sodium, and chloride ions.
An in silico in-house protocol devised to enhance the selective covalent inhibition reported 
by Khan et al. 36 finds application to set up an irreversible bond system between Ag85C 
Serine124 and CyC8β. Dabble interfaces Tool to generate the input files containing the 
topology and coordinates for the simulation of the covalent system.37 The apo and bound 
Ag85C were partially minimised (with restrained with a potential of 10 Å) in two steps 
sequence using 500 steepest descent and full minimisation (without restraint) of 2500 and 5 
steps of a conjugate gradient. Moreover, the study systems underwent a three-step gradual 
heating process from 0–300 K and further restrained with a potential of 10 Å. Finally, a 
potential harmonic restraint of 10 kcal/mol*Å2 for solute atoms and a Langevin thermostat 
with a collision frequency of 1ps were applied to the systems before the stabilisation of the 
system. By keeping pressure and the atom number constant, eight steps equilibrations were 
executed for 2.5 ns while maintaining the pressure of 1 bar using Berendsen-Barostat and the 
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SHAKE algorithm for the hydrogen bond constraint before running 350 ns MD simulations.38, 
39 
The post-MD coordinates and trajectories obtained were analysed using the integrated 
CPPTRAJ and PTRJ modules containing in the AMBER 18 package.40, 41 Subsequently, some 
post-MD analyses including root-mean-square fluctuation (RMSF), the radius of gyration 
(RoG), Dynamic cross-correlation matrix (DCCM), definition secondary structure protein 
(DSSP), others used to investigate the molecular systems in this study. DCCM is widely used 
as a post-MD analysis to estimate the correlation coefficient of inter-residue motions and 
dynamics of a protein; mostly used to compare the dynamic movements of a free protein and 
ligand-residue interactions profile.32 Lastly, the structural and visual analyses obtained with 
the graphic interface of the UCSF Chimera Tool-1.13.126, 42 The data plotted with MicroCal 
Origin 6.0 data analysis software.43 
6.4 Post MD analysis 
6.4.1 Root mean square fluctuations (RMSF) 
The root mean square fluctuation (RMSF) analysis provides the estimation of the properties 
of biological molecules in drug design study, the interactions of protein-protein or protein-
ligand at the atomistic level. It indicates the changes in the fluctuations of a protein structure 
upon the binding of a ligand 36; ligands in this study, selective covalent CyC8β, and open 
model CyC8β-bound. RMSF is the fluctuation of the individual residue of an enzyme or their 
average position in an obtainable MD simulation trajectory. This analysis provides insights 
into the flexibility differences in different regions of Ag85C enzymes in the unbound, 
bound/covalent systems. RMSF is mathematically represented and calculated as follows:
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RMSFi is the RMSF of the ith residue from which the RMSF of the average is taking and 
divided by the RMSF's standard deviation [σ(RMSF)] to yield the resultant standardised 
RMSF [s(RMSFi)]. 
6.4.2 Dynamic correlation coefficient matrix and Principal component analyses
The Dynamic correlation coefficient matrix (DCCM)44 and the Principal component analysis 
(PCA)45 are another two important post-MD simulations analyses that have been used 
extensively in the study of protein-ligand interactions. C-α atoms DCCM, also known as 
dynamic cross-correlation, measures the strength and similarities (i.e., correlation coefficient) 
of the linear relationship in motion between the inter-residues of a protein.46 We calculated 
the dynamic cross-correlation based on the Ag85C fluctuations upon ligand binding to 
compare with the apo system during the simulations using the AMBER18 incorporated 
CPPTRJ module. DCC scales from -1 (if correlation is perfect negative), 0 (no correlation) or 
+1 (if correlation is perfect positive).32 Mathematically, this analysis is as follows:
Where Cy = correlation coefficient, i = ith residue, j = jth residue, while ith and jth are both 
the corresponding displacement vectors, respectively.44
The PCA is another essential post-dynamic analysis used with MD simulations with a 
trajectory to study the protein structures. PCA identified the most significant modes of 
protein fluctuation with the system's motion about the eigenvectors (direction) and 
eigenvalues (magnitude).44 However, the PCA provides insights into the direction and extent 
of the movement of each residue in a protein to understand the principal fluctuation modes in 
the conformational and dynamic changes occurring during simulations. The relative changes 
that occurred in Ag85C protein upon the covalently binding of CyC8β and open model CyC8β 
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conformation were studied using the PCA. The magnitude and vector of the motion of 
enzymes depicted by eigenvalues and eigenvectors and computed using the integrated 
AMBER18 CPPTRJ module.47 The first two principal components, PC1 and PC2, were 
calculated from the dynamics of the enzyme C-α atoms, and the conformational changes of 
the apo and bound Ag85C systems viewed along ev1/PC1 plotted against ev2/PC2 with C-α 
atom Cartesian coordinates.
6.4.3 Thermodynamic calculations
The molecular mechanics/generalised-born surface area (MM/GBSA) method was used to the 
calculations of binding free energy (BFE) of the protein system.41 It is an imperative method 
used to determine the in-depth binding mechanism of the receptor-ligand interacting systems. 
Here, we used the BFE with the MM/GBS technique to estimate the binding affinity within 
the docked Ag85C-CyC8β system to gain insights into their binding landscape.48 Thus, we 
employed this approach to calculate the binding free energies of the inhibitor CyC8β modelled 
in the open conformation using 35 000 snapshots generated from the 350 ns trajectories. The 
MM/GBSA protocol requires that the used explicit solvent be discarded and substituted with 
a dielectric continuum. The binding free energy (ΔG) calculated for the open modelled CyC8β 
and covalently bonded systems expressed thus:
ΔGbind = ΔGcomplex – ΔGreceptor – ΔGligand
ΔGbind = Egas + Gsol – TΔS
Egas = Eint + EvdW + Eele
Gsol = GGB + GSA
GSA = γSASA
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where ΔGbind is the gas-phase summation, Egas denotes the gas-phase energy and solvation 
energy (Gsol) < the entropy (TΔS), Eint = internal energy, Coulomb (Eele), and van der Waals 
energies (EvdW). The Egas estimated from the AMBER FF14SB force field terms. Polar and 
non-polar states' energy contributions accounted for the Solvation free energy, Gsol. The non-
polar solvation energy, SA. GSA was calculated using the solvent-accessible surface area 
(SASA) obtained by a water probe radius of 1.4 Å. In contrast, the polar solvation, GGB, was 
obtained by solving the GB expression. The S denotes the total entropy of the system, which 
was calculated using the normal mode analysis incorporated in AMBER Tools 49 and T is the 
temperature. The interaction entropy (–TΔS) was estimated using 40 frames due to the 
computational cost of calculating the change in conformational energy for large frames using 
normal mode method. The surface tension constant, γ, was set at 0.0072 kcal/ mol*Å2. The 
contribution of each residue to the total binding free energy obtained at the predicted active 
site by carrying out per-residue energy decomposition at the atomic level using MM/GBSA 
method in AMBER 18.40, 41
6.4.4 Per-residue energy decomposition (PRED) analysis
The PRED performed to obtain the contribution of each residue to the total binding free 
energy profile between the inhibitor CyC8β modelled in the open conformation Ag85C 
enzyme. PRED analysis achieved using the MM/GBSA method in AMBER18 GPU.  
6.5 Results and Discussions
6.5.1 Amino acids sequencing of homologs of Mycobacteria Ag85C protein  
Comparative amino acid sequence alignment of the Mycobacterium tuberculosis Ag85C 
enzyme and its four homologs (Figure 6.3). The sequence analysis showed that the active site 
of the protein is 70 % fully conserved (red), including residue SER124 (light blue region) that 
forms a covalent bond with selective covalent inhibitor CyC8β and 20 % partially conserved. 
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Moreover, we observed that a leucine and aspartic residue-rich flexible loop, L1 (green arrow 
region) comprising of residues LEU36, LEU37, ASP38, GLY39, LEU40, ARG41, ALA42, 
GLN43, ASP44, ASP45, and TYR46 in Mtb Ag85C enzyme. L1 residues are more than 90 % 
conserved among the homologs of the Mtb Ag85C enzyme. ASP44 of Ag85C is the only 
partially conserved residue because glutamine (GLU) replaced it in the M. leprae. This loop 
contains three of the active site residues; ASP38, LEU40, ARG41. Thus, we investigated the 
static and dynamical motions of loops L2 to explore its potential as a weak hotspot for 
designing antitubercular drugs. 
Similarly, the second flexible loop, L2 (blue arrow region) is a glycine-rich, proximal to the 
active site, implying possible impactful structural conformational activities upon ligand 
binding. This loop contains residues including CYS209, GLY210, ASN211, GLY212, 
THR213, PRO214, SER215, and ASP216. Loop L2 is 50 % fully conserved and 40 % 
partially conserved among these mycobacteria. Notably, the glycine-rich residues conserved 
in all the five mycobacteria species except M. leprae. Also, the sequence alignment showed 
catalytic triad residues SER124, GLU228, HIS260 (purple downward arrow). Both SER124 
and HIS260 are 100 % conserved among the mycobacteria while GUY228 is conserved in all 
the M. homologs except M. leprae Ag85C, which has the catalytic glycine replaced by serine. 
In this study, the structural similarities and differences in the sequence discussed among the 
M. tuberculosis, M. smegmatis, M. marinum, M. leprae, and M. ulcerans are potential 
hotspots that may be explored in the identification of a promising antimycobacterial 
compound.
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Figure 6.3. Comparative sequence analysis of five Mycobacteria Ag85C enzymes; tuberculosis, 
smegmatis; marinum, leprae, and ulcerans. The active site residues of the Ag85C proteins, including 
SER124, are 70 % fully conserved (red) and 20 % partially conserved. Catalytic triad residues (purple 
downward arrow region). Aspartic acid-rich loop (L1) is > 90 % fully conserved (green arrow region) 
while the glycine-rich loop L2 (blue arrow region) is 50 % fully conserved and 40 % partially 
conserved.
6.5.2 Pre- and post-covalent bond formation between Ag85C and inhibitor CyC8β 
Figures 6.4A showed the catalytic serine residue (SER124) of Ag85C protein before bonding 
to the selective covalent inhibitor (CyC8β), and Figure 6.4B presented the putative covalent 
bond between the protein and the ligand. The covalent bond created using the dabble tool, 
which also generated the parameter and topology files we used for running molecular 
dynamics analysis of the protein-ligand system. The post-MD study carried out in 
comparison with the apo and noncovalent or open model (CyC8β) modelled in an open 
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conformation) systems. Moreover, the figures identified the two loops concisely discussed in 
section 6.5.1: Adeniyi loops L1 and L2 before and after the covalent bond formation.
Figure 6.4. Structure of Ag85C protein showing the catalytic SER124 (yellow) before the covalent 
bond formation (A) and post-covalent bond creation (B). Studied loops L1 (purple) and L2 (sandy 
brown), also named Adeniyi loops at 50 ns MD simulations.
6.5.3 Ligand-residues profile and per-residue energy decomposition (PRED)
Here, we ignored the interactions of the other residues with the ligand (CyC8β) and assumed 
the bonding with SER124 while there might be other interactions in the selective covalent 
inhibition system. Whereas, in the open model ligand-protein system, Figure 6.5A illustrates 
the interaction network between the ligand (CyC8β) and Ag85C residues after 350 ns MD 
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simulations. Figure 6.5B showed the CyC8β docked in the open conformation within the 
active site of the Ag85C enzyme. 
PRED is a reliable, rational drug design approach.41 To obtain the interaction profile between 
CyC8β and Ag85C interface, we performed residues binding free energy (BFE) decomposition 
analysis and determined the individual binding free energy. The total BFE for the CyC8β 
compound was decomposed into individual residue-based contributions using the MM/GBSA 
approach. Figure 6.5C showed the van der Waals (vdW) and electrostatic (elec) interaction 
contributions based on the BFE of CyC8β-Ag85C were estimated to obtain insights into the 
residues and energy constituents having more significant impacts on the total energy. The 
interactions (intermolecular) between the hydrophobic active site residues enhance the 
binding and stability of the CyC8β compound in the pocket. The per-residue decomposition 
energies of the CyC8β-Ag85C complex range between -178 and 19 (kcal/mol). The interacting 
residues and the most energy contributions towards the complex are; ARG41 (-178 kcal/mol), 
ASN221 (-94 kcal/mol), PRO223 (-56 kcal/mol), ALA (-80 kcal/mol), PHE226 (-74 
kcal/mol), HIS260 (-74 kcal/mol), and TRP262 (-80 kcal/mol). Each residue contributed high 
energy towards the complex, but TRP262 contributed the highest total energy. However, 
ARG41 and ASN221 have the highest vdW energy contribution to the binding of the 
inhibitor. Whereas, all the active site residues showed high electrostatic energy contributions 
towards CyC8β-Ag85C complex. These findings can be useful in the search for potential 
identification of antitubercular compounds in the future study of Ag85C protein as a target. 
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Figure 6.5. (Colour online) Visual CyC8β-Ag85C interaction networks (A). Open model CyC8β-Ag85C 
system (B) per residue energy contributions of the protein.
Binding free energy calculations of CyC8β open model-Ag85C binding affinity
The total binding free energy for the CyC8β open model-bound system obtained using the 
MM/GBSA approach. Table 6.2 showed the binding free energy (kcal/mol) for the open 
model-Ag85C system. The electrostatic force (ΔEelec = -975.05 ± 42) contributed almost 9 
times the energy from the van der Waals force (ΔEvdW = -117.67 ± 11). Hence, the binding 
showed a high binding affinity of the CyC8β open model for the interacting residues at the 
active site. Moreover, the binding free energy at gas-phase (ΔGgas = -145.81 ± 42) is useful 
information, which showed that the interactions in the open model-bound system favoured 
occurred at the gas-phase than in the water (Gsolv = -127.84 ± 30). Additionally, the averages 
of bond, angle and dihedral obtained were 832.99 ± 23.97, 2124.04 ± 35.45, and 3640.66 ± 
22.10 respectively.
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Table 6.2. Thermodynamics analysis; summary of MM/GBSA-based binding free energy 
contributions to the CyC8β open model-Ag85C complexa 
       Energy components (kcal mol-1)
Complex      ΔEvdW     ΔEelec      ΔGgas     ΔGGB      ΔGSA      -TΔS        ΔGsolv      ΔGbind
CyC8β-Ag85C    -117.67   -975.05   -145.81   -122.80     3.85       -24.28    -127.84    -131.70 
    (± 1.1)    (± 4.4)    (± 4.4)   (± 2.9)    (± 0.1)    (± 3.3)     (± 2.9)      (± 2.9)
 aΔEelec (electrostatic), ΔEvdw (van der Waals), ΔGbind (calculated total free binding energy) ΔGgas (gas-phase energy) and ΔGsolv 
(solvation free energy), -TΔS (entropy contribution term), T =temperature (298.15 K)
The binding free energy is very difficult to calculate in silico because of the challenge in 
entropy estimation. The solution to all the possible solvent conformations and solute entropy 
requires computing the range of values of the underlying degree of freedoms that correspond 
to different conformations with the same potential energy.50 The estimates of the interaction 
entropy changes during the formation CyC8β-Ag85C complex were obtained from a normal 
mode analysis of the energy-minimized structures. The average entropy terms obtained from 
the analysis are translational (-13.0909 ± 0.0), rotational (-11.2108 ± 0.1), and vibrational 
(0.0198 ± 3.3) The conformational entropy is – TΔS is -24.28 ± 3.3 upon the noncovalent 
binding of compound CyC8β to Ag85C.
Figure 6.6 illustrates the trajectory images of the apo, covalently bound CyC8β-Ag85C, and 
open model CyC8β-Ag85C systems at 0, 100, 200 and 350 ns MD simulations to visualise the 
magnitude of structural changes occurred. 
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Figure 6.6. Representative snapshots comparison among the Apo, covalent bound system, and open 
models at 0, 100, 200 and 350 ns showing the magnitude of structural changes in the Ag85C enzyme.
The two notable changes in apo and covalent bound systems occurred, whereby loops L1 and 
L2 exhibited twisting and transitions, respectively. Loop L2 (enclosed in black oval shapes) 
twisted and shifted towards the active site of Ag85C at 200 and open again at 350 ns MD 
simulations. Similarly, the observable changes in the covalent bound system occurred at 100, 
200, and 350 ns. Moreover, loop L1 (enclosed in red circles) extended because of the 
structural transition of a helix (residues GLY44, TRP45, ASP46, and ILE47). The active site 
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remains closed upon inhibitor binding. Therefore, the active site switches between open and 
closed conformations in the apo system compared to covalent bound and open model 
systems, which exhibited closed and opened binding site structures, respectively. 
6.5.4 Stability and fluctuation patterns of Ag85C systems
The average alpha carbon (C-α) atom root-mean-square deviation (RMSD) of a protein can 
be calculated from the MD simulations trajectories to deduce the stability status of such 
protein. For a protein system to attain stability, it must be subjected to a long-time MD 
simulation. Hence, the structural examination and dynamics analysis were determined based 
on the time scale of the simulations. The C-α atoms RMSD of the apo, covalently bound, and 
open model systems were observed for 350 ns and graphically monitored for convergence 
and stability. Figure 6.7A showed that the CyC8β-bound covalent system and CyC8β-bound 
open model did not converge with the unbound Ag85C. The RMSD of the Ag85C C-α atoms 
displayed high instability upon the binding of the ligand covalently compared to the apo and 
open model systems.
Moreover, the covalent bound system became stable at 150 ns compared to the noncovalent 
system, which maintained a stable structure throughout 350 ns. On the average, the apo, 
covalent CyC8β-bound, and open model CyC8β-Ag85C systems had C-α atoms RMSD values 
of 1.59 Å, 2.05 Å, and 0.91 Å respectively. The mean RMSD difference for the CyC8β 
covalently bound system is significant compared to the apo and the open model bound-CyC8β 
systems. These findings agreed with the visual structural changes obtained from the trajectory 
snapshots (Figure 6.6A).
The induced structural instability induced in Ag85C upon the covalently bound inhibitor 
highly favours the inhibition of protein catalytic function and may indicate conformational 
inactivity of the Ag85C. The variability may also mean the mechanism through which the 
CyC8β covalently bound inhibits the Ag85C function. Moreover, the notable deviations may 
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be associated with the hydrophilic characters of SER124 residue and arginine within the 
active site upon ligand binding. Polar amino acids often exposed to the solvent, which results 
in changes because of charge difference. This behaviour affects the hydrophobic properties of 
the protein, and consequently, the function of the protein.51
Figure 6.7. Comparative RMSD (A), RMSF (B), and PCA (C), for the C-α backbone atoms of 
Ag85C whole system of the unliganded (black), covalently bound system (red), and open model-
bound (green) throughout the 350 ns MD simulations. PCA plot showed projections of 
conformational behaviours of the protein systems along the PC1 and PC2 are the first two principal 
eigenvalues. D show residues 115-150 (red) and residues 55-65 (yellow).
To accurately estimate the degree of structural instability induced by the putative covalent 
inhibitor in both bound modes, we carried out investigations into the dynamic occurrences at 
the active sites and on the ligand in the covalently bound and open model systems throughout 
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350 ns. Figures 6.8A and 6.8B showed the RMSD plots for the active sites of the three 
protein systems. However, the results did not show any notable difference in the motions and 
dynamics, which imply the similarities in the structural behaviour compared to the whole 
protein system. 
Furthermore, RMSF values of the apo and bound systems were estimated to determine the 
impact of the binding of compound CyC8β on the dynamic behaviour of the protein. The role 
of amino acids is critical to conformational features of proteins. However, there may be a 
conformational change in protein due to mechanical events or chemical reactions. Hence, 
direct interactions of the active site of Ag85C with the inhibitor, CyC8β, should induce 
changes in the conformation of the protein by ligand-induced motion. Higher RMSF values 
indicate more flexible movements, considering the average position of the protein residues 
and lower fluctuation values signifies the restriction of conformational changes during the 
simulation. Figure 6.7B presented the C-α atoms RMSF plots for Apo protein, covalently 
CyC8β-bound, and CyC8β open model-bound. The C-α atom RMSF of apo exhibited a higher 
degree of flexibility compared to the open model system, which might be responsible for the 
Ag85C catalytic role of mycolic acid attachment and the synthesis of trehalose moieties. 
Moreover, the lowest RMSF value for the open model CyC8β-bound system compared to the 
apo system may be an indication of the system's compactness. The fluctuation of the Ag85C 
reduced upon the binding of the ligand in open model pose compared to the apo system. 
On the average, the C-α atoms RMSF values of the apo, covalent system, and open model 
system were 0.8 Å, 0.9 Å, and 0.6 Å respectively. The covalently bound system experienced 
a high degree of flexibility due to various conformational changes that occurred while the 
active site was closing. The covalent system showed elevated C-α atoms fluctuations 
throughout the 350 ns simulations and the notable variations in the regions comprising of 
residues 55-65, 110-140, and 210-225. Moreover, a high degree of conformational changes 
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occurs near the loop L1 (residues 38-55) and residues 115-150 in the covalent bound system. 
However, the most top fluctuation occurs in the apo and the covalent bound systems between 
residues 200 and 225, which contains two of the active site residues (223 and 224) and very 
close to loop L2 region (residues 209-220). 
Residues 55-65 and 115-150 are non-active site residues except the catalytic SER124, yet the 
residues showed similar B`-factor values compared to the RMSF values of the active site 
residues including SER124. The findings imply high flexible characteristic for the residues 
(55-65 and 115-124) upon ligand binding. Inferentially, these non-active site residues have 
high B`-factor tendency, which is an indication that the vibrational and the fast motions of the 
Ag85C protein C-α atoms. Subsequently, this implies clear biological significance like the 
active site residues. 
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Figure 6.8. C-α atom RMSD of the Ag85C protein active site (A) for the unbound (black), covalent 
bound (red), and noncovalent bound ligand system (green). RMSD (B) for the covalently docked 
ligand (black) and noncovalently or open model bound (red) systems.
Perhaps, the elevated flexibility reflected the mechanism by which the covalent ligand 
selectively inhibits the functions of the protein whereby the system interactions occurred due 
to conformational adjustments.52 Hence, the motion behaviours would hinder the enzyme 
from functioning at the optimum level, leading to the interruption of the chain of proteins that 
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involve in the synthesis of TDM/TMM and covalent attachment of mycolic acids in the 
mycobacterial cell walls.
Moreover, the RMSF values of the covalent bound system indicate a strong interacting 
propensity between the selective covalent inhibitor and SER124 residues. The binding 
residues of Ag85C-CyC8β complex include ASP38, LEU40, ARG41, SER124, ILE222, 
PRO223, PHE226, LEU227, GLU228, and HIS260. The catalytic SER124 is in-between the 
α3-helix and the β5-strand in the active site. The approach of irreversible covalent inhibition of 
biological targets using covalent compounds to cure pathogenic diseases has remained 
promising in the drug design area53, and the dynamic perspectives in this study corroborated 
with the experimental protocol reported on the putative covalent inhibition of the Ag85C role 
through the interaction of SER124 residue with the phosphorus oxygen atom of the Cis (β-
isomer)-monocyclic enolphosphorus Cycliphostin (CyC8β) compounds. 
6.5.5 Principal component analysis
To further explore the dynamics and motions of Ag85C, the Principal correlation analysis 
(PCA) was carried out on the C-α atoms of Ag85C using the CPPTRJ module in the 
AMBER18 GPU. The conformational patterns of the free and bound systems were projected 
along with the first two principal components (PC1 and PC2) of the individual vector (ev1 vs 
ev2). Figure 6.7C shows the general motions shifts for the unliganded and liganded systems 
along PC1 and PC2. The plot showed distinct conformations and clear separation of motions 
along the essential subspaces of two principal components. The apo and CyC8β covalently 
bound systems exhibited highly dispersed movements along both PC1 and PC2, and the 
CyC8β open model system displayed a compact structure. 
Though the C-α atoms of open model CyC8β system did not move like the selective covalent 
inhibition system, it did not move like the free protein either. Therefore, it could imply that 
the binding of the open model CyC8β is different from the covalent system. The induced 
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dispersions in the bound protein systems may simply indicate structure-activity in 
comparison with free Ag85C. The apo structure showed dispersed motion shifts; the 
movement shifts of CyC8β covalently bound is more dispersed while CyC8β open modelled 
showed highly compact movements. These findings still agreed with the above-detailed 
results, which, taken together, imply that the binding of the CyC8β compound actively 
favourable for the inhibition of TDM/TMM and the prevention of mycolic acid attachment.
6.5.6 Dynamic cross-correlation matrix (DCCM)
The dynamic cross-correlation matrix was determined during 350 ns MD simulations to 
obtain the position of the C-α atoms of the unbound and bound systems.54 This method gave 
us the insights into the inhibitory impact of CyC8β in the Ag85C systems by estimating the 
inter-residual motions and dynamics of Ag85C protein in the CyC8β covalently bonded and 
CyC8β open model systems compared with the apo system. Figure 6.9A-C showed the C-α 
atom motions indicating highly positive correlated motions (red to yellow), highly 
negative/anti-correlated movements (cyan to black), and similar correlations (green). 
The Apo Ag85C displayed the highest degree of positively correlated movements, followed 
by the CyC8β covalently bound system (Figure 6.9A). The decreasing magnitude of positive 
correlation follows the Apo > covalent bound > open model. However, Figure 6.9C showed 
significantly reduced a positive relationship in the CyC8β open model, indicting fluctuation 
reduction in the Ag85C C-α atoms, and low average RMSF value. The SER124 selective 
covalent inhibition system induced a tremendous increase in the fluctuations of the C-α atom 
Ag85C; these results agreed with the high average RMSF findings. The Dashed oval shape 
(Figure 6.9A) indicates SER124 residue to which CyC8β is selectively bound showed 
decreased positively correlated motions (red) to anti-correlated movements. Inferentially, 
these properties differentiate the inhibitory action/mechanism of the ligand when it bounds 
covalently to the protein from open model bound. In other words, CyC8β covalently bonded to 
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Ag85C SER124 residue inhibited its catalytic functions differently when the CyC8β bound to 
openly modelled to the protein. Compared to the free Ag85C, the higher fluctuations in the 
covalent system or the lower in the CyC8β open modelled system may imply the enzyme 
inactivity to function efficiently in the TDM/TMM synthesis and the mycolic acids 
attachment to the cell wall.  
Figure 6.9. Dynamic cross-correlation matrix presenting the correlations of residues in the Apo (A), 
Covalently bound CyC8β system (B), and Open model bound CyC8β (C). The colour legends on the 
right of each plot indicate the status of correlated motions.
6.5.7 Comparative Ag85C protein loop dynamics and distance matrices 
Loops are highly mobile structures that may occur in stable and unstable protein structures, 
and their variability due to solvent exposure often influences the folding, twisting, stability, 
and function of proteins.55 They may serve as mediators in biological processes, including 
protein-ligand, protein-protein, and signalling.50 The characterisation of protein using wet 
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techniques such as X-ray crystal or NMR is often challenging due to their amphipathic nature 
and the ligand-binding requirements.56 During the protein crystallisation, secondary structures 
such as helix and strand may unfold/transition directly to the loop due to the hydrogen 
bonding reduction and other reasons.57 The study of loop dynamics and motions uncovers 
important useful information in understanding protein conformational activity. Targeting 
weak spots such as active loops in the Ag85C enzyme is one of the opportunities by which 
we can develop novel efficacious antitubercular agents through drug design research.
The X-ray crystal structure of Ag85C resolved with some loops, and we investigated the 
static properties, dynamics, and motions of the two essential loops: loop 1, L1 (residues 36-
46); located within the active site and loop 2, L2 (residues 209-216) because it is proximal to 
the active site. Figures 6.10A-C showed both loops in apo, selective covalent inhibitor bound, 
and the open model systems. There was no notable change in the two loops of the apo 
structure compared to the bound systems which showed conformational transitions that can 
be attributed to the dynamic interaction with CyC8β. 
Ag85C Loop (L1) is hydrophobic but also characterised by aspartic-rich and aromatic side-
chain position of TYR46 that can allow high variability in the protein's function and inhibitor 
binding. The covalent system of Ag85C-CyC8β showed that this loop interacted with the 
inhibitor to a greater extent when compared to the open model system. Therefore, the loop 
structure is significant for the binding of the ligand to Ag85C. Again, this is evident in the 
twisting that we observed as the ligand interacted during the simulations. Interestingly, we 
discovered that the conformational unfolded α-helix residues ASN47, GLY48, TRP49, 
ASP50, ILE51, ASN52, THR53, PRO54, and ALA55 to loop and extend the length of loop 
L1 in the covalent bound system. Whereas CyC8β open model system only lost α-helix 
residues THR53 and PRO54 to transition into a loop structure.
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Similarly, Ag85C Loop (L2), is glycine-rich and is also characterised by hydrophobic 
residues. Figure 6.10B showed loss of the L2 loop residues ASP209, LEU210, and GLY214 
(proximal to the active site) to 310-helix and a turn structure in the selective covalent CyC8β 
system. These changes did not occur in both apo and CyC8β open model systems. This 
conformational change was simply due to the interaction of the selective covalent inhibitor. 
Objectively, loop L2 and the transitioned residues were involved in the binding of the ligand. 
Besides, loop L2 remained closed throughout the 350 ns simulations in the selective covalent 
inhibition system. At the same time, it exhibited opening and closing in the unbound Ag85C 
but actively opened in the CyC8β open model system. 
Figure 6.10. Visual conformational transitions in the secondary structures of the post 350 ns MD 
simulations; potential loops in Ag85C protein in the Apo (A), selective covalent CyC8β (B), and open 
model CyC8β (C) bound systems. Loop (L2) (purple) and Loop (L1) (sandy brown)
We, therefore, measured the dynamical events involved in these conformation transitions of 
the Ag85C enzyme as induced by the various CyC8β-binding modes to investigate further the 
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role of the loops in the function of the protein and CyC8β binding. To understand the 
dynamics and motions regarding the inhibitor's binding, we calculated the C-α RMSD and C-
α RMSF for loop L1 and L2 to determine their stabilities and deviations over a simulation 
period of 350 ns MD. Respectively, the C-α RMSD and RMSF plots for apo, selective 
covalent inhibition, and CyC8β open model systems of Loop L1 and L2 are presented in 
Figures 6.11 and 6.12. 
Figure 6.11. C-α RMSD (A) and RMSF (B) plots of Loop L1 of unbound and bound systems; Apo 
(black), Covalent bond system (red), and open model system (green). C illustrated the twisting and 
folding of loop L1 as it interacted with the protein active site as simulation time increases.
The RMSD value of the apo L1 converged with the open model system but not with the 
covalent system (Figure 6.11A). Instead, RMSD of apo L2 converged with the covalent 
inhibition system but not an open model system. The average C-α RMSD values of L1 in 
apo, selective covalent inhibition and open model CyC8β systems were 3.00 Å, 2.79 Å, and 
1.51 Å and the average C-α RMSD values of L2 were 1.64 Å, 2.86 Å, and 1.56 Å 
respectively for the same systems. In the CyC8β open model system, L1 and L2 are 
205
consistently stable as compared to the unbound system, the low average RMSD values. Loop 
L1 was unstable in the covalent bound system, while loop L2 was stable. The average C-α 
RMSF values of L1 for apo, covalent and CyC8β open model systems were 3.26 Å, 3.16 Å, 
and 0.82 Å respectively and the average C-α RMSF values of L2 were respectively 0.73 Å, 
1.06 Å, and 0.58 Å for the same systems. Such findings matched and may indicate inhibition-
induced instability in the Ag85C structure due to the binding of ligand CyC8β. 
Figure 6.12. C-α RMSD (A) and RMSF (B) plots of Loop L2 of unbound and bound systems; Apo 
(black), Covalent bond system (red), and open model system (green). C illustrated the movement of 
loop L2 to cover the protein active site as simulation time increases.
We used the distance (D) metric to investigate the inhibitory activity of this protein on the 
two different poses of binding of the ligand.39 The measurement of distance (D) is the most 
frequently used metric for describing the curling and twisting motions in proteins.58, 59 Finally, 
the distance between two different residues and a loop residue covering the active site, 
causing the opening and closing of the active site residue, was considered in this study. 
Distances (D) between the opposite residues LEU164 and PRO223 located in the α4- and α8-
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helix, respectively, estimated in the selective covalent and open model CyC8β. The snapshots 
taken at times (ns) 0-49, 50-99, 100-149, 150-249, and 250-350 used to determine the 
distances between the C-α residues LEU164 and PRO223 of bound and unbound systems. D 
(Å) between LEU164 and PRO223 in apo measured were 12.49, 11.92, 12.19, 12.79, and 
10.78, an indication that the active site underwent open and closed conformation and 
displayed similarities with CyC8β open model system. Figure 6.13 showed that distance (D) 
between the C-α residues LEU164 and PRO223 decreased with increasing simulation time 
until the selective covalent CyC8β system active site was closed. Hence, the closed 
conformation of the active of Ag85C upon the binding of the selective covalent inhibitor 
could only enhance the protein's conformational activity and the inhibitory action, and these 
results also support the findings as mentioned earlier. 
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Figure 6.13. Estimated distance (D) between LEU164 and PRO223 of the CyC8β covalently bound 
Ag85C using the snapshots taken at 0-49, 50-99, 100-149, 150-249, and 250-350 ns MD simulations. 
The D values were 10.399 Å, 8.213 Å, 7.506 Å, 5.156 Å, and 4.444 Å.
6.5.8 Defined Secondary structure (DSS) of Mtb antigen 85C protein
Defined Secondary structure protein (DSSP) analysis used to characterise/assign any protein 
elements, including loops, α-helices, coil, β-sheets, among others that do not unfold directly 
or adequately.51 The most common DSSP element assignors are None, Para, Anti, 310, Alpha, 
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Turn, and Bend indicated as legends on the far right-hand side of each chart scaled from 0-7 
except the None. Having observed the static Ag85C protein, especially the loops proximal to 
the active site, we monitored the visual transition or unfolding behaviour of these upon ligand 
binding in comparison with free Ag85C structure. In other words, a defined secondary 
structure protein analysis carried out to further gain insights into the inhibitory activity of 
CyC8β bound covalently and CyC8β open model against the Mtb enzyme catalytic functions 
using the 350 ns trajectories obtained during MD simulation. Figure. 6.14(A-C) represents 
the DSSP plots for the unbound (A), covalent system (B), and open model system (C).
The Apo and CyC8β open model DSSP charts showed insignificant changes in their secondary 
structure elements except around the residues 41-61, the region where THR53 and PRO54 in 
the CyC8β open model-Ag85C system transitioned to the 310-helix from 70-80 ns. Whereas 
there were notable changes in the structural elements of Ag85C L1 upon the binding of the 
selective covalent inhibitor as revealed by the visual molecular dynamic tool. Similarly, in 
the same 41-61 region of covalently bound CyC8β-Ag85C system, Figure 6.13B showed that 
residues ASN47, GLY48, TRP49, ASP50, ILE51, ASN52, THR53, PRO54, and ALA55 
were transitioned from alpha to mixture Turn and Bend throughout the 350 ns simulations. 
These losses of α-helices could be due to the reduction in the hydrogen bonds compared to 
the unbound protein.
Figure 6.14C chart showed that no changes observed in the L2 of CyC8β open model-Ag85C 
and unliganded Ag85C systems. Whereas there were significant losses of loop residues to 310-
helix among the Ag85C residues 219-226 upon the covalent CyC8β-bound from 160-220 ns 
and 330-350 ns. Interestingly, this region also contained the residues ILE222, LYS225, and 
PHE226 observed to undergo visual losses of alpha to loop. 
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Figure 6.14. The DSSP charts for Ag85C protein systems taken throughout 350 ns MD simulations; 
unliganded Ag85C (A), covalently bound CyC8β-Ag85C (B), and open model CyC8β (C)
6.5.9 Solvent accessible surface area (SASA)
Solvent accessible surface area (SASA) measures the area of the protein exposed to the 
solvent molecules.60 SASA is estimated from the coordinates of thermodynamic interactions 
between protein and water. It provides insights about the protein residues that exposed to 
water and those that buried in the active site to contribute to the hydrophobic stabilisation of 
protein structure. In this study, we determined changes in the accessibility of protein to 
solvent by computing SASA using the "surf" command in the AMBERTOOLS 18 GPU 
CPPTRAJ module that implemented a linear combination of pairwise overlaps (LCPO) 
algorithm. 61 Figure 6.15 calculable SASA of the unbound Ag85C and bound systems 
obtained from set trajectory coordinates of between Ag85C protein systems and water. The 
SASA calculations showed that the residual exposure of apo and open model systems was 
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consistent throughout the 350 ns simulation. At the same time, there were fluctuations in the 
residual exposure of the Covalent bound CyC8β-Ag85C.
Figure 6.15. Schematic representation of the solvent-accessible surface area of Apo (black), CyC8β 
covalent bound (red), and Open bound (green).
The SASA of the covalent system was high compared to the apo and open model systems. 
The high SASA values could simply be due to the exposure of the active site hydrophobic 
residues to enclosing solvent62, which explained why the instability (RMSD average) was also 
high.63 On the other hand, the increase in SASA value in the covalently-bound CyC8β 
indicated a restructured active site. The exposure of the active site hydrophobic residues to 
enclosing solvent may be associated with the selective covalent inhibition mechanism of this 
compound and eventual loss of protein functions. Finally, this SASA increase value may 
perhaps be due to the compressibility of the protein resulting from high induced-pressure.64
6.6 Conclusion
211
This scientific idea of studying the molecular mechanism of Ag85C and the putative covalent 
inhibitory mode of action of cis (β-isomer)-monocyclic enolphosphorus cycliphostin (CyC8β) 
using combined bioinformatics tools and computational methods provides a novel approach 
to design new antitubercular drugs. These findings obtained at the molecular level furnished 
us with the structural and dynamic behaviour of Ag85C protein and its interactions with the 
inhibitor that would assist in the experimental study. The detailed bioinformatics and 
molecular dynamics analyse, and the findings presented in this work are innovative. 
Sequence alignment of the homologs of Ag85C including Mtb, M. smegmatis, M. marinum, 
M. leprae, and M. ulcerans showed that the unique structural features among the amino acids 
of these mycobacteria are conserved. The individual active site features exhibited different 
levels of conservation; catalytic triad residues SER124, GLU228, HIS260 is 70 % conserved, 
Adeniyi loop (L1) is 90 % conserved, and Adeniyi loop L2 was 50 % entirely and 30 % 
partially conserved. On this note, these structural similarities among the Ag85C are weak 
spots to employ in targeting the protein by a selective covalent inhibition compound that can 
cure mycobacterial infections. The interacting residues obtained from the PRED analysis for 
the open model CyC8β-bound system provides a basis for the identification of potential drugs. 
Also, Adeniyi loop L1 is critical for the therapeutic activity because it acts as a switch 
between the open conformation and closed conformation. The transition of the residues also 
occurred upon binding of the CyC8β open model system but was not with many residues, 
unlike the covalent system. 
These explained the decreased distance between an active site residue proximal to loop L2-
amino acid (opposite) and the high-energy transitioned primary structure of Ag85C upon 
binding of the selective covalent inhibitor and the high binding affinity (-26.03 kcal/mol) of 
open model CyC8β system observed in the energy calculations. The binding of the CyC8β-
bound covalent inhibitor prompted the conformational shifts resulting from the instability, 
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flexibility, secondary structure transitions, correlated dynamics, and decreased distance. The 
results obtained for the selective covalent inhibitor bound system are quite promising. 
However, the findings obtained for the open model CyC8β especially the high free binding 
energy, consistent stability, and flexibilities are potential hotspots for the present/future drug 
identification that would facilitate drug design and development. Based on the free binding 
energy calculations and the characteristic hydrophobic interacting residues including 
PRO223, ALA224, PHE226, TRP262, and catalytic nucleophile HIS260 obtained from CyC8β 
open model bound Ag85C, I would suggest a virtual screening study to identify possible 
inhibitors of Ag85C as a molecular target. 
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There have been highly devoted unrelenting interdisciplinary efforts in a quest to develop an 
anti-TB drug in over a century that could put a lasting end to the menace of tuberculosis. 
Many drugs have been very effective at sometimes but later lost their efficacies because of 
the continuous evolution of the active Mycobacterium tuberculosis strains. These new Mtb 
strains develop mutation-mediated or acquired drug resistance against the current 
antitubercular drugs; the condition that has remained the top global challenge in the two 
decades. 
The present study was intended to gain a complex understanding that describing the structural 
and molecular behaviours of the weak spots in the protein, specifically, the loops covering the 
active site and the binding residues of the three studied targets crucial to the drug resistance, 
survival, and virulence of the Mtb. The project incorporated the application of bioinformatics 
tools to obtain the structural sequence (for NagA and Ag85C). Moreover, a homology 
modelling was carried out to create an Mtb menG 3D model and its homologs in NagA and 
Ag85C for sequence analysis. An investigation of unique similarities and differences among 
the homologs of the Mtb proteins were determined for information on the drug design of a 
polypharmacological agent. 
The MD analyses and findings presented here are innovative. Sequence alignment of 
homologs of Mtb NagA among the other selected mycobacterial species showed that unique 
primary structures were conserved. The interacting residues and loops of Ag85C among the 
mycobacteria were conserved. The effectiveness of menG inhibitors DG70 and CyC8β for 
menG and Ag85C respectively was examined based on the per-residue energy decomposition 
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analysis and the overall binding free energy contributions. The findings showed the most 
integral chemical frame of the inhibitors. This information ascertains the inhibitory. The 
Thompson loop in the menG assumed an open conformation in the unbound structure and a 
tightly closed conformation in DG70-menG complex.
Similarly, Adeniyi loop in the Ag85C also opened in the unbound protein and closed upon 
the ligand binding. The binding of the selective covalent inhibitor (CyC8β) to Ag85C revealed 
some weak hotspots in the protein that can be explored. Mutation analysis of the NagA 
D267A, H56Q, H56N, and H56A mutants revealed destabilizing effects at the binding site of 
the protein.  
However, two of the top challenges and shortcomings we encountered during this study 
including the problem of parameterization of Zinc and cadmium metals critical to the 
catalytic functions of the target NagA, optimization issue of the transition state inhibitor of 
NagA, etc.
More than six months, it was difficult running the molecular dynamics (MD) simulations and 
MMGB(PB)SA calculations for the ligand-bound target because the metals situated at the 
NagA protein active site were causing intraatomic bonding of the ligand (N-
methylhydroxyphosphinyl-D- glucosamine-6-phosphate). Therefore, the dynamics and 
motion characterization data of the ligand-protein interactions could be achieved in this 
study. It is our intention to obtain the parametrization of these metals in future to understand 
the characteristic behaviour of the interactions of NagA upon the binding of N-
methylhydroxyphosphinyl-D- glucosamine-6-phosphate. 
Altogether, this study presents requisite findings into the binding terrains and mechanism of 
inhibition of NagA, menG, and Ag85C protein towards the design and development of a drug 
for the cure of tuberculosis or other mycobacterial infection.
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7.1 Future perspectives
Considering the vital roles of the three studied targets (NagA, menG, Ag85C) and our 
findings regarding the dynamics and structural characterisation findings obtained in this 
work, further study like searching for a promising lead (Pharmacophore) using Structure-
based Computer-aided drug design (CADD) strategy can performed. Presently, the only 
known inhibitor of NagA is the transition state of its natural substrate. There are two metals 
(Zn and Cd) at the active site of NagA hthat ave catalytic significance. However, running 
molecular dynamics simulations for the target was very complicated, which could not be 
achieved during the short time of this study. Optimization and characterization of the 
structural dynamics and functional motion in the presence of the metals in future could be 
integrated into the design of potential NagA inhibitor.
Second, the menG crystallized structure and its binding site have not been; it does not seem to 
have been deposited into the Protein data bank (PDB). It would be interesting to characterize 
the motion and dynamics feature of the protein. Moreover, the target can be used to explore 
an effective inhibitor in pharmacophore modelling.
Other Future research focus include:
1. building Mesoporous silica nanoparticles (MSN) as delivery system and studying the 
interactions of a few drugs with the MSN to understand controlled release mechanism and 
sustainable delivery, 
2. apply NAMD and DFT to molecular dynamics to gain dynamic and motion insights 
into some targets of Mycobacteriun tuberculosis and Plasmodium falciparum, and
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3. possibly do pharmacophore and compound screening works of the ligands and target 
studied in this project research using the structure-based virtual screening(SBVS).
Supplementary Information
Figure. 4.S1. Different views of post-minimized apo-structures of Mycobacteria NagA enzymes 
demonstrated the effect of relaxation on the crystal structures. MS-NagA, Mtb-NagA, MM-NagA, 
MU-NagA, MA-NagA, and MC-NagA enzymes are represented in red, yellow, orange, green, blue, 
and purple.
225
Figure 5S1. Ramachandran plot validation of the active site of the modeled Mtb menG. 
Figure 5S2. Per-residue decomposition of a menG-DG70 complex using the previous predicted active 
site that reported.  
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Figure 5S3 Secondary structure (α-helices and β-sheets) transformation to Loop structures over a 300 
ns trajectory.
Figure 5S4. Illustrations of DSSP for Apo (A), ApoDMK9 (B), and ApoDG70 (C) systems over 300 
ns MD simulation.
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Table 5S1. Mean RMSD and RMSF of the Apo, DMK9-, and DG70-bound 
Loop residues
System      40-54       102-112  211-220
 Average RMSD (Å)
Apo 5.26 ± 0.63     1.62 ± 0.17 4.77 ± 0.63
ApoDMK9 4.03 ± 0.84     1.60 ± 0.17 3.45 ± 0.30
ApoDG70 5.84 ± 1.03     2.69 ± 0.98 3.19 ± 0.43 
  
Average RMSF (Å)
Apo 3.04 ± 0.80     1.32 ± 0.31 2.44 ± 0.67
ApoDMK9 2.86 ± 0.85     1.22 ± 0.23 1.29 ± 0.17
ApoDG70 3.34 ± 1.67     1.74 ± 0.69 2.07 ± 0.64
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